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Abstract 
 
This thesis describes a series of experiments investigating the neural underpinnings of the 
µHIILFDF\¶RUµYDOXH¶RIfood reinforcers in the control of operant behaviour. A number of 
methods have been devised for measuring reinforcer value. The experiments described in 
this thesis employed the progressive-ratio schedule, in which the number of responses 
required to obtain a reinforcer is progressively increased with each successive reinforcer. 
The performance of rats on this schedule was analysed using a quantitative model of 
schedule-FRQWUROOHG EHKDYLRXU .LOOHHQ¶V  µ0DWKHPDWLFDO 3ULQFLSOHV RI
5HLQIRUFHPHQW¶ 035 PRGHO $Q DGYDQWDJH RI WKLV DSSURDFK LV WKDW 035 SURYLGHV D
theoretical basis for discriminating between the effects of interventions on µPRWLYDWLRQDO¶
DQG µPRWRU¶ DVSHFWV RI operant behaviour. According to MPR, schedule-controlled 
EHKDYLRXU PD\ EH FKDUDFWHUL]HG E\ DQ µactivation¶ parameter, a, which measures the 
reinforcer efficacy or value, a µresponse time¶ parameter, į, which measures the 
minimum inter-response time, and a µcoupling¶ parameter¶ ȕ which expresses the weight 
in short-term memory assigned to the most recent response.  
 
Chapter 1 reviews the background literature related to the main themes of the project: the 
neurobiology and behavioural functions of the orexinergic and the dopaminergic systems 
of the brain, and the use of the progressive-ratio schedule in behavioural neuroscience. 
Special emphasis is given to MPR and its application to behavioural neuroscience. 
 
Experiment 1 (Chapter 2) examined the effect of destruction of orexinergic neurones of  
the lateral hypothalamic area (LHA), which have been proposed to control reward 
processes and food intake. Orexinergic neurones were destroyed by intracerebral 
injection of a selective neurotoxin, the orexin-B-saporin conjugate (OxSap). OxSap-
induced lesions had no effect on the parameter a and did not alter food intake. However, 
they did increase the response time parameter į, suggesting that the lesion had a motor  
debilitating effect.  
 
Experiment 2 (Chapter 3) investigated the effect of disconnecting the LHA from the 
ventral tegmental area (VTA), a major area of projection of the orexinergic neurones. 
Functional disconnection was achieved by unilateral injection of OxSap into the LHA on 
one side and into the VTA on the contralateral side of the brain. The lesion had no effect 
 - xi - 
on a or any other of the motivational measures used, or on food intake. However į was 
increased, suggesting that the lesion mainly affected motor functioning.   
 
Since OxSap has a preferential destructive effect on neurones that express the orexin-2 
(OX2) receptor, the possibility was considered that the putative role of orexins in 
regulating reinforcer value may be mediated by orexin-1 (OX1) receptors, rather than 
OX2 receptors. In order to explore this possibility, Experiment 3 (Chapter 4) examined 
the effect of acute functional disconnection of the LHA from the nucleus accumbens 
shell (AcbS), an area rich in OX1 receptors. Disconnection was achieved by unilateral 
OxSap-induced lesions of the LHA and infusion of the OX1 receptor antagonist, SB-
334867-A (1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride) 
into the contralateral AcbS via indwelling intracerebral cannulae. The results showed a 
reduction of the activation parameter a, with no effect on any of the other parameters. 
These findings are consistent with the notion that OX1 receptors are involved in the 
control of the reinforcer value, whereas the OX2 receptors are more involved in the 
control of motor-related processes.  
 
Experiment 4 (Chapter 5) examined the effect of cyproheptadine, a drug with 5-
hydroxytryptamine (5HT2A) and histamine (H1) receptor blocking action. 
&\SURKHSWDGLQH¶V HIIHFW RQSURJUHVVLYH-ratio schedule performance was compared with 
the effectV RI WKH µDW\SLFDO¶ DQWLSV\FKRWLF GUXJ FOR]DSLQH ZKLFK VKDUHV PDQ\ RI
F\SURKHSWDGLQH¶V SKDUPDFRORJLFDO DFWLRQV DQG WKH µFRQYHQWLRQDO¶ DQWLSV\FKRWLF
haloperidol, whose principal action is antagonism of D2-like dopamine receptors. In 
addition, the effects of two drugs with known effects RQ IRRG LQWDNH ǻ9-
tetrahydrocannabinol (THC) and chlordiazepoxide, were also examined. Cyproheptadine 
and clozapine increased both a and į Haloperidol reduced a and increased į and 
chlordiazepoxide increased a.  Unexpectedly, THC had no effect on the parameters of 
MPR; this negative result was explored further in Experiment 6 (see below). 
 
Experiment 5 (Chapter 6) examined the differential involvement of D1-like and D2-like 
dopamine receptors in the control of progressive-ratio schedule performance reinforced 
with a sucrose solution or corn oil. Performance maintained by both reinforcers 
conformed to the equation derived from MPR. Blockade of D2-like receptors by 
haloperidol equally affected performance maintained by corn oil and sucrose, reducing a 
 - xii - 
and increasing į. However blockade of D1-like receptors by SKF-83566 (bromo-2,3,4,5-
tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide) reduced both a and 
į in rats trained with the sucrose reinforcer but had no effect on the rats reinforced with 
corn oil. This is consistent with the notion that D1-like and D2-like dopamine receptors 
exert differential influences on the values of different kinds of food reinforcer. 
 
Experiment 6 (Chapter 7) examined the effect of THC on progressive-ratio schedule 
performance of rats reinforced with corn oil and sucrose. The rats were tested under food 
deprived and free feeding conditions. In addition, the effect of THC on food intake was 
assessed. The results confirmed that THC did not affect any of the parameters of MPR. 
When the animals were transferred from the food deprived to the free feeding condition 
they showed a reduction of a but no change of į. This is in agreement with the 
assumption of MPR that a and į are independent parameters. Finally, there was a trend 
for THC to increase sucrose consumption and to reduce corn oil intake, suggesting that 
cannabinoid receptors may mediate different effects on the reinforcing values of these 
two foods. 
 
Chapter 8 summarises the results of the experiments from the project, and discusses some 
of their implications. The implications of the findings of Experiments 1-3 for the role of 
orexinergic mechanisms in the regulation of reinforcer value and motor processes are 
discussed. The results of Experiments 4 and 5 are considered in the context of the 
putative involvement of dopamine receptors in reinforcement processes and the effects of 
conventional and atypical antipsychotics on motivated behaviour. The failure of THC to 
affect progressive-ratio schedule performance (Experiments 4 and 6) is discussed in the 
FRQWH[WRIWKHUHODWLRQVKLSEHWZHHQUHLQIRUFHUµYDOXH¶DQGIRRGFRQVXPSWLRQ7he general 
implications of these findings for behavioural pharmacology and MPR are considered. 
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1.1. Overview of thesis 
 
The work described in this thesis was an attempt to use a quantitative model of schedule-
controlled operant behaviour (Killeen 1994) to address some questions about the 
neurobiological mechanisms underlying the maintenance of voluntary behaviour by food 
reinforcement. Three experiments investigated the putative role of orexinergic neurones 
in reinforcement processes. A series of experiments examined the putative involvement 
of dopamine receptors in reinforcement processes, and compared the sensitivity of 
operant performance to disruption b\ µFRQYHQWLRQDO¶ DQG µDW\SLFDO¶ DQWLSV\FKRWLFV DQG
cyproheptadine, a drug with 5-hydroxytryptamine (5-HT) and histamine receptor 
antagonist properties. A final experiment explored the sensitivity of operant performance 
WR ǻ9-tetrahydrocannabinol (THC). In HDFK FDVH UDWV¶ SHUIRUPDQFH RQ the progressive-
UDWLR VFKHGXOHRI UHLQIRUFHPHQWZDVDQDO\VHGXVLQJDQHTXDWLRQGHULYHG IURP.LOOHHQ¶V
(1994) model, and the effects of interventions (cerebral lesions, intracerebral drug 
treatment, or systemic drug treatment) on the parameters of the model were examined. 
 
This introductory chapter reviews the background literature to the main topics of the 
thesis; topics that are related more particularly to individual experiments are reviewed in 
the introductory sections of the relevant chapters. In the next section the anatomy, 
pharmacology and principal behavioural functions of the orexinergic pathways are 
reviewed. This is followed by a brief account of the ascending dopaminergic pathways, 
and a selective review of evidence for the involvement of these pathways in positive 
reinforcement. This section also includes an overview of the effects of antipsychotic 
drugs (which are known to interact with dopaminergic mechanisms: King and 
Waddington 2004) on operant behaviour. The final major section of the Introduction 
VXPPDUL]HV .LOOHHQ¶V  PRGHO WKH Mathematical Principles of Reinforcement 
(MPR) model, focussing on the application of this model to performance maintained by 
progressive-ratio schedules.    
 
1.2.  Orexins 
 
1.2.1. Anatomy  
 
Orexin A and B, also known as hypocretin 1 and 2, are neuropeptides (33 and 28 amino-
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acids respectively) that were simultaneously discovered by two independent groups in 
1998. Although the first name used was hypocretin, it was changed to orexin, from the 
Greek word orexis which means desire for food, due to the fact that the central 
administration of orexin produces an increment of  food intake. 
 
In the rat brain the orexin-containing neurones are principally localised symmetrically 
and bilaterally in the hypothalamus and adjacent regions. One major group of orexin-
containing neurones is located in the lateral hypothalamic area (LHA). Other clusters of  
orexinergic neurones are found in the perifornical area of the hypothalamus (PFA), the 
posterior hypothalamus, the dorsomedial hypothalamic nucleus (DMH), the zona incerta, 
and the subincertal and subthalamic nuclei. 
  
Both orexins are encoded by the same gene. They are derived from a common precursor, 
prepro-orexin (prepro-OX) (Sakurai et al. 1998), also called prehypocretin (de Lecea et 
al. 1998).  
  
Although  orexinergic neurones are few in number, approximately 50,000 in total in the 
human brain (Fronczek et al. 2005), these neurones  project practically to the entire brain, 
including the cerebral cortex, olfactory bulb, hippocampus, basal ganglia, amygdala, 
thalamus, anterior and posterior hypothalamus and various brainstem regions (see below) 
(Date et al. 1999; de Lecea et al. 1998; Peyron et al. 1998(b)). 
 
Orexinergic neurones of the LHA project to both the nuclei of origin and the projection 
fields of the mesolimbic dopaminergic pathways (ventral tegmental area [VTA] and the 
nucleus accumbens), which are widely believed to constitute a crucial component of the 
³PRWLYDWLRQDODQGUHZDUGV\VWHP´ (Harris and Aston-Jones 2006; Salamone and Correa 
2002; Wise 2004(a); 2004(b)). Orexinergic neurones of the LHA and PFA project to 
noradrenergic neurones of the locus coeruleus, serotonergic neurones of the raphe nuclei, 
histaminergic neurones of the tuberomamillary nuclei and cholinergic neurones in the 
basal forebrain (Peyron et al. 1998(a); Peyron et al. 1998(b); Scammell and Winrow 
2011; Yoshida et al. 2006). These regions have all been implicated in the regulation of 
behavioural arousal and the sleep/wakefulness cycle (see Scammell and Winrow 2011). 
The putative behavioural roles of these orexinergic projections are reviewed in Section 
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The orexins bind to two G protein mediated receptors named Orexin receptor 1 (OX1 
receptor) and Orexin receptor 2 (OX2 receptor). Orexin receptor mRNA is expressed 
broadly throughout the brain. Areas that contain a high level of OX1 receptor mRNA are 
the tenia tecta, the indusium griseum, the septohippocampal nucleus, the bed nucleus of 
the stria terminalis, the paraventricular thalamic nucleus, the CA1 and CA2 regions of the 
hippocampus, the amygdala, the raphe nuclei and locus coeruleus.  OX2 receptors are 
expressed in high density in the olfactory tubercle, layer VI of the cerebral cortex, the 
shell of the nucleus accumbens, the paraventricular and central medial thalamic nuclei, 
the LHA, PFA and tuberomammillary nuclei of the hypothalamus, the subthalamic 
nucleus, the VTA, the anterior pretectal nucleus and the CA3 region of the hippocampus 
(Lu et al. 2000; Trivedi et al. 1998). It has also been shown that orexin A and OX1 
receptor mRNA are expressed in peripheral tissues (Johren et al. 2001; Randeva et al. 
2001). However as orexin expression in peripheral tissues is relatively low, it has been 
argued that it is unlikely that orexins exert significant peripheral effects (Scammell and 
Winrow 2011). 
 
Orexinergic neurones themselves express orexin receptors (autoreceptors). For example, 
orexinergic neurones account for a substantial proportion of OX2 receptor expression in 
the LHA (Gerashchenko et al. 2001). However, other neuronal populations in the LHA 
also express OX2 receptors, suggesting that orexinergic transmission plays a significant 
role in the local intrahypothalamic circuitry in addition to its role in the efferent 
projection from this region. Hypothalamic neurones that express orexin receptors include 
melanocortin concentrating hormone (MCH)-containing, adenosine deaminase (ADA)-
containing and  histaminergic neurones (Blanco-Centurion et al. 2007; Frederick-Duus et 




As indicated above, there are two types of orexin receptor, OX1 and OX2 receptors. The 
two forms of orexin (orexin A and orexin B) have different affinity profiles for these 
receptors. Orexin A has a higher affinity than orexin B for OX1 receptors; however both 
orexins bind to OX2 receptors with approximately the same affinity (Sakurai et al. 1998). 
No selective synthetic OX1 and OX2 receptor agonists are available at the present time. 
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To study the orexin system, orexin A and B have been administered centrally (see 
Section 1.2.3). The neuropeptide Y receptor agonist, rat pancreatic polypeptide (RPP) has 
been found to induce Fos expression in orexinergic neurones (Campbell et al. 2003) and 
has also been used to stimulate the orexinergic system in behavioural studies (Borgland 
et al. 2009; Borgland et al. 2006; Harris et al. 2005; Jones et al. 2001; Sakurai et al. 1998; 
Thorpe et al. 2005a; Thorpe et al. 2006; Thorpe and Kotz 2005) (for discussion, see 
Section 1.2.3). 
 
The first orexin receptor antagonist to be developed was SB-334867-A (1-(2-
methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride). This is still the 
most selective and potent OX1 receptor antagonist available  (Scammell and Winrow 
2011; Smart et al. 2001).  SB-334867-A binds to OX1 receptors with nanomolar affinity 
and inhibits the OX1 receptopr-mediated calcium response at similar concentrations. SB-
334867-A also inhibits the OX2 receptor-mediated calcium response but only at 
substantially higher concentrations (Smart et al. 2001). Another OX1 receptor antagonist 
with similar affinity and selectivity  is SB-408124 (Dugovic et al. 2009). 
 
To disentangle the possible differential roles of the two orexin receptors, the specific 
OX2 receptor antagonist JNJ-10397049 (N-(2,4-dibromophenyl)-N'-[(4S,5S)-2,2-
dimethyl-4-phenyl-1,3-dioxan-5-yl]-urea) ) was developed (Silveyra et al. 2007). Studies 
using this antagonist have indicated differential effects of OX1 and OX2 receptors in 
reward process and the promotion of wakefulness (Dugovic et al. 2009; Shoblock et al. 
2010) ; see Section 1.2.3). Another orexin receptor antagonist is the dual OX1/OX2 
receptor antagonist, almorexant (ASCT-078573), which has recently been used in clinical 
trials for the treatment of sleep disorders, including insomnia, and drug addiction 
(Brisbare-Roch et al. 2007; Roecker and Coleman 2008; Winrow et al. 2009). 
 
To futher understand the behavioural functions of the orexinergic pathways, studies that 
entail the destruction of orexinergic cells or cells bearing the orexin receptors have been 
carried out on animals. A novel neurotoxin was developed by the conjugation of the 
ribosome-inactivating protein saporin (Sap) (Stirpe and Barbieri 1986; Stirpe et al. 1983) 
and the endogenous orexin receptor ligand orexin B. Since orexin B binds preferentially 
to OX2 receptors, the conjugate, known as OxSap (Advanced Targeted Systems, USA), 
has a selective neurotoxic action on neurones bearing these receptors. Since orexinergic 
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neurones themselves express OX2 receptors, OxSap has a powerful destructive action on 
these neurones, and when injected into the LHA produces a marked depletion of orexin-
containing neurones (Gerashchenko et al. 2001). Although it is well documented that 
OxSap destroys orexinergic neurones in the LHA  (Anaclet et al. 2009; Blanco-Centurion 
et al. 2007; Di Sebastiano et al. 2010a; Di Sebastiano et al. 2010b; Frederick-Duus et al. 
2007; Furlong and Carrive 2007; Gerashchenko et al. 2003; Gerashchenko et al. 2001; 
Vetrivelan et al. 2009), it has been reported that OxSap also affects other, non-
orexinergic, neurones which bear the OX2 receptor, including MCH, histaminergic and 
cholinergic  neurones (Blanco-Centurion et al. 2007; Frederick-Duus et al. 2007; Furlong 
and Carrive 2007; Gerashchenko et al. 2001; Ocampo-Garces et al.). However, some 
recent studies did not find a significant loss of MCH-containing neurones when OxSap 
was injected  in the LHA (Di Sebastiano et al. 2010a; Di Sebastiano et al. 2010b). It is 
thought that the specificity of OxSap is dose-dependent and that smaller doses seem to be 
more selective for orexinergic neurones (Anaclet et al. 2009; Gerashchenko et al. 2006; 
Vetrivelan et al. 2009) than higher doses (Furlong and Carrive 2007; Gerashchenko et al. 
2006; Mistlberger et al. 2003). 
 
1.2.3. Behavioural functions 
 
The orexins are proposed to be implicated in a broad variety of functions including 
feeding, reward processing, addictions, regulation of the sleep-wakefulness cycle, 
behavioural arousal and the distribution of muscle tone (de Lecea et al. 1998; de Lecea 
and Sutcliffe 1999; Piper et al. 2000; Sakurai 1999; 2002; 2005).  
 
1.2.3.1. Behavioural arousal and the sleep/wakefulness cycle 
 
Central administration of orexins results in an increase of behavioural arousal, locomotor 
activity (John et al. 2000; Jones et al. 2001; Thorpe et al. 2005a; Thorpe et al. 2006; 
Thorpe and Kotz 2005; Thorpe et al. 2005b) and wakefulness  (Bourgin et al. 2000; 
Eriksson et al. 2001; Espana et al. 2001; Piper et al. 2000). Futhermore the level of 
orexin in cerebrospinal fluid (CSF) is higher during the period of wakefulness, and this 
level decreases during sleep. This diurnal fluctuation of orexin levels has been found in 
different organisms including humans (Estabrooke et al. 2001; Grady et al. 2006; 
Mileykovskiy et al. 2005; Salomon et al. 2003; Yoshida et al. 2001; Zeitzer et al. 2003). 
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Narcoleptic patients have a deficit of orexin-containing neurones compared with non-
narcoleptic humans (Peyron et al. 2000). Siegel (2004) suggested that disruption of the 
normal synthesis of orexins due to genetic alterations or degeneration of the orexinergic 
neurones or orexin receptors may cause narcolepsy in humans. This neurological disorder 
is characterized by uncontrollable somnolence during the day time and alteration of rapid 
eye movement (REM) sleep (Mignot 1998). This sleep alteration is characterized by a 
short REM sleep latency and a fast transition from waking state into REM sleep with a 
very short sleep onset period (Siegel 2004). Many, but not all, patients with narcolepsy 
experience cataplexy (brief periods of paralysis triggered by strong emotions) (Scammell 
and Winrow 2011). The majority of narcoleptic patients have undetectable or very little 
orexin A in their CSF (Nishino 2007; Nishino et al. 2000). These findings are in 
accordance with human post-mortem studies that showed a reduction of more than 80% 
of orexin-containing neurones in the hypothalamus (Peyron et al. 2000). All these studies 
are consistent with the proposal that the orexin system is involved in the pathogenesis of 
human narcolepsy  (Harris and Aston-Jones 2006; Scammell and Winrow 2011). 
 
Orexin has also been studied in relation to the sleep disorder narcolepsy. Rodents whose 
orexinergic pathways have been ablated and prepro-orexin knockout mice show 
symptoms that mimic those present in human narcolepsy. Similar symptoms were found 
in dogs and mice that lack the OX2 receptor (Chemelli et al. 1999; Hara et al. 2001; Lin 
et al. 1999; Willie et al. 2001). These findings led Lin et al (1999) to conclude that the 
cause of canine narcolepsy is a malfunctioning of the OX2 receptor and also that orexin 
is a major sleep modulating transmitter. However, there is some evidence that mice 
lacking both OX1 and OX2 receptors exhibit a more severe narcoleptic syndrome than 
those lacking only OX2 receptors, and that cataplexy occurs only in animals that lack 
both types of orexin receptor (Hondo et al. 2009; Scammell and Winrow 2011).  
 
 
1.2.3.2. Feeding and energy balance  
 
Sakurai et al. (1998) were the first in inject orexin A and B intracerebroventricularly and 
found that both of these neuropeptides induced food intake; however, the effect of orexin 
A was stronger and lasted longer than that of orexin B. The effects of orexin 
administration are substantially less potent than those produced by other orexigenic 
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peptides such as neuropeptide Y (Edwards et al. 1999; Sakurai et al. 1998).  
 
More recent studies have confirmed the increment in food intake induced by centrally 
administered orexin under different experimental conditions (e.g. free feeding vs food 
restricted) and in different areas in the brain (ventricles, nucleus accumbens and ventral 
tegmental area) (Farr et al. 2005; Nair et al. 2008; Thorpe et al. 2005a; Thorpe et al. 
2006; Thorpe and Kotz 2005; Thorpe et al. 2005b). Orexin precursor (Prepro-OX) levels 
have been found to be augmented upon fasting and reduced after food consumption 
(Lopez et al. 2000). A role for orexinergic mechanisms in feeding is also suggested by 
the finding that systemic administration of  the OX1 receptor antagonist SB-334867 
(Haynes et al. 2002; Haynes et al. 2000) reverses the rise in food intake after the central 
administration of orexin A (Rodgers et al. 2000; Rodgers et al. 2001; Thorpe and Kotz 
2005).  
 
These findings indicate that the central administration of orexins induces an increase of 
food intake. However, the implications of this for the regulation of body weight remain 
unclear, since orexins have been implicated in the regulation of metabolic rate and 
locomotor activity, both of which have an impact on energy consumption (Kannan et al. 
2007; Samson et al. 1999; Shirasaka et al. 1999). For example, some studies have found 
that daily central administration of orexin-A induced weight loss in rats (Novak and 
Levine 2009; Yamanaka et al. 1999). A further example of the complex interactions 
between orexinergic mechanisms, energy consumption and body weight is provided by a 
study using transgenic mice that lack orexinergic neurones (Hara et al. 2001). These mice 
developed obesity despite the fact that their food intake was less than that of wild type 
mice. The authors concluded that this result was due to a decrement in locomotor activity 
in the orexin-deficient mice, when compared to wild type mice, during the dark phase of 
the daily cycle, which resulted in reduced energy expenditure in the orexin-deficient mice 
(Hara et al. 2001). Espana et al. (2002) found that when orexin A was administered to 
rats during the dark phase of the cycle it did not produce an increase of food intake. The 
authors suggested that this lack of effect was due to the fact that rats are more active 
during the night. They also suggested that the orexin-A-induced increase in food intake 
that occured during the day was due to an increase of arousal (Espana et al. 2002). 
 
Interestingly, there is evidence that the effect of orexins on energy expenditure is not 
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necessarily brought about by behavioural changes. Injection of orexin A into various 
hypothalamic nuclei, including the arcuate nucleus, the medial preoptic area, the 
dorsomedial nucleus and the LHA increases oxygen consumption and thermogenesis in 
anaesthetized as well as conscious animals (Novak et al. 2006; Wang et al. 2003). 
Summarising this literature, Teske et al. (2010) proposed that orexins directly stimulate 
energy expenditure as well as promoting behavioural activity which results in further 
energy expenditure.  
  
1.2.3.3. Reinforcement and drug addiction 
 
Another area of investigation in relation to the orexinergic neurones of the LHA is their 
putative role in µUHZDUGVHHNLQJ¶DQGaddiction to drugs. There is evidence that orexins 
enhance neuronal activity in the mesolimbic dopaminergic projection from the VTA to 
the nucleus accumbens, which is believed to play a prominent role in reinforcement 
processes and drug addiction (Wise 1978; 2004(b)). For example, Borgland et al. (2006) 
found that locally administered orexins increased both the acute response of VTA 
neurones to glutamate and the longer-term functional plasticity (long-term potentiation) 
of these neurones induced by repeated stimulation by glutamate. Moorman and Aston-
Jones (2007, unpublished experiments cited by Aston-Jones et al. 2009) found that 
orexins had an excitatory effect on VTA neurones, as well as enhancing the increase in 
firing of these neurones evoked by stimulation of the medial prefrontal cortex. Orexin 
receptors are present in considerable numbers in the nucleus accumbens, one of the main 
projection regions of the mesolimbic dopaminergic pathway (Martin et al. 2002; Trivedi 
et al. 1998); immunohistochemical studies have confirmed the presence of orexin-
containing terminals in the nucleus accumbens, and retrograde tracing studies have 
demonstrated direct orexinergic projections from the LHA to the shell of the nucleus 
accumbens (Fadel et al. 2002; Peyron et al. 1998(b)). 
 
Behavioural evidence consistent with a role of the LHA orexinergic system in 
reinforcement comes from a variety of sources. For example, injection of orexin A into 
the cerebral ventricles (Sakurai et al. 1998) or directly into the LHA (Dube et al. 1999; 
Sweet et al. 1999; Thorpe et al. 2006; Thorpe et al. 2005b) induces feeding in rodents. 
Consumption of high-energy diet has been found to be preferentially enhanced by orexin 
A (Clegg et al. 2002), and the OX1 receptor antagonist SB-334867 administered 
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systemically or into the ventral tegmental area (a prominent projection region of the LHA 
orexinergic neurones), has been found to attenuate spontaneous or opiate-induced 
consumption of high-fat diet (Choi et al. 2010; Zheng et al. 2007).  More direct evidence 
for an involvement of orexins in reinforcement processes derives from the finding that 
conditioned place preference induced by food or opiate reinforcement is associated with 
activation of LHA orexinergic neurones, and that conditioned place preference can be 
attenuated by systemic administration of SB-334867 (Harris et al. 2005). Stimulation of 
these neurones by injection of the neuropeptide Y receptor agonist RPP into the LHA 
was found to reinstate a previously extinguished conditioned place preference for 
morphine, and this effect was also blocked by SB-334867 (Harris et al. 2005).  
 
There have been several reports of the effect of manipulating orexinergic function on 
schedule-controlled operant behaviour. Most of these studies have employed the 
progressive-ratio schedule of reinforcement, in which the number of responses required 
in order to obtain a reinforcer (the response/reinforcer ratio) is progressively increased 
(Hodos 1961; Hodos and Kalman 1963). As the ratio is increased, response rate declines, 
until the subject eventually stops responding, The ratio at which responding ceases for 
VRPHVSHFLILHGSHULRGGHILQHVWKHµEUHDNSRLQW¶$GPLQLVWUDWLRQRIRUH[LQ$LQWRWKHWKLUG
ventricle (Choi et al. 2010) or directly into the LHA (Thorpe et al. 2005) increased the 
breakpoint and facilitated food intake. Moreover, SB-334867 reduced the breakpoint 
when the reinforcer was cocaine or a highly palatable food (Borgland et al. 2009; Choi et 
al. 2010; Nair et al. 2008; Sharf et al. 2010a). Since the breakpoint is often used as an 
LQGH[RIWKHVXEMHFW¶VPRWLYDWLRQDOVWDWHRUWKHLQFHQWLYHYDOXHRIUHLQIRUFHUV(Aberman et 
al. 1998; Barr and Phillips 1999; Bowman and Brown 1998; Cheeta et al. 1995; Hodos 
1961; Richardson and Roberts 1996; Thorpe et al. 2005a), these findings are consistent 
with the notion that the orexinergic projection from the LHA forms part of the neural 
substrate of reinforcement. 
 
Furthermore clinical evidence supports the involvement of the orexin system in 
addictions. For instance, patients suffering from narcolepsy are treated with 
psychostimulant drugs related to amphetamines (Nishino and Mignot 1997); however, 
they seldom become addicted to them (Akimoto et al. 1960; Guilleminault et al. 1974). 
As reviewed above, narcolepsy is associated with deficient orexinergic function. Similar 
results were found with rodents whose orexinergic neurones had been ablated; these 
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animals showed reduced susceptibility to morphine dependency compared to normal 
animals (Georgescu et al. 2003).   
 
1.2.3.4. Arousal and reinforcement: a µdichotomy of RUH[LQHUJLFIXQFWLRQ¶" 
 
It has been proposed that the orexinergic neurones of the hypothalamus may be divided 
into two anatomically distinct groups which subserve different behavioural functions 
(µGLFKRWRP\ RI RUH[LQHUJLF IXQFWLRQ¶ Harris and Aston-Jones 2006). The first group 
corresponds to the orexinergic neurones of the LHA. This group is purported to be 
involved in the regulation of reward processing for both food and drugs. The second 
group of orexinergic neurones are those found in the PFA and DMH, which according to 
WKHµGLFKRWRP\RIorexinergic IXQFWLRQ¶theory (Harris et al. 2005) react to stressors, and 
may be primarily responsible for the role of orexins in wakefulness and arousal. Lu et al. 
(2003) used µVWUHVV¶ LQGXFHG E\ IRRW-shock in order to re-establish extinguished drug 
seeking behaviour. This was associated with activation of the orexinergic neurones in the 
PFA and DMH but not in the LHA, consistent with the notion that the former group of 
orexinergic neurones subserves arousal, but not reinforcement processes (Harris et al. 
2005). Similar findings have been reported when the stress was induced by restraint or 
cold-exposure, which increased Fos expression (a marker for neuronal activation: 
Hoffman et al., 1993) in PFA orexinergic neurones (Sakamoto et al. 2004; Winsky-
Sommerer et al. 2004). 
  
Further evidence for a role of PFA/DMH orexinergic neurones in arousal was provided 
by Estabrooke et al. (2001). These authors studied the activation of orexinergic neurones 
during wakefulness and sleep under different conditions (sleep deprivation, wakefulness 
induced with drugs, animals living in the dark, and animals maintained in a light/dark 
cycle). To measure the activation of orexinergic neurones, Eastabroke et al. used a 
double immunohistochemical labelling method for Fos and orexin, combined with 
physiological sleep recording. They found a positive correlation between Fos expression 
in the orexinergic neurones in the PFA and the percentage of time spent awake. 
Furthermore there was a greater change in Fos expression during the daytime in the PFA 
than in the LHA (Estabrooke et al. 2001). 
 
However, there are some data that appear not to support WKHµGLFKRWRP\RIRUH[LQHUJLF
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function¶ theory (Harris and Aston-Jones 2006). There is some evidence that not all 
reward seems to produce an increment of Fos expresion in LHA orexinergic neurones. 
This was reported in a experiment carried out by the authors RIWKHµGLFKRWRP\¶WKHRU\
with a conditioned place preference task using novel objects (Harris et al. 2005). In 
addition, several studies did not find significant differences in the activation of 
orexinergic neurones between LHA and DMH in stress studies with animals (Berridge et 
al. 1999; Espana et al. 2003). Finally in a study of pharmacologically-induced fat 
ingestion (Zheng et al. 2007), and in a reward study where animals were expecting 
chocololate or chow (Choi et al. 2010), there was an increment in the number of orexin-
positive neurones in the PFA but not in the LHA.  
 
$ IXUWKHU SUREOHP IRU WKH µGLFKRWRP\ RI RUH[LQHUJLF IXQFWLRQ¶ WKHRU\ UHODWHV WR WKH
interpretation of some of the behavioural tests that have been used to assess 
reinforcement processes. It has been argued that some of the findings that have been 
attributed to the putative role of orexinergic mechanisms in reinforcement may also be 
interpreted in terms of their role in the control of muscle tone and motor output (Berridge 
et al. 2010; Siegel 2004; 2005) Thus, Berridge et al. (2010) have pointed out that 
increased levels of arousal induced by either aversive or appetitive stimuli may facilitate 
the reinstatement of conditioned place preference (Stewart 2000), and it is therefore 
possible that WKH HIIHFW RI RUH[LQHUJLF PDQLSXODWLRQV RQ µUHZDUG VHHNLQJ¶ (Harris et al. 
2005) may reflect reward-independent changes in arousal rather than changes in the 
value of positive reinforcers (Berridge et al. 2010). 
 
To summarize, it can be said that although there is a consensus about the involvement of 
the orexinergic system in the regulation of sleep and wakefulness, the role of orexins in 
reinforcement processes remains controversial. This suggests that there is a need for 
further investigation of this aspect of orexinergic function.  
 
 
1.3. The central dopaminergic system 
 
1.3.1. Historical background  
 
The neurotransmitter dopamine (2-(3,4-dihydroxyphenyl)ethylamine) was first 
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synthesized by Barger and Ewens in 1910. However, it was thought that this monoamine 
was a mere mediator in the biosynthesis of the catecholamines noradrenaline and 
adrenaline. It was not until 1958 that Carlsson and colleagues demonstrated the existence 
of dopamine in the brain and provided the first evidence for the independence of 
dopamine as a neurotransmitter. These workers used an improved version of the 
fluorimetric method of Von Euler and Floding (1955) in combination with an ion-
exchange chromatography technique. Although dopamine and noradrenaline were found 
to be present in equal concentrations in the central nervous system (CNS) (Carlsson et al. 
1958), the anatomical distributions of the two catecholamines were different. For 
example, dopamine was found in the striatum in high concentrations, whereas there were 
very low concentrations of noradrenaline (Bertler and Rosengren 1959; Dahlstrom and 
Fuxe 1965). Later, the fluorescence histochemical method of Hillarp and Falk enabled 
dopamine to be detected in discrete neuronal pathways (Andén et al. 1966; Dahlstrom 
and Fuxe 1965). The first dopaminergic pathways to be discovered were the 
dopaminergic projections from the substantia nigra (A9 cell group) to the corpus striatum 
and from the VTA (A10 cell group) to the limbic areas of the brain.  
 
During the half-century since its first recognition as a central neurotransmitter, dopamine 
has become in one of the most extensively studied neurotransmiters, due to its crucial 
importance in a wide variety of neurodegenerative and psychiatric disorders, including 
3DUNLQVRQ¶V GLVHDVH VFKL]RSKUHQLD GHSUHVVLRQ GUXJ DGGLFWLRQ DQG DWWHQWLRQ GHILFLW
hyperactivity disorder (for reviews see: Bjorklund and Dunnett 2007; Grace et al. 2007; 
Iversen and Iversen 2007; Marsden 2006).  
 
1.3.2. Anatomy of the dopaminergic pathways  
 
Classically the dopaminergic system has been divided into three principal pathways that 
are described below. 
 
1.3.2.1. The nigrostriatal dopaminergic pathway 
  
This pathway projects from the substantia nigra pars compacta (SNc, the A9 group of 
monoamine-containing neurones) to the dorsal striatum. It plays a critical role in 
organising the functions of the basal ganglia. The principal components of the basal 
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ganglia are: the corpus striatum, which is subdivided into the caudate nucleus and the 
putamen, the globus pallidus, the substantia nigra (see below) and the subthalamic 
nucleus. This group of nuclei participates in the modulation of a broad variety of 
behaviours including learning, working memory and motor control. 
 
The substantia nigra is divided into two cellular groups based on cytoarchitectonic and 
chemical characteristics. The first is the SNc, which is principally composed of 
dopaminergic neurones whose somata project to the striatum (Cebrian et al. 2005). The 
SNc is subdivided again into the dorsal and the ventral tiers  (Haber and Fudge 1997; 
Prensa et al. 2009). The second group is the substantia nigra pars reticulata (SNr) which 
FRQWDLQVWKHFHOOERGLHVRIȖ-aminobutyric acid (GABA)-ergic neurones, innervating the 
pedunculopontine tegmental nucleus, thalamus and the superior colliculus (Halliday and 
Tork 1986; Olszewski and Baxter 1954; Poirier et al. 1983; Prensa et al. 2009). Together 
with the globus pallidus, the SNr provides the principal inhibitory output pathways of the 
basal ganglia (Gerfen 2004).   
 
As discussed below (section 1.3.5.1) the nigrostriatal dopaminergic pathway plays a very 
important role in extrapyramidal motor control. Degeneration of this pathway underlies 
WKHPRYHPHQWGLVRUGHURI3DUNLQVRQ¶VGLVHDVHDQGEORFNDGHRIGRSDPLQHUHFHSWRUVLQWKH
FRUSXV VWULDWXP SURGXFHV µH[WUDS\UDPLGDO PRWRU V\PSWRPV¶ very similar to those 
REVHUYHGLQ3DUNLQVRQ¶VGLVHDVH(Trevitt et al. 1997). 
 
1.3.2.2. The mesolimbic dopaminergic pathway 
  
The mesolimbic dopaminergic pathway projects from the dopaminergic neurones in the 
midbrain ventral tegmental area (VTA: the A10 neuronal group) to the limbic system, 
particularly to the nucleus accumbens, the nuclei of the stria terminalis, some areas of the 
amygdala and hippocampus, lateral septal nuclei, the enthorinal cortex, the mesial and 
orbital frontal cortex and the anterior cingulate cortex. Some authors treat the subcortical 
DQG FRUWLFDO EUDQFKHV RI WKH SDWKZD\ DV VHSDUDWH HQWLWLHV µPHVROLPELF¶ DQG
µPHVRFRUWLFDO¶GRSDminergic pathways). However, there is no compelling evidence that 
the two branches arise from separate neuronal groups within the VTA (Gerfen 2004).  
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The mesolimbic/mesocortical dopaminergic projection has been implicated in a wide 
range of behavioural functions, including arousal, emotional behaviour, motivation and 
reinforcement functions (see sections 1.3.5.2 ± 1.3.5.5). Carlsson (1974) was among the 
first to suggest that overactivity of the mesolimbic dopaminergic projection may be the 
pathophysiological basis of schizophrenia. The antipsychotic efficacy of D2-like 
dopamine receptor antagonists has long been recognized (Seeman et al. 1976); more 
recently the selective blockade of dopamine receptors in limbic structures has been 
proposed as the basis of the superior clinical profile of some atypical antipsychotic drugs 
(Schoemaker et al. 1997) (see also section 1.3.4).  
   
1.3.2.3. The tubero-infundibular dopaminergic pathway  
 
This pathway comprises dopamine-containing cells of the tuberal, arcuate and 
paraventricular nuclei of the hypothalamus that project to the intermediate lobe of the 
pituitary gland and median eminence. This system plays a very important role in the 
regulation of hormone release from the pituitary gland. For example, prolactin release 
from the anterior pituitary is maintained under inhibitory control by tuberoinfundibular 
dopaminergic neurones, the effect of the transmitter being mediated by D2 dopamine 
receptors. As reviewed below (see section 1.3.4), the principal pharmacological action of 
conventional antipsychotic drugs is the antagonism of D2 receptors. A known side-effect 
of these drugs is hyperprolactinemia, which can result in impotence and gynaecomastia 
in sensitive individuals (see Freeman et al 2000; Stahl 2002). 
 
1.3.2.4. Dopamine and the cortico-striato-thalamo-cortical circuits 
 
There is widespread agreement that the cerebral cortex and the basal ganglia are 
FRQQHFWHGE\PXOWLSOHµFRUWLFR-striato-thalamo-cortical (CSTC) circuits¶ (Alexander et al. 
1986, 1990). It is believed that these circuits are, to a large extent, both topographically 
and functionally separate from one another, although it is increasingly recognised that 
some interconnections do exist between them (Gerfen 2004; Haber 2003; Uylings et al. 
2003) 7KH EDVLF SULQFLSOHV RI WKH &67& FLUFXLWV DUH LOOXVWUDWHG E\ WKH µPRWRU ORRS¶ D
diagram of which is shown in Figure 1.1. 
 




































Fig. 1.1. 'LDJUDP RI WKH SULQFLSDO QHXURQDO SDWKZD\V WKDW FRPSULVH WKH µPRWRU ORRS¶
(Alexander et al. 1990). Filled circles are GABAergic neurones; unfilled circles 
glutamatergic neurones; hatched are dopaminergic neurones. Gpi, internal segment of the 
globus pallidus, GPe, external segment of the globus pallidus; PMC, premotor cortex; 
SMA, supplementary motor area; MC, motor cortex; STN, subthalamic nucleus; VL/VA, 
ventral lateral and ventral anterior SNr, substantia nigra pars reticulata ; SNc substantia 
nigra pars compacta. D1-like dopamine receptors are purported to modulate activity in the 
µGLUHFW¶ RXWSXW SDWKZD\ E\ GHSROarising the GABAergic neurones. D2-like dopamine 
UHFHSWRUVPRGXODWHDFWLYLW\LQWKHµLQGLUHFW¶SDWKZD\E\K\SHUSRODULVLQJWKHVHQHXURQHV
Therefore the release of dopamine in the putamen is proposed to have the overall effect 
of suppressing the inhibitory influence of the GPi and the SNr on the thalamic output to 
the motor cortex. 
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Excitatory (glutamatergic) cortifugal fibres project from the motor cortex to the caudate 
nucleus and putamen. These fibres make synaptic contact with medium spiny neurones, 
the most numerous type of neurone of the corpus striatum. These GABAergic neurones 
send inhibitory projections to the output nuclei of the basal ganglia (the internal segment 
RIWKHSDOOLGXP>*3L@DQGWKH61UYLDDµGLUHFWSDWKZD\¶*$%$HUJLFQHXURQHVRIWKH
caudate nucleus and SXWDPHQ SURMHFW GLUHFWO\ WR WKH RXWSXW QXFOHL DQG DQ µLQGLUHFW
SDWKZD\¶ *$%$HUJLF QHXURQHV RI WKH caudate nucleus and putamen project to the 
external segment of the pallidum [GPe], which sends a GABAergic projection to the 
subthalamic nucleus, which in turn sends excitatory efferents to the GPi and SNr). The 
nigrostriatal dopaminergic fibres project to the striatal origins of both the direct and 
indirect output pathways (see Figure 1.1); it is believed that GABAergic neurones of the 
indirect pathway express inhibitory D2-like dopamine receptors, whereas  neurones of the 
direct pathway are believed to mainly express excitatory D1-like receptors (Alexander et 
al. 1990; Gerfen 2004).   
 
In addition WRWKHµPRWRUORRS¶WKHUHLVDQRFXORPRWRUFLUFXLWWKDWLQFRUSRUDWHVWKHIURQWDO
H\H ILHOGV DQG WKUHH µOLPELF FLUFXLWV¶ WKDW FRQQHFW WKH PDMRU UHJLRQV RI WKH SUHIURQWDO
cortex to the ventral striatum. In primates, these prefrontal regions are the dorsolateral 
[DLPFC], medial [MPFC] and orbital [OPFC] prefrontal cortices). It is now generally 
accepted that rats possess functionally specialized prefrontal regions that are homologous 
with the OPFC, MPFC and DLPFC of primates; these are represented by the OPFC, the 
ventral MPFC (vMPFC, including the pre- and infralimbic cortices), and dorsal MPFC 
(dMPFC, including the dorsal anterior cingulate gyrus) (Uylings et al. 2003; Vogt et al. 
2004). In the rat, these regions receive partially segregated input from the mediodorsal 
thalamus (Groenewegen and Witter 2004), and project to different parts of the striatum; 
the OPFC and vMPFC project mainly to the ventromedial striatum (ventral caudate-
putamen and AcbC) (Palomero-Gallagher and Zillies 2004; Vogt et al. 2004) whereas 
there are connections between the dMPFC and the medial dorsal striatum (Gerfen 2004). 
Thus each prefrontal cortical region participates in a separate CSTC circuit. A particular  
IHDWXUHRIWKHVHµOLPELF¶&67&FLUFXLWVLVWKHGXDOLQQHUYDWLRQRIWKHFRUWLFDODQGVWULDWDO
components of the circuits by dopaminergic afferents from the VTA (Bjorklund and 
Lindvall 1984; Tzschentke 2001). In general, the dopaminergic input is denser in the 
striatum than in the prefrontal cortex, and dopamine uptake appears to play a less 
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important role in the inactivation of dopamine in the cortex than in the striatum (see 
below, section 1.3.3). 
  
It is widely believed that the various CSTC circuits subserve different behavioural 
functions. In man, damage to the DLPFC is commonly associated with cognitive 
dysexecutive symptoms, MPFC lesions with disturbances of motivation and emotion, and 
OPFC lesions with impulsive/disinhibited behaviour (Tekin and Cummings 2002). 
Behavioural specialization of CSTC circuits has also been demonstrated in the rat 
(Cardinal et al. 2002; Robbins and Everitt 2002; Uylings et al. 2003). For example, 
lesions of the medial and lateral striatum and its input from the dMPFC have been found 
to produce deficits in attentional performance  (Christakou et al. 2001; Rogers and Hagan 
2001); lesions of the vMPFC have been found to impair detection of instrumental 
contingencies (Balleine and Dickinson 1998); and lesions of the OPFC and AcbC can 
impair detection of changes of reinforcer value (Gallagher et al. 1999) and disrupt inter-
temporal choice (Bezzina et al. 2008a; Bezzina et al. 2007; da Costa Araújo et al. 2009; 
Kheramin et al. 2002). 
 
1.3.3. Synthesis and metabolism of dopamine 
 
The synthesis of dopamine (see Cooper et al 2003; Elsworth and Roth 1997) starts with 
the dietary amino-acid tyrosine. Tyrosine is accumulated in dopaminergic neurones by an 
energy-dependent uptake mechanism. In the dopaminergic neurones tyrosine is converted 
into 3,4-dihydroxyphenylalanine (L-DOPA) by the action of the enzyme tyrosine 
hydroxylase (TH), which is the rate-limiting step in the synthesis of dopamine (Nagatsu 
et al. 1964). L-DOPA is the immediate precursor of dopamine; conversion of L-DOPA to 
dopamine is brought about by the non-specific enzyme, L-aromatic amino acid 
decarboxylase. This process occurs so rapidly that levels of L-DOPA in the brain are 
virtually undetectable (see Cooper et al 2003). The production of dopamine can be 
increased by the administration of L-DOPA. In contrast, administration of tyrosine does 
not reliably increase the level of dopamine as, in normal circumstances, tyrosine 
concentrations are high in the brain and well above the dissociation constant of the 
enzyme TH; in other words, the enzymatic process that converts tyrosine to L-DOPA is 
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close to saturation under normal physiological conditions (see Cooper et al 2003; 
Elsworth and Roth, 1997; Squirrel et al 2001).  
 
Once dopamine is synthesised, it is stored in vesicles, which protects it from enzymatic 
degradation in the cytosol. Endogenus mechanisms regulate the synthesis of dopamine by 
altering the rate of conversion of tyrosine to L-DOPA by the enzyme TH. Dopamine and 
other catecholamines act as end-products that directly inhibit TH. The rate of L-DOPA 
production by TH is also regulated by presynaptic dopamine autoreceptors which are 
activated by the release of dopamine from nerve terminals. (See Cooper et al 2003; 
Squirel et al 2008; Deutch et al 2004). 
 
Synaptically released dopamine acts at a variety of post-synaptic receptors (see below). 
Inactivation of released dopamine is brought about principally by re-uptake into 
dopaminergic neurones via a high-affinity dopamine transporter (DAT) (Amara and 
Kuhar 1993; Gainetdinov and Caron 2003). DAT molecules are most abundant in the 
terminal membrane close to the synaptic cleft. However they are also found outside the 
synaptic cleft, which may indicate that DAT inactivates dopamine molecules that escape 
from the synaptic region. Psychostimulant drugs such cocaine or amphetamine bind to 
DAT,  preventing dopamine transport and uptake (Mortensen and Amara 2003).   
 
Once dopamine is released, it can be converted into three metabolites (see Cooper et al 
2003). In the basal ganglia, the principal mode of inactivation consists of reuptake via 
DAT. Following reuptake, dopamine is either re-stored in vesicles or metabolised by the 
mitochondrial enzyme monoamine oxidase to dihydroxyphenylacetic acid (DOPAC). 
However, in some areas of the brain which contain relatively little DAT (e.g. the 
prefrontal cortex), dopamine is mainly metabolized extracellularly by catechol-O-
methyltransferase (COMT) to form 3-methoxytyramine (3-MT). Both DOPAC and 3-MT 
are finally metabolised to homovanillic acid (HVA).  
 
1.3.4. Dopamine receptor pharmacology 
 
The first indication of the presence of specific dopamine receptors in the central nervous 
system was the demonstration of the activation of adenylyl cyclase by dopamine, first in 
the pituitary and then in the brain. This was followed by the discovery of a common 
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binding site for dopamine and neuroleptic (antipsychotic) drugs including phenothiazines 
(e.g. chlorpromazine) and butyrophenones (e.g. haloperidol) (see Kebabian et al. 1972; 
Seeman et al. 1976). Although this site was first named the neuroleptic receptor, its name 
was changed to the dopamine receptor site (Kebabian and Calne 1979). Studies of the 
regional distribution of dopamine receptors showed that dopamine receptors occur both 
postsynaptically and presynaptically (autoreceptors located on  dopaminergic neurones). 
At the same time, functional studies led to the classification of dopamine receptors based 
on whether or not dopamine receptor stimulation led to an increase in the production of 
cyclic adenosine monophosphate (cyclic AMP) by the enzyme adenylyl cyclase. 
Dopamine receptors coupled positively to adenylyl cyclase came to be known as D1 
receptors, and dopamine receptors whose stimulation either inhibited or not affect 
adenylyl cyclase as D2 receptors. This classification was used until the new techniques of 
gene cloning were developed, which extended this classification to five subtypes (D1 ± 
D5 UHFHSWRUV ZKLFK KDYH EHHQ JURXSHG LQWR WZR µVXEIDPLOLHV¶ of G-protein coupled 
(metabotropic) receptors, the D1-like subfamily (including D1 and D5 receptors), and the 
D2-like subfamily (including D2, D3 and D4 receptors) (see Misale et al 1998; Cooper et 
al 2003; Alexander et al. 2009).  
 
Understanding of the functions mediated by dopamine receptors has been greatly 
factilitated by the development of selective dopamine receptor agonist and antagonist 
drugs. It has been shown that dopamine receptors with the same pharmacological features 
may have different metabolic effects depending on the area of the brain in which they are 
expressed. For instance the D2 receptors are found in the nucleus accumbens and the 
dorsal striatum; stimulation of these receptors has no effect on adenylyl cyclyse activity 
in the accumbens, whereas it inhibits the enzyme in the dorsal striatum.   
 
1.3.4.1. D1 dopamine receptors                                                                                                                                 
 
D1 receptors are principally found in caudate nucleus, putamen, nucleus accumbens, 
olfactory tubercle and amygdala. The fact that this receptor has not been found in the 
substantia nigra or VTA may indicate that this receptor does not act as an autoreceptor 
(see Cooper et al 2003; Meador-Woodruff 1994). This receptor binds benzazepines with 
high affinity, including the full agonist SKF-81297 (6-chloro-1-phenyl-2,3,4,5-
tetrahydro-1H-3-benzazepine-7,8-diol) (Andersen and Jansen 1990; Arnt et al. 1992; 
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Izenwasser and Katz 1993) and the antagonists SKF-83566 (bromo-2,3,4,5-tetrahydro-3-
methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide) and SCH-23390 (7-chloro-8-
hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine) (Molloy et al. 1986; 
Vieira-Coelho and Soares-da-Silva 2000; Waddington 1986). 
 
1.3.4.2. D2 dopamine receptors 
 
These receptors are widely expressed throughout the brain. They are present in the 
substantia nigra, VTA, and hypothalamus. They are also highly expressed in the caudate 
nucleus, putamen, nucleus accumbens, olfactory tubercle, and various regions of the 
cerebral cortex (see Cooper et al 2003; Meador-Woodruff 1994). In the substantia nigra, 
VTA and hypothalamus, D2 receptors are present on dopaminergic neurones of the 
nigrostriatal, mesolimbic and tuberoinfundibular dopaminergic pathways. Stimulation of 
these D2 autoreceptors inhibits dopamine release.  
 
D2 receptors have a high affinity for µFRQYHQWLRQDO¶ DQWLSV\FKRWLF Qeuroleptic) drugs. 
These drugs, especially the butyrophenones (e.g. haloperidol and spiperone) and the 
benzamides (e.g. sulpiride, amisulpride, eticlopride and raclopride) are highly selective 
antagonists of the D2-like UHFHSWRU µVXEIDPLO\¶ EXW KDYH VLPLOar affinities for different 
PHPEHUV RI WKH µVXEIDPLO\¶ 2WKHU µFRQYHQWLRQDO¶ DQWLSV\FKRWLFV IRU H[DPSOH WKH
phenothiazines (e.g. chlorpromazine) have more complex pharmacological profiles, 
although the ability to block D2-like receptors is a prominent feaWXUHRIDOOµFRQYHQWLRQO¶
antipsychotics (Lawler et al. 1999; Moreland et al. 2004; Patel et al. 1997; Perrault et al. 
1997; Schotte et al. 1996; Seeman and Van Tol 1994; Sokoloff et al. 1990; Van Tol et al. 
1991).  
 
Selective agonists exist for D2-like receptors, but none of these shows clear distinction 
between D2, D3 and D4 receptors (see below). Among the most extensively studied of 
these agonists are quinpirole and bromocriptine (Seeman and Van Tol 1994; Sokoloff et 
al. 1990; Van Tol et al. 1991).     
 
1.3.4.3. D3 dopamine receptors 
 
D3 receptors are principally found in the nucleus accumbens, in contrast to the dorsal 
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striatum, where D2 receptors predominate over D3 receptors. Other areas where D3 
receptors are expressed, but to a lesser extent, include the substantia nigra and VTA 
(where they may act as autoreceptors) (see Meador-Woodruff 1994). The D2-like 
receptor agonists 7-OH-DPAT ((+)-7-hydroxy-2-aminopropylaminotetralin) shows some 
preference for D3 over D2 receptors (Mulder et al. 1987; Seeman and Van Tol 1994). 
Nafadotride is a D3 receptor antagonist with a somewhat lower affinity for D2 than D3 
receptors (Fliestra and Levant 1998; Pilla et al. 1999). Conventional antipsychotics show 
little selectivity for D2 over D3 receptors (Alexander et al. 2009).  
 
1.3.4.4. D4 dopamine receptors 
 
The D4 receptors are the least abundantly expressed of all receptors in the D2-like 
receptor subfamily (Jaber et al. 1996). D4 receptors are expressed in the cortex, 
hypothalamus, amygdala, thalamus and cerebellum (Meador-Woodruff 1994). Most 
conventional antipsychotics are effective D4 receptor antagonists, although sulpiride and 
eticlopride show a modest preference for D2 and D3 receptors over D4 receptors (Seeman 
and Van Tol 1994). Some atypical antipsyhcotics (e.g. clozapine) have high affinity for 
the D4 receptor, in contrast to benzamides (e.g. sulpiride). A relatively selective D4 
receptor antagonist is L-745870 (3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1H-
pyrrolo[2,3-b]pyridine), which is effective in some animal models of executive function 
(Zhang et al. 2004; Moustgaard et al. 2008). Sonepiprazole (U-101,387) is another potent 
D4 receptor antagonist which has does not block amphetamine-induced locomotor 
activity, and does not produce the extrapyramidal effects caused by D2 receptor 
antagonists (Merchant et al. 1996). A full potent agonist at D4 receptors WAY-100635 (N 
-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide), a 
drug better known for its potent action as a 5-HT1A receptor antagonist (Marona-Lewicka 
and Nichols 2009).  
 
1.3.4.5. D5 dopamine receptors 
 
These receptors are expressed in a few areas of the brain including the hippocampus, 
thalamus and hypothalamus (Meador-Woodruff 1994). At present there are few selective 
ligands available which allow studying the functional differences between D1 and D5 
receptors, and few data are available at the present time about the specific properties of 
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the D5 receptor (Giorgioni et al. 2008). There are no selective agonists for D5 receptors, 
but 4-Chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol has been reported 




Henri Laborit was the first to use chlorpromazine as a tranquilizer agent for patients 
undergoing surgical procedures. Soon this drug and other phenothiazines, and later 
butyrophenones (e.g. haloperidol), were used to treat the positive symptoms associated 
with schizophrenia (Kane 1989). This group of drugs are known as the µtypical¶
µFRQYHQWLRQDO¶RUµILUVWJHQHUDWLRQ¶antipsychotics (see King and Waddington 2004). The 
high affinity of conventional antipsychotics for D2-like receptors, and the similar order of 
potency of these drugs in receptor binding studies and in clinical practice (Seeman et al. 
LVRQHRIWKHFRUQHUVWRQHVRIWKH³GRSDPLQHWKHRU\´RIVFKL]RSKUHQLDZKLFKSRVLWV
that schizophrtenia is associated with hyperactivity in the mesolimbic/mesocortical 
dopaminergic pathway, which may be corrected by blockade of D2-like receptors in the 
cerebral cortex and subcortical limbic structures (see King and Waddington 2004).  
 
A major shortcoming of typical antipsychotic drugs in clinical practice is their propensity 
to produce extrapyramidal side-effects. It is generally agreed that these side-effects arise 
from blockade of D2-like receptors in the dorsal striatum, the target region of the 
nigrostriatal dopaminergic pathway (see Cunningham-Owens 1999). Another 
shortcoming of these drugs is that they are not effective in treating the negative 
symptoms of schizophrenia (see King and Waddington 2004). ,QFRQWUDVWWKHµDW\SLFDO¶
antipsychotics drugs, also known as second-generation antipsychotics (e.g. clozapine, 
quetiapine, olanzapine) are less liable to induce extrapyramidal side-effects, and are 
claimed to be more effective in treating the negative symptoms and cognitive deficits of 
schizophrenia (Corrigan et al. 2003; Müller-Spahn 2002). 
 
7KH ILQGLQJ WKDW µDW\SLFDO¶ DQWLSV\FKRWLFV have lower affinity for D2-like receptors and 
also have high affinity for other types of receptor, including 5-hydroxytryptamine-2 (5-
HT2) receptors has led some authors to question the central role of D2-like receptors in 
antipsychotic action (Meltzer et al. 1989), although other authors still regard antagonism 
of D2-like receptors as the key common feature of all antipsychotic drugs (Kapur et al. 
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2000).  
 
Several competing explanations have been proposed for the clinical efficacy of atypical 
antipsychotics. One theory proposes that effective antipsychotic action requires the dual 
action of blockade of D2-like dopamine receptors and blockade of 5-HT2A and/or 5-HT2C 
receptors, a profile exemplified by clozapine (Meltzer et al. 1989; Meltzer 1995). Other 
writers have pointed to the differential effects of typical and atypical antipsychotics on 
different subtypes of D2-like receptors: atypical antipsychotics (such as clozapine) act 
preferentially on D3 and D4 receptors, which are found mainly in the limbic system (see 
above), whereas the typical antipsychotics (such as haloperidol) act mainly at the D2 
receptors which are predominantly found in the caudate and putamen (see above) (see 
Cooper et al 2003; Kandel et al 2000; Mailman and Murthy 2010; Squirel et al 2008).  
 
Yet another theory proposes that a final common pathway of the action of atypical 
antipsychotics is 5-HT1A receptor-mediated release of dopamine in the medial prefrontal 
cortex (Bantick et al. 2001; Ichikawa et al. 2001; Chou et al. 2003).  However, although 
clozapine is known to act as a partial agonist at 5-HT1A receptors, not all atypical 
antipsychotic drugs share this action. Moreover, some behavioural effects of clozapine 
that had been attributed to 5-HT1A receptor stimulation have been found not to be 
antagonized by the 5-HT1A receptor antagonist WAY-100635 (see Zhang et al. 2005a, 
2005b). 
 
Aripiprazole has been described as belonging to a third generation of antipsychotics. Like 
clozapine, this drug has a prefential high affinity for D2 and D3 receptors and also 5HT1A, 
5HT2A and 5HT2B receptors. However, in contrast to clozapine, aripiprazole acts as a 
partial agonist at D2-like receptors (Lawler et al. 1999; Davies et al. 2004; DeLeon et al. 
2004). It has been proposeG WKDW WKLV SURSHUW\ RI DULSLSUD]ROH HQDEOHV LW WR µVWDELOL]H¶
dopaminergic function, elevating hypo- and suppressing hyper-dopaminergic activity 
(Byars et al. 2002; Potkin et al. 2003). Although there is some debate about the 
mechanism of action, it seems to be effective on treating both positive and negative 
symptoms of schizophrenia (Mailman and Murthy 2010; Swainston Harrison and Perry 
2004). 
 
,QVXPPDU\ WKHSKDUPDFRORJLFDODFWLRQVRIµW\SLFDO¶DQWLSV\FKRWLFV LVZHOOHVWDEOLVKHG; 
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these drugs are all antagonists of D2-like dopamine receptors, and a strong case can be 
made for attributing both their therapeutic and their adverse effects to this action. In 
FRQWUDVWµDW\SLFDO¶DQWLSV\FKRWLFVKDYHFRPSOH[DQGYDULHGSKDUPDFRORJLFDOSURILOHVDQG
a unified theory of their mode of action remains elusive (see King and Waddington 2004; 
see Chapter 5 for further discussion).  
 
1.3.5. The behavioural role of dopamine 
 
Dopamine is a neurotransmitter which is implicated in a wide number of behaviours, 
some of the most important of which are described below. 
 
1.3.5.1.  Dopamine and motor function 
 
One of the most important pieces of evidence for the involvement of dopamine in the 
FRQWURORIPRWRUIXQFWLRQVFDPHIRUWKHVWXGLHVRI3DUNLQVRQ¶VGLVHDVHin humans, which 
involves degeneration of the nigrostriatal dopaminergic pathway (see Robbins and 
Everitt 2002). 3DUNLQVRQ¶V GLVHDVH LV FKDUDWHUL]HG E\ D SURJUHVVLYH GHSOHWLRQ RI
dopaminergic neurones from the SNc. Patients suffering from 3DUNLQVRQ¶V GLVHDVH
experience muscular rigidity, tremor, difficulties with the initiation of movement and loss 
of postural reflexes (see Cooper et al 2003; Kandel et al 2000). The principal treatment 
PRGDOLW\ IRU 3DUNLQVRQ¶V GLVHDVH LV V\VWHPLF WUHDWPHQW ZLWK /-DOPA, the precursor of 
dopamine. Although the precise mechanism of L-'23$¶V WKHUDSHXWLF HIILFDF\ LV
uncertain, it is generally agreed that it results in a restoration of striatal dopaminergic 
function (see Tintner and Jankovic 2002).  
 
7KHLQYROYHPHQWRIWKHGRSDPLQHV\VWHPLQ3DUNLQVRQ¶VGLVHDVHKDVDOVREHHQPRGHOOHG
in animals. A widely employed model in early research in this area was the µWXUQLQJ
URGHQW¶PRGHOLQZKLFKUDWVUHFHLYHGXQLODWHUDO injections of the selective neurotoxin 6-
hydroxydopamine (6-OHDA) into the SNc or caudate nucleus (Ungerstedt 1971b; c). 
This results in unilateral degeneration of the nigrostriatal dopaminergic pathway. The 
lesion does not result in gross abnormality of spontaneous locomotor behaviour. 
However systemic treatment with a postsynaptically acting dopamine receptor agonist 
(e.g. apomorphine) causHVWKHUDWWRURWDWHFRQWUDYHUVLYHO\LHµDZD\IURP¶WKHOHVLRQHG
side), due to asymmetrically enhanced receptor stimulation in the lesioned hemisphere 
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FDXVHG E\ UHFHSWRU µXSUHJXODWLRQ¶ IROORZLQJ the loss of dopaminergic afferents in the 
striatum. In conWUDVWV\VWHPLFWUHDWPHQWZLWKDQµLQGLUHFWDJRQLVW¶HJd-amphetamine), 
which releases endogenous dopamine from presynaptic terminals, produces ipsiversive 
rotational behaviour due to asymmetrically reduced receptor stimulation in the lesioned 
hemisphere caused by loss of dopaminergic terminals from the lesioned side (Blandini et 
al. 2008; Meredith and Kang 2006). Interestingly, although rats with unilateral dopamine 
depleting lesions generally show near-normal spontaneous locomotor behaviour, bilateral 
6-OHDA lesions render rats severely hypokinetic and aphagic; death from starvation may 
ensue unless the rats are manually fed (Ungerstedt 1971 a,b,c).  
 
In general, increased dopaminergic activity tends to produce behavioural hyperactivity 
whereas suppression of dopaminergic activity has the opposite effect. Very high doses of 
d-amphetamine and dopamine receptor agonists induce stereotyped behaviours (such as 
licking or self-chewing) whereas lower doses produce increments of locomotor 
behaviour (Jackson and Westlind-Danielsson 1994). Stereotyped behaviours are believed 
to be caused by overstimulation of dopamine receptors in the dorsal striatum, whereas 
hyperlocomotion is mediated by an increase of dopaminergic activity in the nucleus 
accumbens (Joyce and Iversen 1984; Kelley et al. 1989; Kelley et al. 1988; Kelly and 
Iversen 1976; Kelly et al. 1975; Koob et al. 1978; Solomon and Staton 1982). 
 
Locomotor activity can be induced by the administration of both D1-like (Desai et al. 
2005; Nergardh et al. 2005) and D2-like receptor agonists (Eilam and Szechtman 1989; 
Van Hartesveldt et al. 1992) and the opposite effects are produced by the administration 
of the respective antagonists (Hoffman and Beninger 1985; Jackson et al. 1989a; Jackson 
et al. 1989b; Jackson and Westlind-Danielsson 1994; Wanibuchi and Usuda 1990). The 
dopaminergic input to WKH µPRWRU ORRS¶KDVEHHQGLVFXVVHd earlier (section 1.3.2.4). As 
LQGLFDWHGDERYHVWULDWDOQHXURQHVRIWKHµGLUHFW¶SURMHFWLRQDUHWKRXJKWPDLQO\WRH[SUHVV
excitatory D1 receptors; while QHXURQHV RI WKH µLQGLUHFW¶ ORRS DUH EHOLHYHG PDLQO\ WR
express inhibitory D2 receptors. Since the direct and indirect pathways are believed to 
exert opposing effects on the striatal output structures (SNr and GPi), the two receptor 
populations may be expected to exert summatory effects on overall striatal output. This 
may account for the qualitatively similar effects of D1-like and D2-like receptor agonists 
and antagonists on motor functions (see Gerfen 2004).  
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1.3.5.2. Dopamine and arousal and the sleep/wakefulness cycle 
 
Until recently, little attention was paid to dopamine in the regulation of the 
sleep/wakefulness cycle despite the fact that it was known that dopamine modulates sleep 
and waking (Monti and Monti 2007). In part, this was due to the fact that the firing rate 
of dopaminergic cells in the substantia nigra and VTA had been reported not to change 
with behavioural state (Hobson et al. 2000). Nevertheless Lu et al (2006) recently 
reported that in the periaquiductal gray area (which projects to areas related with sleep-
wake control) there are µwake-active¶ dopaminergic neurones. It was hypothesized that 
these dopaminergic neurones formed part of the monoaminergic ascending wake-
promoting arousal system, along with the 5-HTergic, noradrenergic, orexinergic and 
histaminergic neurones of the dorsal raphé, locus coeruleus, lateral and/or perifornical 
hypothalamic areas, and tuberomammillary nucleus, respectively (Saper et al. 2005).  
 
Dopamine concentration during rapid-eye-movement (REM) sleep and the waking state 
is higher in the accumbens and prefrontal cortex than during non-REM (slow wave, 
SWS) sleep (Lena et al. 2005). There is also evidence from studies with mice that show 
abnormally high dopamine levels during REM sleep. This abnormality can be reversed 
by D2 receptor antagonists. Electrophysiological recordings from neurones of the VTA 
and SNc indicate that the mean firing rate varies little across the sleep/wakefulness cycle; 
however there are changes in the pattern of firing, characterized by increases in burst 
firing during wakefulness and REM sleep compared to SWS (Monti and Jantos 2008). 
 
There is also clinical evidence for an important role of dopamine in sleep and 
wakefulness. Daytime sleepiness associated with narcolepsy can be treated with 
amphetamine and related drugs, one of whose actions is to promote dopamine release 
(Mitler et al. 1994). Furthermore, it LVNQRZQWKDWSDWLHQWVZLWK3DUNLQVRQ¶VGLVHDVHand 
schizophrenia often have associated sleeping problems such as day-time sleepiness and a 
REM sleep disorder (Adler 2005; Gagnon et al. 2002; Miller et al. 1983; Tandon et al. 
1992).  
 
Behavioural findings in animals are also consistent with a role of dopamine in sleep. 
Pharmacological manipulation using D1-like receptor agonists not only induces 
locomotor activity (see previous section), but also promotes waking and reduces both 
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REM and SWS in rats.  This effect can be reversed by D1-like receptor antagonists (Bo et 
al. 1988; Kropf and Kuschinsky 1993; Monti et al. 1990; Ongini et al. 1993; Ongini et al. 
1985; Trampus et al. 1993; Trampus and Ongini 1990). D2-like receptor agonists 
(quinpirole and bromocriptine) also induce SWS and REM sleep at low doses in rats, 
whereas high doses produce the opposite effect. Both these effects can be blocked by the 
D2-like receptor antagonist haloperidol (Isaac and Berridge 2003; Monti et al. 1988; 
Monti et al. 1989; Ongini et al. 1993). The opposite effects of low and high doses of D2-
like receptor agonists may be explained by a preferential effect of lower doses at D2-like 
autoreceptors on neurones of the VTA and SNc, the less sensitive post-synaptic receptors 
being stimulated only by higher doses (see Monti and Monti 2007). 
 
In summary, although there is a strong body of evidence that shows that the dopamine 
system modulates the sleep/wakefulness cycle, the exact mechanism of this interaction is 
not fully understood at present (see Monti and Monti 2007; Saper et al. 2005; Schwartz 
and Roth 2008; Squire et al 2008). 
 
1.3.5.3. Dopamine and food intake  
 
The homeostatic system in the hypothalamus responds to metabolic and satiation signals 
from the intestine. This system controls the amount of food intake in accordance with the 
energetic need of the organism (Abizaid et al. 2006a; Morton et al. 2006). However, in 
conditions where high caloric food is available and little effort is required to obtain it, 
this system is insufficient to explain the overcomsuption of food (Berthoud 2004). One 
growing idea is that D µreward system¶, which evolved during times when food was 
scarce, takes control over the homeostatic system. This reward system is assumed to 
respond not only to food but also to the smell, taste, sight or any other sensory cue that 
predicts it (Palmiter 2007). It has long been suspected that the mesolimbic dopaminergic 
pathway, especially the projection from the VTA ro the nucleus accumbens, plays a 
pivotal role in thiVK\SRWKHWLFDOµreward system¶ (Kalivas and Volkow 2005; Stricker and 
Zigmond 1984; Volkow and Wise 2005; Wang et al. 2001; Wise 2006; Yamamoto 2006).  
 
The first evidence that implicated the dopaminergic system in the regulation of food 
intake came from studies of the effects of centrally administered 6-hydroxydopamine (6-
OHDA) (Ungerstedt 1971a). When administered intraventricularly or injected into the 
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substantia nigra, this neurotoxin reduced food intake and body weight (Ungerstedt 1971a; 
Zigmond and Stricker 1972). This led some authors to hypothesize that dopaminergic 
neurones in the midbrain specifically participate in the control of the motivation to eat 
(Volkow and Wise 2005; Wise 2004(b); 2006), and that the effects of dopamine 
depletion resembled the lateral hypothalamic syndrome (see Squire et al 2008). Further 
evidence for an involvement of the dopaminergic system in the regulation of food intake 
came from demonstrations that feeding induced by electrical stimulation of the lateral 
hypothalamus (Phillips and Nikaido 1975) or by food deprivation  (Wise and Colle 1984; 
Wise et al. 1978b) could be blocked by systemic administration of  the D2-like receptor 
antagonist pimozide. More recent studies using genetically modified mice lacking the 
enzyme tyrosine hydroxylase, which converts tyrosine to DOPA (see section 1.3.3), 
showed that these animals suffered from adipsia and aphagia which, if untreated, led to 
premature death. However, injection of L-DOPA allowed the animals to survive 
(Palmiter 2007; Zhou and Palmiter 1995).   
 
Early studies of the role of dopamine in food intake focused on the nigrostriatal 
pathways. It was noted that in 3DUNLQVRQ¶V GLVHDVH, a disorder in which this pathway 
degenerates, there is frequently marked weight loss (Durrieu et al. 1992). However, it can 
be argued that this effect may be due to the associated cognitive and movement deficits 
associated with the condition (Bachmann and Trenkwalder 2006; Hodge and Butcher 
1980). There are also some disagreements about the results of animal studies. It has long 
been known that lesions of the SNc in rodents produce body weight loss (Baez et al. 
1977) and reduce food intake (Smith et al. 1972; Ungerstedt 1971b). However, more 
recent studies have shown that partial lesions of the SNc produce motor impairment but 
not feeding deficits or body weight loss (Pioli et al. 2008). Furthermore, animals lacking 
striatal dopamine will consume normal food if it is placed in the mouth (Cannon and 
Palmiter 2003). This led to the suggestion that the nigrostriatal pathway is needed for 
feeding-related behaviour, including goal-directed  movement and food seeking 
behaviour, rather than food intake per se (Palmiter 2008). 
  
More recent work has generally focused on the mesolimbic dopaminergic pathway. It has 
been suggested that the VTA is involved in food motivation (Papp and Bal 1986; 1987), 
drug self-administration (Corrigall et al. 1992), goal-directed behavior, motor control, 
and the recognition of rewarding stimuli (Narayanan et al. 2010), rather than feeding 
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behaviour itself.  
 
Pharmacological manipulation of dopaminergic neurones in the VTA affects food intake 
(Ljungberg et al. 1992; MacDonald et al. 2004; Naleid et al. 2005). Furthermore, 
microdialysis experiments report alteration of dopamine levels in the nucleus accumbens 
when the LHA or VTA are stimulated or in response to food intake (Bassareo and Di 
Chiara 1999; Church et al. 1987; Hernandez and Hoebel 1988). Electrophysiological 
studies have shown that the mesolimbic dopaminergic system is activated during search 
for food (Schultz 1997; 2007) and in the presence of food reinforcers  (Hyland et al. 
2002); Romo and Schultz 1990; Schultz and Romo 1990). In addition dopaminergic 
neurones respond to unexpected and novel rewards (Ljungberg et al. 1992; Mirenowicz 
and Schultz 1994). All these data suggest that the mesolimbic dopaminergic system is 
more involved with food reward processes rather than food consumption itself 
(Narayanan et al. 2010). 
 
The dopaminergic target areas have also been the object of study in relation with food 
intake. For instance accumbal dopamine depletion has no effect on feeding (Salamone et 
al. 1993; Weissenborn and Winn 1992); in contrast, it markedly affects food-reinforced 
lever pressing in operant behaviour tasks (Ishiwari et al. 2004; Roberts et al. 1977; 
Salamone et al. 2003). D1/D2 receptor antagonists injected in the nucleus accumbens 
affect locomotor behaviour but not total food consumption (Baldo et al. 2002). These 
data support the idea that the mesolimbic dopaminergic system is related with µHIIRUW-
related feeding behaviour¶ but not with free feeding (Salamone et al. 2007). In contrast, 
dopamine depletion in nigrostriatal projection regions, including the lateral striatum, 
decreases feeding (Salamone et al. 1993). Other dopaminergic projection areas, including 
the amygdala and prefrontal cortex, appear not to be crucial for the regulation of free 
feeding (see Narayanan et al 2010). 
 
The dopaminergic system in the midbrain is also affected by circulating hormones which 
are involved in food intake and energy metabolism. These hormones include leptin, 
insulin and ghrelin. 
 
Leptin is an anorexigenic hormone synthesised in the adipose tissue which circulates in 
the blood; its level is proportional to the fat content in the body (Palmiter 2007). Leptin 
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has a powerful action on dopaminergic neurones; when administered directly into the 
VTA, it decreases both food intake and the firing of dopaminergic neurones. Moreover 
leptin UHFHSWRU µknockdown¶ mice, which lack leptin receptors in the VTA, consumed 
more food but did not gain body weight in comparison to control mice (Hommel et al. 
2006).  
 
Insulin is an anorexigenic hormone produced in the pancreas which is crucial for the 
regulation of circulating glucose. Insulin levels are increased after food ingestion,  
promoting the use of glucose by the tissues (Palmiter 2007). There is evidence that 
relates insulin with the dopamine system. Insulin receptors are co-localized with insulin 
receptors on dopaminergic neurones of the VTA, and central insulin administration 
promotes dopamine uptake in the VTA. Behavioural studies have shown that 
intraventricularly administered insulin reverses the effect of food deprivation on operant 
performance rewarded by food or electrical brain stimulation, suggesting that insulin 
receptors may contribute to the regulation of central motivational processes (Figlewicz 
2003; Figlewicz et al. 2003).  
 
Ghrelin is an orexigenic peptide hormone which is produced in the stomach. 
Dopaminergic neurones of the VTA express ghrelin receptors (Abizaid et al. 2006) (see 
also Narayanan et al 2010; and Palmiter 2007). When administered into the VTA or 
nucleus accumbens ghrelin produces an increment of food intake (Abizaid et al. 2006; 
Naleid et al. 2005).  
 
In summary, the evidence reviewed in this section clearly indicates that pharmacological 
and endocrinological manipulation of the mesolimbic dopaminergic pathway can alter 
food intake. Although it remains unclear exactly what behavioural processes underlie 
these effects, there is a growing body of evidence for dopaminergic regulation of 
motivation and/or reinforcement processes, rather than a direct control of ingestive 
behaviour (see Palmiter 2007; Narayanan 2010).  
  
 
1.3.5.4. Dopamine and reinforcement and drug addiction 
 
Some clarification is needed in order to distinguish the different uses of the terms 
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µreward¶ and µreinforcer¶. For instance, Salamone et al (2007) defined reinforcement as 
follows: ³Positive reinforcement refers to a process by which a response is followed by 
the presentation of stimulus that typically is contingent upon that response; these events 
are followed by an increase in the probability of the occurrence of that response in the 
future´  Although from the Skinnerian point of view the term µUHLQIRUFHU¶ does not 
include any subjective or emotional connotation, its use in the literature generally implies 
a motivational component (Salamone and Correa 2002). The term µreward¶ is often used 
LQWHUFKDQJHDEO\ ZLWK µUHLQIRUFHPHQW¶ DOWKRXJK WKH IRUPHU WHUP XVXDOO\ FDUULHV
connotations of emotions and feeling of pleasure (Everitt and Robbins 2005; Wang et al. 
2009). 
 
The notion that catecholaminergic neurotransmission may play a key role in the 
rewarding properties of food and other reinforcers has a long history. Initially, interest 
was focused on the noradrenergic system (Stein 1968). Later research placed greater 
emphasis on the dopaminergic system, although a contributory role of the noradrenergic 
system was supported by a substantial body of evidence (see Crow and Deakin 1985; 
Bradshaw and Szabadi 1989). The µdopamine K\SRWKHVLVRIUHZDUG¶Wise 1978, 1982) 
arose from findings on the effects of 6-OHDA-induced lesions of the dopaminergic 
pathways (Fibiger 1978) and effects of neuroleptics (conventional antipsychotics) on 
operant learning and on operant performance maintained by positive reinforcers (Wise 
1982). The dopamine hypothesis of reward (Wise 1978) claims that the dopaminergic 
system, in particular the dopaminergic input to the nucleus accumbens, actively 
participates in the rewarding properties of natural rewards such as water, food and sex. In 
addition this system is presumed to be activated by drugs of abuse (Wise 2004(b)). The 
K\SRWKHVLVLQFRUSRUDWHVWKHPRUHUHVWULFWHGµDQKHGRQLDK\SRWKHVLVRIQHXUROHSWLFDFWLRQ¶
(Wise 1982), which proposes that neuroleptics reduce the rewarding impact of 
reinforcers by blocking D2-like receptors. 
 
The origin of these hypotheses can be traced to original experiments that showed that rats 
could be trained to work for brain stimulation reinforcement, in electrical self-stimulation 
paradigms, when certain areas of the brain were stimulated (Olds and Milner 1954). Olds 
and Milner (1954) indentified areas localized in the LHA and surrounding areas which 
would support self-stimulation; these DUHDVFDPHWREHNQRZQDVµSOHDVXUHFHQWUHV¶ (Olds 
1956). The importance of dopamine for self-stimulation received support when the 
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dopamine system was targeted using antipsychotics. These drugs reduced electrical self-
stimulation, whereas amphetamine increased self-stimulation (Olds and Travis 1960; 
Stein 1962). The effects of these drugs on food-reinforced behaviour parallelled their 
effects on operant behaviour maintained by electrical brain stimulation (Wise 1982).  
 
The anhedonia hypothesis of neuroleptic action (Wise 1982) encountered controversy 
since it was first created. The detractors of the theory argued that the apparent 
µanhedonia¶ effects mainly reflected motor deficits rather than reward related deficits 
(Ahlenius 1995; Freed and Zec 1982; Gramling et al. 1984; Koob 1982). Another, more 
recent, criticism of the anhedonia hypothesis is that neuroleptics produce a deficit in goal 
seeking or motivation to gain the reward (in other words, the µwillingness¶ of the animals 
to make an effort to obtain the reward), but not a devaluation of the receipt of the reward 
(Baldo and Kelley 2007; Berridge and Robinson 1998; Robinson et al. 2005; Salamone 
and Correa 2002).  
 
The effect of lesions of the dopaminergic terminal fields in the nucleus accumbens has 
also proved controversial; some studies found that such lesions failed to disrupt operant 
behaviour (Salamone et al. 1997). Salamone et al. (2005) proposed that dopamine in the 
accumbens needs to be considered as a modulator of functions related with motivational 
behaviours, rather than a mediator of reward (Salamone et al. 2005). Among the 
behaviours that may be modulated by dopaminergic transmission in the nucleus 
accumbens are: motivation, the execution of effort, effort-related decision making and 
behavioural activation over time (see Salamone et al. 2005).  
 
It has been suggested that dopaminergic mechanisms may play a specific role in 
conditioned reinforcement (Beninger and Phillips 1980; Robbins et al. 1983). The D2-like 
receptor antagonist pimozide has been found to block the acquisition of conditioned 
reinforcement (Beninger and Phillips 1980), whereas the dopamine releasing agent d-
amphetamine, administered either systemically (Robbins et al. 1983) or directly into the 
nucleus accumbens (Taylor and Robbins 1984), potentiates responding for a previously 
established conditioned reinforcer. Intra-accumbens injections of the D1-like receptor 
agonist SKF-38393 (1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol) or the D2-
like receptor agonist quinpirole mimicked the effect of d-amphetamine (Wolterink et al. 
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1993), whereas intra-accumbens injections of 6-OHDA attenuated it (Taylor and Robbins 
1986). 
 
Manipulation of the dopaminergic system does not only affect operant behaviour 
PDLQWDLQHG E\ µQDWXUDO¶ UHLQIRUFHUV EHKDYLRXU FRQWUROOHG E\ GUXJ UHLQIRUFHUV LV DOVR
affected. This has been widely regarded as evidence for a role of the dopamine system in 
addiction. For instance microdialysis experiments in rats showed that extracellular 
dopamine in the nucleus accumbens is increased after the administration of almost all 
drugs of abuse including ethanol, nicotine, amphetamine, opiates and cocaine (Carboni et 
al. 1989; Di Chiara et al. 2004; Di Chiara and Imperato 1988a; b; Imperato and Di Chiara 
1986; Imperato et al. 1986). This effect was also observed in non-human primates and in 
functional brain imaging studies in humans (Bradberry et al. 2000; Di Chiara et al. 2004; 
Drevets et al. 1999). This increment of dopamine levels after drug administration is most 
apparent in the case of the accumbens shell (AcbS) in comparison with accumbens core 
(AcbC) (Di Chiara 2004). Studies using intracerebral drug administration also indicated 
that the accumbens shell is more sensitive than the accumbens core (Ikemoto 2003; 
Ikemoto et al. 1997; McBride et al. 1999).  
 
More evidence for the involvement of the dopamine system in drug reinforcement came 
from pharmacological studies. Administration of dopamine receptor antagonists either 
systemically or centrally has been shown to decrease self-administration of cocaine or 
amphetamines (Koob 1992). Administration of opiates increases the firing of VTA 
neurones and increases the release of dopamine in the nucleus accumbens. However, 6-
OHDA-induced lesions of the mesolimbic system or administration of dopamine receptor 
antagonists have been found not to affect heroin-self administration (Di Chiara and North 
1992; Koob 1992). This may suggest that the reinforcing properties of opiates are 
mediated by both dopaminergic and non-dopaminergic mechanisms. Nicotine is an 
effective reinforcer in self-administration paradims. Nicotine is an agonist of nicotinic 
acetylcholine receptors. Administration of dopamine receptor antagonists and lesions of 
the mesolimbic dopaminergic system impaired nicotine self-administration, suggesting 
an interaction between dopaminergic and cholinergic mechanisms in the rewarding effect 
of nicotine (Picciotto et al. 1998; see also Squire 2008). Finally, alcohol self-
administration can be attenuated by dopamine receptor antagonists; however, 6-OHDA 
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induced lesions of the nucleus accumbens did not alter responding for alcohol (Koob 
1992; Koob and Le Moal 2001). 
 
As indicated above, manipulation of the dopaminergic system can affect multiple aspects 
of operant behaviour (Choi et al. 2005; Kelley 2004; Kelley et al. 2005; Smith-Roe and 
Kelley 2000; Wise 2004(b)), including processes that operate in food-seeking and 
consumption, but which are deemed to be distinct from the µpleasure¶ derived from 
primary reinforcers such as food (Everitt and Robbins 2005; Salamone and Correa 2002; 
Salamone et al. 2007; Salamone et al. 2005). For instance, lesions of the nigrostriatal 
projection induced by the selective neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) impaired the learning of a sequenced motor task (Matsumoto et al. 
1999) DQ HIIHFW WKDWKDVEHHQDWWULEXWHG WRDFKDQJH LQ WKHRUJDQLVP¶V µZLOOLQJQHVV¶ WR
expend effort in its quest for reinforcers (see Salomone 2007). Low doses of D2-like 
receptor antagonists reduced lever pressing, but had less effect on nose-poking 
(Ettenberg et al. 1981), suggesting that dopamine receptor antagonism affects motor 
performance. In another experiment rats were trained under progressive-ratio and 
continuous reinforcement (fixed ratio [FR] 1) schedules; haloperidol (0.03 mg/kg) 
suppressed responding on the progressive-ratio schedule but not on the FR 1 schedule 
(Caul and Brindle 2001). Similarly, dopamine depletion in the nucleus accumbens 
reduced lever pressing under FR 5 but not under FR 1 (Ishiwari et al. 2004). Similar 
results have been obtained with other ratio schedules (Aberman and Salamone 1999; 
Salamone et al. 2001). All these findings have been taken to indicate that dopaminergic 
transmission in the accumbens is an important determinant of the amount of effort that an 
organism can exert; the fact that responding on FR 1, which entails relatively little effort 
to obtain a reinforcer, is unaffected by dopaminergic manipulations has been taken as 
evidence that dopaminergic mechanisms are not involved in motivational processes 
(Salamone et al. 2007). Although this argument appears intuitively reasonable, it may not 
fit comfortably with theoretical interpretations of the interactions of motor and 
motivational processes in ratio schedule performance (Killeen 1994); this issue will be 
examined in some detail in section 1.4.3. 
 
Another approach to dissociating the effects of dopaminergic manipulation on motor and 
motivational processes makes use of quantitative analysis of operant behaviour. An 
example of this approach is the analysis of variable-interval schedule performance based 
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RQ +HUUQVWHLQ¶V  K\SHUEROLF µUHVSRQVH VWUHQJWK¶ HTXDWLRQ VHH %UDGVKDZ DQG
6]DEDGL$FFRUGLQJWR+HUUQVWHLQ¶VHTXDWLRQUHVSRQVHUDWHLVDK\SHUEROLFIXQFWLRQ
of reinforcement rate, defined by two free parameters, Rmax, which represents the motor 
capacity of the organism, and KH, which expresses reinforcer efficacy (lower value of 
this parameter indicate higher reinforcer efficacy) (Bradshaw and Szabadi 1989;  the two 
parameters are designated k and r0 in Herrnstein's [1970] paper). Morley et al. (1984, 
1987) found that the D2-like receptor antagonist pimozide reduced Rmax but had no effect 
on KH, suggesting that the drug affected motor rather than incentive processes. However, 
other workers found that pimozide and other dopamine receptor antagonists also affected 
KH. (Heyman et al. 1987). The basis for this discrepancy has not been resolved. 
 
Recently another mathematical model which may dissociate effects of drugs and brain 
manipulations on  motor versus motivational processes is the µMathematical Principles of 
Reinforcement¶ model (MPR) (Killeen 1994). This model has been used in studies of 
systemic treatment with antipsychotics and other centrally acting drugs, and lesions of 
several brain structures including the nucleus accumbens (Bezzina et al. 2008b; Bezzina 
et al. 2008c; Bizo and Killeen 1997; Ho et al. 2003; Kheramin et al. 2005; Mobini et al. 
2000; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b) This is the core theme 
of this thesis and will be discussed in detail in the experimental chapters of the thesis (see 
also section 1.4).  
 
In summary, although there is compelling evidence for a role of dopamine in the control 
of behaviour by reinforcers, the view that dopaminergic neurotransmission is primarily 
responsible for the µhedonic¶ properties of all reinforcers remains controversial. One of 
the difficulties that besets this area is that operant behaviour entails multiple behavioural 
mechanisms, and the interaction between these mechanisms is imperfectly understood 
(Berridge 1996; Di Chiara et al. 2004; Salamone and Correa 2002; Salamone et al. 1997). 
 
1.3.5.5. Dopamine and higher cognitive functions 
   
Several methodologies have been developed to evaluate some of the aspects 
encompassed E\ WKH WHUPµcognitive functions¶ such as working memory, attention and 
executive functions, temporal judgement and decision making. A role for dopaminergic 
PHFKDQLVPVKDVEHHQSURSRVHG LQ VRPHRI WKHVH IXQFWLRQV ,Q VRPHFDVHV GRSDPLQH¶V
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putative role has been attributed to its involvement in more basic behavioural processes 
WKDWPD\EHHQWDLOHGLQSHUIRUPDQFHLQFRPSOH[µFRJQLWLYH¶WDVNV 
 
For instance, a number of studies have examined the effect of manipulating the 
dopaminergic system on performance on the 5-choice serial reaction time task (5CSRTT: 
Robbins 2002). This task yields several behavioural measures which are thought to 
reflect different cognitive processes. Response accuracy is regarded as an index of 
µattention¶WKHQXPEHURISHUVHYHUDWLYHHUURUVSURYLGHVDPHDVXUHRIµcompulsivity¶ the 
UHDFWLRQ WLPH SURYLGHV D PHDVXUH RI µdecision speed¶ DQG WKH QXPEHU RI SUHPDWXUH
UHVSRQVHV \LHOGV D PHDVXUH RI µLPSXOViviW\¶ (Chudasama and Robbins 2006; Robbins 
2002). It has been reported that D1-like receptor partial agonist SKF-38393 injected into 
the medial prefrontal cortex  improved the µattentional¶ measure and the D1-like receptor 
antagonist SCH-23390 decreased it (Granon et al. 2000). This effect was also replicated 
with a similar paradigm, the combined attention memory task (CAM) (Chudasama and 
Robbins 2004). In this paradigm the D1-like receptor agonist SKF-81297 affected the 
µattentional¶ measure (Chudasama and Robbins 2004).  
 
The effect of manipulation of the dopaminergic system RQ µGHFLVLRQ PDNLQJ¶ KDV DOVR
been examined. This process is thought to be based on cost/benefit analysis (Salamone 
1996; Salamone and Correa 2002; Salamone et al. 2007; Salamone et al. 1991). In one 
version of this kind of experiment, organisms are given a choice between a less preferred 
food (standard chow) at minimal cost, and a highly-preferred food at higher cost (FR5). 
In non-treatment situations rats generally obtained more of their food from responding on 
the more effortful FR5 alternative. D1-like and D2-like receptor antagonists and accumbal 
dopamine depletion shifted the UDWV¶ preferences from the high-cost to the low-cost 
reinforcer (Cousins et al. 1996). In another experiment using a T-maze task, one of the 
arms (A) was baited with 4 pellets of food which could only be obtained by climbing 
over a  high barrier, whereas the other arm (B) had no barrier. Dopamine depleted and 
control rats climbed the barrier in arm A if no food was available in arm B. However 
when 2 pellets were presented in arm B and 4 pellets in arm A, the lesioned animals 
shifted their preference to B whereas the control rats continued to prefer arm A. The 
authors suggested that the mesolimbic dopaminergic system is a crucial pathway in the 
regulation of effort-related decision making (Cousins et al. 1996).  
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Dopaminergic manipulation has also been found to affect choice between outcomes that 
differ with respect to delay of reinforcer deliver\µLntertemporal choice¶ In this type of 
task, selection of a smaller immediate reinforcer in preference to a larger delayed 
reinforcer is ofWHQ ODEHOOHG µLPSXOVLYH FKRLFH¶ $LQVOLH  &DUGLQDO HW DO 
reported that preference for the larger delayed reinforcer was reduced by d-amphetamine 
when no intra-delay signals were presented, whereas the opposite effect was seen when 
the delay to the larger reinforcer was signalled by a light. According to Cardinal et al. 
(2000), facilitation of accumbal dopaminergic transmission induced by d-amphetamine 
SURPRWHG µLPSXOVLYHQHVV¶ DQG DOVR HQKDQFHG WKH FRQGLWLRQHG UHLQIRUFLQJ HIIHFW RI WKH
intra-delay stimulus (see above, section 1.3.5.4). Destruction of the dopaminergic input 
to the OPFC has also been found to affect inter-temporal choice. Kheramin et al. (2004) 
found that rats with 6-OHDA-induced lesions of the OPFC tended to prefer the larger 
and more delayed of two reinforcing outcomes more than sham-lesioned rats; however 
the difference between the two groups depended critically on the presence of a delay to 
the smaller reinforcer. Analysis based on a quantitative model of inter-temporal choice 
(Ho et al. 1999) suggested that the lesion had a dual effect ± LQFUHDVLQJ WKH UDWV¶
sensitivity to both the delay of reinforcement and the relative sizes of the reinforcers. 
 
Further indirect evidence for the involvement of dopamine in cognitive processes come 
from human studies. For example, amphetamine-related drugs can improve the 
attentional deficits seen in attention-deficit/hyperactivity disorder (ADHD). This has led 
to the hypothesis that dopaminergic deficits in the prefrontal cortex are part of the cause 
of this disorder (see Sagvolden et al. 2005). The cognitive deficits experienced by 
schizophrenic patients and patients suffering IURP 3DUNLQVRQ¶V GLVHDVH have also been 
attributed to dysfunction of the dopaminergic system (for review, see Braver and Todd 
1999; Sawamoto et al. 2008; see also section 1.3.2.4).  
 
 
1.4. Progressive-ratio schedules and the measurement of reinforcer value 
 
1.4.1. Historical background 
 
$QXPEHURIGLIIHUHQWDSSURDFKHVKDYHEHHQXVHG WRDVVHVV WKHµHIILFDF\¶RU µYDOXH¶RI 
UHLQIRUFHUV LQFOXGLQJ PHWKRGV EDVHG RQ +HUUQVWULQ¶V  TXDQWLWDWLYH ODZ RI HIIHFW
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(see Heyman and Monaghan 1987; Bradshaw and Szabadi 1989; Stellar and Rice, 1989), 
µSODFHSUHIHUHQFH¶SDUDGLJPV&DUUHWDOand the survival of responding following 
reinforcer µGHYDOXDWLRQ¶ RU H[WLQFWLRQ (Fouriozos et al. 1978; Pickens et al. 2005) (see 
Wise 1989 for a critique of some of these methods).  One method that has been especially 
popular in behavioural pharmacological research is the progressive-ratio schedule of 
reinforcement. The progressive-ratio schedule was  developed by William Hodos in 1961 
as a method to study the motivational properties of reinforcers (Hodos 1961). At the time 
of its creation it was very innovative. One of the most widely used techniques to measure 
PRWLYDWLRQ DW WKH WLPH ZDV WKH µobstruction technique¶ (Moss 1924). This technique 
consisted in placing some obstacle (for instance an electrified grid) between the animal 
and the reinforcer (for instance food). In this situation the intensity of the electric current 
could be manipulated as well as others variables such as food deprivation level or 
reinforcer magnitude/quality. The principle behind this technique was that the electric 
current that an animal would be able to tolerate to obtain the reinforcer should correlate 
with motivational variables such as the food deprivation level (Moss 1924). The current 
intensity that stopped the animal from crossing the grid was called the µbreaking point¶ 
(Hodos1961). This technique presented several problems, especially those related with 
the establishment of reliable breaking points and the requirement of using aversive 
stimuli such as electric shock.  
 
Hodos (1961) designed the progressive-ratio schedule to overcome some of the problems 
related with the obstruction technique. Hodos (1961) described the progressive-ratio as a 
method to measure reward strength by measuring the maximum number of responses that 
an animal will make in order to get a reinforcer. With this method a breakpoint could be 
obtained that was more sensitive to changes in reinforcer magnitude and deprivation 
level. In his first experiment, Hodos (1961) trained rats to press a lever on a progressive-
ratio 2 (i.e., in order to obtain each successive reinforcer the rat had to increase the 
number of responses by 2 so the ratio progression was 2, 4, 6, 8, «). When the rat 
stopped responding for 15 minutes the session was terminated and the highest ratio 
completed was called the breakpoint. Hodos (1961) showed that the breakpoint was 
sensitive to reinforcer quality (different concentrations of condensed milk) and food 
deprivation level (i.e. no deprivation vs. 80% of their free feeding body weight). Hodos 
(1961) suggested that the progressive-ratio schedule would be a good method for 
DVVHVVLQJWKHHIILFDF\RIGUXJUHLQIRUFHUVLQµself-administration¶ paradigms.  
 - 40 - 
 
In a second experiment (Hodos and Kalman 1963) two more variables were tested, 
namely the ratio step size and the volume of a sucrose reinforcer.  The breakpoint 
increased as a function of the reinforcer volume. The breakpoint also increased as a 
function of step-size, although the number of reinforcers earned in a session declined (see 
Hodos and Kalman 1963). 
 
Since its creation, the progressive-ratio schedule has been extensively used in assessing 
the efficacy of drugs and other reinforcers. For example it has been used in drug self-
administration paradigms to measure the reinforcing properties of psychomotor 
stimulants (Depoortere et al. 1993; French et al. 1995; Li et al. 1994; McGregor et al. 
1994; McGregor and Roberts 1993; 1995; Roberts 1989; Roberts et al. 1994; Roberts et 
al. 1989) and opiates (Roberts and Bennett 1993; Shaham and Stewart 1994), and 
electrical stimulation oI GLIIHUHQW EUDLQ UHJLRQV LQ µVHOI-VWLPXODWLRQ¶ SDUDGLJPV 
(Depoortere et al. 1999; Hodos 1965; Keesey and Goldstein 1968) (for an extended 
review see also Richardson and Roberts 1996; Arnold and Roberts 1997). However some 
problems related with the interpretation of the breakpoint when these drugs were 
administered are discussed below.  
 
There are several ways of executing the progressive ratio schedule. For instance in its  
original form, the response/reinforcer ratio increased after each reinforcer delivery 
DFFRUGLQJWRWKHDULWKPHWLFSURJUHVVLRQ«2WKHUDULWKPHWLFSURJHVVLRQVKDYH
been used, such as increments of 5 or 10 responses following each reinforcer. Some 
experimenters have preferred geometric progressions (e.g. 5, 10, 20, 40) (Hoffmeister 
1979). A disadvantage of arithmetic progressions is that the increment becomes less and 
less discriminable as the schedule advances (for example, an increment of 10 responses 
marks a substantial change from a ratio of 10, but is probably indiscriminable when the 
preceding ratio is 200). Geometric progressions based on simple doubling of the response 
requirement have the disadvantage that the breakpoint is generally reached after a very 
small number of ratios. A compromise was suggested by Roberts and Richardson (1992), 
who used the exponential progression (1, 2, 4, 6, 9, 12, 15, 20, 25,«) derived from the 
formula (5×e0.2n)-5, rounded to the nearest integer, where n is the position in the 
sequence of  ratios. The response increment requirement can also be increased at the start 
of each daily session (Griffiths et al. 1979; Griffiths et al. 1978; Hoffmeister 1979), 
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although the more common arrangement is for the response requirement to be increased 
after each reinforcer has been delivered (Bedford et al. 1978; Bezzina et al. 2008a; 
Bezzina et al. 2008b; den Boon et al. 2011; Hodos 1961; Kheramin et al. 2005; Mobini et 
al. 2000a; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). (How these 
different methodologies can affect the breakpoint is briefly discussed in section 1.4.2.) 
 
1.4.2. The breakpoint and some of its shortcomings 
 
The great majority of behavioural pharmacological studies using the progressive-ratio 
schedule have relied on the breakpoint as the principal dependent variable, on the 
DVVXPSWLRQWKDWWKLVSURYLGHVDYDOLGLQGH[RIWKHµHIILFDF\¶RUµYDOXH¶RIWKHUHLQIRUFHU
However there has been increasing criticism of the use of this measure in recent years 
(Arnold and Roberts 1997; Killeen et al. 2009; Richardson and Roberts 1996; Rickard et 
al. 2009). 
 
Perhaps the biggest problem related with this measure arises from the lack of a generally 
accepted methodology. For instance, there is no general agreement about the appropriate 
session duration, which varies from less than an hour to 18 hours in different studies 
(Arnold and Roberts 1997; Richardson and Roberts 1996). Neither is there agreement 
about the most appropriate ratio step size, despite the fact that this measure can affect the 
breakpoint (Hodos and Kalman 1963; see below). The kind of progression used (for 
instance, arithmetic or geometric) is another very important factor that is known to affect 
the breakpoint (Killeen et al. 2009). Furthermore, the breakpoint itself is arbitrary; there 
is no concensus about the amount of time that must elapse without any responding before 
the breakpoint is deemed to have been attained. For instance some authors have used a 
breakpoint criterion of 3 minutes (Dantzer 1976), others as long as 60 minutes (Roberts 
1989). It has also been noted (Killeen et al. 2009) that the breakpoint is intrinsically 
unreliable because it is defined by a single data point (i.e. the ratio immediately 
preceding the criterion period of non-responding); no account is taken of responding that 
occurs in preceding ratios. Another problem with the breakpoint, which applies 
particularly to behavioural pharmacological experiments is that if the drug being tested 
alters the breakpoint, this will alter the length of the experimental session, which is 
clearly a problem when drugs with relatively short plama half-lives are being tested.   
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Because of these problems, some authors have attempted to produce a standard protocol 
for the progressive-ratio schedule. For example, Richardson and Roberts (1996) 
described an µoptimal¶ progressive ratio protocol to be used in cocaine self-
administration paradigms, and also they discuss methodological factors (such as the type 
of ratio progression, the breakpoint criterion, etc) that need to be considered. Other 
authors have attempted to avoid some of the problems associated with variations of the 
session duration by using a standard session length and adopting the highest ratio 
completed within the time-limited experimental session, rather than the breakpoint, as the 
performance criterion (Aberman et al. 1998; Hamill et al. 1999; Ho et al. 2003; 
Weatherley et al. 2003).  
 
In agreement with early observations of the sensitivity of the breakpoint to  motivational 
variables (Hodos 1961; Hodos and Kalman 1963), Skjoldager  et al. (1993) found that the 
breakpoint increased with the magnitude of the reinforcer and with the severity of food 
deprivation. In addition, they tested the effect of varying the height of the lever, and 
found that the breakpoint changed as a consequence of changes in this (presumed non-
motivational) variable (Skjoldager et al. 1993). 7KHVHQVLWLYLW\RIWKHEUHDNSRLQWWRµQRQ-
PRWLYDWLRQDO¶IDFWRUVZDVQRWHGE\Aberman et al (1998) who argued that haloperidol¶V 
effect of reducing the breakpoint was probably due to a motor debilitating effect that 
prevented the rats from responding (Aberman et al. 1998).  
 
Although the breakpoint does not reliably discriminate between motivational and motor 
influences of neurobiological interventions, quantitative analysis of response rates in 
successive ratios in the schedule may provide a basis for deriving separate indices of 
motor and motivational processes. Quantitative analyses of progressive-ratio schedule 
performance based on behavioural economic theory are discussed in the next section. 
Then, in section 1.4.4., the theory of schedule controlled behaviour developed by Killeen 
(1994), the Mathematical Principles of Reinforcement [MPR] model is described. MPR 
forms the theoretical substrate of the experimental work described in this thesis. 
 
1.4.3. Behavioural economic analysis of progressive-ratio schedule 
 
Behavioural economics is a broad area of knowledge that was born as an opposition to 
the traditional neo-classical economic theory. According to classical theory the world is 
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inhabited by rational human beings intent on maximi]LQJ WKHLUDFFHVV WRJRRGV µhomo 
economicus¶ (Thaler and Mullainathan 2008). In contrast, behavioural economists argue 
that this traditional economic approach ignores the important insights into human 
behaviour, including economic behaviour, that derive psychological studies (Thaler and 
Mullainathan 2008).   
 
An important aspect of behavioural economics to which psychologists have contributed 
LV WKH WKHRU\ RI µdecision making¶ Principles derived from behavioural analytic 
approaches (using animals) have been used to develop models of decision making that 
have been successfully applied to improve understanding of human behavioural 
economics (Ainslie 1975; 2001; Bradshaw 2008; Logue 1988; Rachlin 2006). The fusion 
of behavioural and economic approaches has given rise to theories of the economic 
behaviour of small businesses, families and individuals operating with limited resources 
µPLFURHFRQRPLFWKHRULHV¶(Robin and Parkin 2001).  
 
Another area of particular interest for behavioural economists, from the microeconomics 
perspective, is consumer demand (Hursh 1980; Rachlin et al. 1976). This special interest 
was due, among other reasons, to the analogy found between performance on schedules 
of reinforcement (for instance the progressive-ratio schedule) and demand curves (see 
Bradshaw  2008; Hursh and Silberberg 2008). Typically in a progressive-ratio schedule 
(Fig. 1.2 left hand panel) the response rate increases as a function of the ratio size until 
the subjects reach the maximum. After that the response rate decreases until eventually 
the subjects stop responding (see section 1.4). The progressive-ratio schedule has been 
extensively used in the field of behavioural economics to further understand motivated 
behaviours. The response rate function shown in the left-hand panel of Fig. 1.2 can be 
converted into a demand curve (Fig 1.2 right-hand panel), in which µFRQVXPSWLRQ¶LH
the rate of reinforcement) LVSORWWHGDJDLQVWWKHµSULFH¶LHWKHUHVponse requirement or 
response/reinforcer ratio) in double-logarithmic coordinates. The demand curve 
illustrates the important economic concept of elasticity of demand. The relatively flat 
initial segment of the demand curve indicates that consumption is maintained at a high 
OHYHOGHVSLWHWKHHVFDODWLQJSULFHLHGHPDQGLVUHODWLYHO\µLQHODVWLF¶ZKLOHWKHVWHHSHU
terminal segment shows that increases in price eventually lead to extinction of demand 
(Hursh and Silberberg 2008). When demand is totally inelastic, changes in price have no 
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effect on demand. In contrast, elastic demand implies that relatively small changes in 
price cause substantial changes in demand.  
   
 


















Fig. 1.2. Economic analysis of progressive ratio schedule performance. The left-hand 
graph shows mean rate of responding by 15 rats as a function of the number of responses 
(ratio) required to obtain a sucrose reinforcer; the right-hand graph shows the same data 
GLVSOD\HGDV DGHPDQG IXQFWLRQ LQZKLFK µFRQVXPSWLRQ¶ UHLQIRUFHPHQW UDWH LV SORWWHG
DJDLQVW µSULFH¶ LQ GRXEOH-logarithmic co-ordinates (Figure reproduced from Bradshaw 




Another important concept in behavioural economics is the substitutability of reinforcers 
(Rachlin et al. 1976). In particular it has been investigated how reinforcers can be 
interchanged and which are the variables that participate in this process. A very 
important variable is the availability of another reinforcer which is able to replace the 
first one. For instance, if coffee price goes very high the consumption of coffee may 
decrease and the consumption of tea may increase, as the latter maybe a good substitute 
for coffee. However, when the price of petrol is increased due to high tax, the 
consumption of petrol generally does not decline, probably because, for the majority of 
consumers, there is no satisfactory and readily available substitute to replace personal 
transport. This illustrates the close relationship between elasticity of demand and 
substitutability (Bradshaw 2008). 
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Some researches have applied these principles to the study of drug abuse in humans (see 
Johnson and Bickel 2006; Rodefer and Carol 1997). In contrast to what is popularly 
believed, the consumption of drugs of abuse is very sensitive to price change and the 
availability of other substitute drugs of abuse (Greenwald and Hursh 2006; Shahan et al. 
2001). One model used in the study of drugs of abuse is the consumer demand model. 
This model proposes that the price (number of responses) needed in order to obtain a 
drug is an essential factor to predict the total amount of drug that would be consumed 
(Licata and Rowlett 2011). This is based on animal studies where increasing the price of 
food (e.g. increasing the number of responses under fixed-ratio schedules) reduced the 
total amount of food intake by animals and drug intake by humans (Bickel et al. 2000; 
Hursh et al. 1988; Hursh and Silberberg 2008).  
 
An alternative way of conceptualizing the influence of the response requirement in ratio 
VFKHGXOHVLVLQWHUPVRIµODERXU¶ For example, in order to assess the role that responding 
SOD\V LQ FRQVXPSWLRQ $OOLVRQ  GHYHORSHG WKH µODERXU VXSSO\ PRGHO¶ (Allison 
1983; Allison and Boulter 1982). In this model the basic assumption is that consumption 
(for instance drug administration) declines as function of increasing effort to obtain the 
commodity (for instance increasing the response/reinforcer ratio). Moreover, this model 
also hypothesizes that when labour is too high, the relationship between consumption and 
labour will reverse and labour will decrease as a result of decreasing income (Allison 
1983; Allison and Boulter 1982; Licata and Rowlett 2011).  
 
Behavioural economic analysis of ratio schedule performance has been used extensively 
in behavioural pharmacology research. It is sometimes claimed that the elasticity of 
demand provides a quantitative measure of WKHµLQWULQVLFYDOXH¶RIUHLQIRUFHUV (Hursh and 
Silberberg 2008). For example, in a study of the effect of the cannabinoid receptor 
antagonist rimonabant in normal and genetically obese rats on ratio schedule responding 
for sucrose, Rasmussen et al. (2011) stated WKDW ³>WKH@ GHPDQG HTXDWLRQV TXDQWLI\ WKH
value of a reinforcer by its VHQVLWLYLW\WRSULFH>UDWLR@LQFUHDVHV´ The authors found that 
rimonabant dose-dependently increased elasticity, and concluded that the drug had 
reduced the essential value of sucrose. However, there are problems with the use of 
elasticity as a measure of reinforcer value. For example, elasticity is influenced by  the 
height of the initial segment of the demand function, which expresses the rate of 
consumption when the unit price is minimal (see Fig. 1.2). Various ways of normalizing 
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demand curves to take this into account have been recommended (Hursh and Silberberg 
2008). However, the process of normalization has its own problems. Thus, Foster et al. 
(2009) recently reported data from hens responding for different wheat-based reinforcers, 
in which normalized demand curves yielded the lowest elasticity value associated with 
the food that was least preferred in free-choice tests.  
 
Another shortcoming of demand curves for analysing progressive-ratio schedule 
performance is that, like the breakpoint, they do not provide a basis for identifying the 
effects of interventions on motor performance, since, in conventional demand curves, 
response rate is DEVRUEHG LQWR WKH GHILQLWLRQ RI µFRQVXPSWLRQ¶ The potential for 
distinguishing between reinforcer value and motor influences on performance on 
progressive-UDWLRVFKHGXOHVLVDPDMRUDGYDQWDJHRI.LOOHHQ¶VPRGHOGHVFULEHGLQ




As indicated above, the breakpoint, or alternatively the highest completed ratio, presents 
VRPH SUREOHPV DQG WKHVH FDQ EH DGGUHVVHG E\ XVLQJ .LOOHQ¶V PDWKHPDWLFDO PRGHO
Mathematical Principles of Reinforcement .LOOHHQ ,Q.LOOHHQ¶VPRGHO WKHUHDUH
three factors which affect the control of behaviour by reinforcers. Firstly, reinforcers are 
purported to activate behaviour, and the duration of activation provides an index of the 
HIILFDF\ RU µLQFHQWLYH YDOXH¶ RI WKH UHLQIRUFHU Secondly, the model recognizes that 
response rate is limited by biological constraints imposed, for example, by the motor 
system of the animal. Thirdly, it is proposed that schedules of reinforcement differ with 
UHVSHFWWRWKHGHJUHHWRZKLFKWKH\HQDEOHUHLQIRUFHUVWREHFRPHµFRXSOHG¶WRWKHLQGH[
response. These three factors are represented by three parameters which feature in the 
fundamental equations of his theory.  
 









   [1] 
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where N is the response/reinforcer ratio. The parameter a (specific activation) defines the 
amount of time for which a reinforcer is able to activate behaviour; ȕ µFXUUHQF\
SDUDPHWHU¶ UHSUHVHQWV WKH ZHLJKW LQ VKRUW WHUP PHPRU\ DVVLJQHG WR WKH ODVW UHVSRQVH
before the delivery of the reinforcer, and measures the efficiency with which  a particular 
reinforcement schedule couples operant responses to reinforcers; į is a parameter that 
expresses the minimum time that the animal requires to emit a response (i.e. it is the 
reciprocal of the theoretical maximum response rate).  
 
 
Fig. 1.3 Theoretical response rate function (top graph) defined by Equation 1 (Killeen 
1994). Ordinate: response rate (R); abscissa: response/reinforcer ratio (N). The graph 
exemplifies the measurement of the parameters a and į: the projected point of 
intersection of the function with the ordinate is at R įDQGWKHVORSHRIWKHGHVFHQGLQJ
limb of the function is -1/a; the point of intersection with the abscissa µH[WLQFWLRQUDWLR¶ 
is jointly determined by į and a (N=a/į). The three lower graphs illustrate the 
hypothetical effects of a change in each of the three parameters of Equation 1; in each 
graph, the continuous line shows the baseline function, and the dotted line the changed 
function: (i) a change in į alters the peak of the function and the extinction ratio; (ii) a 
change in a alters the slope of the descending limb of the function and the extinction 
ratio; (iii) a change in ȕ alters the slope of the ascending limb of the function. See text for 
details. Figure adapted from Mobini et al. (2000). 
 
 
Although Equation 1 was originally developed for fixed-ratio schedules (Killeen 1994), it 
is also able to describe accurately performance on progressive-ratio schedules (Bezzina et 
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al. 2008a; Bezzina et al. 2008b; Ho et al. 2003; Kheramin et al. 2005; Mobini et al. 
2000a; Reilly 2003; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b; den 
Boon et al. 2011). Figure 1.3 illustrates response rates on ratio schedules as predicted by 
Equation 1. 
 
.LOOHHQ¶V PRGHO KDV EHHQ XVHG WR detect the effects of magnitude and quality of 
reinforcers, brain lesions and systemic drug administration on motivational and motor-
related processes (Bezzina et al. 2008b; Bezzina et al. 2008c; Covarrubias and Aparicio 
2008; den Boon et al. 2011; Kheramin et al. 2005; Mobini et al. 2000; Reilly 2003; 
Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b) (see section 1.4.5). 
 
The relation between behavioural activation and incentive value derives from Killeen et 
al¶V (1978) studies which showed that unconditioned locomotor behaviour was triggered 
by reinforcers and that the duration of activation was in proportion with the magnitude 
and rate of reinforcement. Killeen et al. (1978) placed food deprived pigeons in an 
activity enclosure. Then they fed them once and recorded the behaviour for 30 minutes. 
They observed that the pigeons became active when the food was delivered and that this 
activation declined exponentially with time until the animals were settled  (Killeen 1982; 
Killeen et al. 1978). When food was presented according to a periodic schedule, 
successive food deliveries produced a cumulative effect on the activation level which 
grew toward an asymptote. In addition they found that this cumulative effect became 
associated with the context in which the pigeons were fed (Killeen 1982; Killeen et al. 
1978).  
 
 7KH VSHFLILF DFWLYDWLRQ SDUDPHWHU ³a´ KDV EHHQ SURSRVHG DV D TXDQWLWDWLYH LQGH[ RI
reinforcer efficacy (Killeen 1994; Killeen and Sitomer 2003). This suggestion has 
received some empirical support, as this parameter has been proved sensitive to 
manipulation of reinforcer size and quality (Bizo and Killeen 1997; Covarrubias and 
Aparicio 2008; Reilly 2003; Rickard et al. 2009). In this respect, a behaved similarly to 
KHWKHSDUDPHWHURI+HUUQVWHLQ¶VHTXDWLRQZKLFKLVDOVRpurported to express the 
incentive value of the reinforcer (Heyman and Monaghan 1987).  
 
One of the purported advantages of applying Equation 1 to progressive-ratio schedule 
performance is that it provides a theoretical basis for distinguishing between the 
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influences of motor and motivational processes (Killeen 1994; Reilly 2003). Bizo and 
Killeen (1997) provided experimental support for this assumption. In an experiment with 
pigeons, WZRµPRWLYDWLRQDO¶YDULDEOHV the size of a reinforcer and the time that pigeons 
had access to a food hopper, were manipulated; a was affected by both manipulations 
(Bizo and Killeen 1997). In contrast, when the motor requirements of the operant task 
were manipulated (key-SHFNLQJYHUVXVWUHDGOHSUHVVLQJįZDVKLJKHULQWKHFDVHRIWKH
more effortful response.  
 
In a recent experiment, Rickard et al (2009) reinforced rats with a range of volumes of a 
sucrose solution (6 ± 300 µl). As expected, a increased as a function of reinforcer 
volume. This increment of a was accompanied by an increment of į, which was 
attributed to longer post-reinforcement pauses caused by post-prandial behaviour 
associated with the larger reinforcer sizes (see below). 
 
According to Equation 1 the breakpoint is predicted by the ratio of two parameters, Dį 
(see Fig. 1.2). Therefore, an increase in the breakpoint can be produced either by a 
reduction in į or by an increase in a, and vice versa. Consequently, it has been proposed 
that the parameter a of Equation 1 can provide a more reliable index than the breakpoint 
to measure motivation (Bezzina et al. 2008b; Bezzina et al. 2008c; den Boon et al. 2011; 
Kheramin et al. 2005; Mobini et al. 2000; Reilly 2003; Rickard et al. 2009; Zhang et al. 
2005a; Zhang et al. 2005b). More specifically, the parameter a has been proposed to be 
used to construct a quantitave scale to measure the incentive value of reinforcers (Reilly 
2003).  
 
Equation 1 was originally developed to describe performance on fixed- and variable-ratio 
schedules; however, it also provides a good description of overall response rates on 
progressive-ratio schedules (Bezzina et al. 2008b; Bezzina et al. 2008c; Covarrubias and 
Aparicio 2008; den Boon et al. 2011; Kheramin et al. 2005; Mobini et al. 2000; Reilly 
2003; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). The application of 
Equation 1 to progressive-ratio schedule performance has been used successfully to 
detect the effects of brain lesions and drug administration on motivational and motor-
related processes (Bezzina et al. 2008b; Bezzina et al. 2008c; Covarrubias and Aparicio 
2008; den Boon et al. 2011; Kheramin et al. 2005; Mobini et al. 2000; Reilly 2003; 
Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). A recent study of the effect 
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of reinforcer size on progressive ratio schedule performance (Rickard et al., 2009) 
revealed that while Equation 1 provided a good description of overall response rate, its fit 
to the µUXQQLQJ¶ UHVSRQVH UDWH UHVSRQVH UDWH FDOFXODWHG DIWHU H[FOXVLRQ RI WKH 
postreinforcement pause (Bizo et al., 2001)) was less satisfactory. Running response rate 
was, however, well described by a logistic function (see section 2.1). 
 
  R = Ri /(1+[N/b]c)         [2] 
 
where Ri is a parameter expressing the initial (maximum) response rate, b expresses the 
rate of decay of the function, and the exponent c modulates the curvature of the function. 
Rickard et al. (2009) found that b was monotonically related to reinforcer size, while Ri 
was unaffected by changes in reinforcer size.  
 
The currency parameter ȕ derived from the MPR model has been less extensively studied 
in the field of behavioural pharmacology. Hence there are fewer empirical data to support 
the theoretical significance of this parameter. ȕ corresponds to the weight in short-term 
memory given to the most recent response (Killeen 1994). The weight given to individual 
responses decreases progressively as they become remote from the delivery of the 
reinforcer. It is assumed that this memory decay function conforms to the exponentially 
weighted moving average (Killeen 1981).  According to Killeen (1994), ȕ is a weight 
without dimensions; if ȕ is close to 1 all the weight falls on the last response. However, 
when ȕ is close to 0 the weight is distributed across a longer sequence of responses. 
Based on a re-analysis of previously published data, Killeen (1994) estimated that a value 
of ȕ of 0.25 was W\SLFDORISLJHRQV¶NH\SHFNUHVSRQGLQJRQUDWLRVFKHGXOHV 
 
1.4.5. Application of MPR to behavioural pharmacology 
 
Despite more than 30 years of intensive research, there is no clear consensus about the 
putative role of the dopaminergic system in reward processes. Some authors claim that 
the manipulation of the mesolimbic dopaminergic system, for example by blockade of 
D2-like dopamine receptors in the nucleus accumbens, degrades the incentive value of 
reinforcers. Other authors, however, claim that the effects of such manipulations on 
operant behaviour are due to motoric factors (see section 1.3.4.4; Salamone et al. 2007; 
Wise 2008). A similar controversy exists with respect to the orexinergic system. 
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However, it has been claimed that the orexinergic system may be involved in both 
motoric and motivational processes and that each of these processes is controlled by 
different neuronal sub-populations (Harris and Aston-Jones 2006; see section 1.2.3.4).  
 
One of the principal objectives of the project described in this thesis is to explore the 
potential utility of MPR in examining the the roles of these neural systems in the control 
of motor and motivational processes. There is a small but growing literature on the 
application of MPR in behavioural neuroscience research. This literature is reviewed in 
the present section. 
 
For over a decade MPR has been used to analyse the effects of acute systemic drug 
treatment on progressive-ratio schedule performance (Bezzina et al. 2008b; Bezzina et al. 
2008c; den Boon et al. 2011; Kheramin et al. 2005; Mobini et al. 2000; Reilly 2003; 
Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). For instance, there have 
been several studies examining the effects of conventional antipsychotics (D2-like 
dopamine receptor antagonists) (den Boon et al. 2011; Mobini et al. 2000; Zhang et al. 
2005a). In all these experiments, the D2-like receptor antagonist haloperidol invariably 
reduced the breakpoint; analysis of the response rates using Equation 1 indicated that this 
was brought about not only by a reduction of the incentive value of food reinforcers (as 
defined by a reduction of the activation parameter a), but also by an impairment of motor 
capacity (as defined by an increment in the response time parameter į). The effect of 
haloperidol has been replicated with other D2-like dopamine receptor antagonists, 
including cis-flupenthixol, raclopride and pimozide (Zhang et al. 2005a). 
 
The psychostimulant and dopamine-releasing agent d-amphetamine has also been tested 
using MPR: Mobini et al. (2000) used the progressive-ratio schedule and Reilly (2003) a 
five-component multiple fixed-ratio schedule. Both studies found that d-amphetamine 
increased į. However, the two studies differed with respect to the observed effects on a. 
Mobini et al (2000) found a dual effect, lower doses of d-amphetamine (0.2mg kg-1) 
reducing a and higher doses increasing it (0.8mg kg-1). In contrast, Reilly et al (2003) 
found an increase in a across a broad range of doses, although a reduction of a was seen 
with doses that were considerably higher than those used by Mobini et al. (2000) (3.2mg 
kg-1). The basis of this discrepancy is unclear, although Reilly (2003) noted a number of 
methodological differences between the two studies, including different schedules (see 
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above), different reinforcers, and random (Reilly 2003) versus progressive (Mobini et al. 
2000) presentation of the ratios.  
 
Clozapine is an atypical antipsychotic which has a relatively low affinity for D2-like 
dopamine receptors and high affinity for 5-HT2A and 5-HT1A receptors (see section 
1.3.4.6). 6HYHUDO VWXGLHV KDYH H[DPLQHG FOR]DSLQH¶V HIIHFW RQ WKH SDUDPHWHUV RI 035 
(den Boon et al. 2011; Mobini et al. 2000; Zhang et al. 2005a; Zhang et al. 2005b). 
Clozapine has consistently been found to increase both a and į. Although the breakpoint 
is increased with lower doses of clozapine, higher doses tend to reduce it. According to 
MPR, the breakpoint is jointly determined by a and į. In the case of clozapine, the 
UHGXFWLRQRIWKHEUHDNSRLQWLVDWWULEXWDEOHWRWKHLQFUHDVHLQįVLQFHa was increased by 
the drug. This is therefore an example of the breakpoint being reduced by the effect of a 
GUXJ RQ µmotor¶ SURFHVVHV DQG LOOXVWUDWHV WKH GLIILFXOWLHV WKDW PD\ DULVH ZKHQ WKH
breakpoint is used as an index of incentive value. The dual effect of clozapine on a DQGį
has been replicated with other atypical antipsychotics (quetiapine, olanzapine, 
ziprasidone: Zhang et al. 2005a). The qualitatively different profiles of effect of 
conventional and atypical antipsychotics on the parameters of Equation 1 has recently 
been confirmed by den Boon et al. (2011). 
 
MPR was used by Ho et al (2003) to test the effect of the selective 5-HT1A receptor 
agonist 8-OH-DPAT. This drug was previously used in feeding experiments and the 
operant µself-stimulation¶ HOHFWULFDO EUDLQ VWLPXODWLRQ UHLQIRUFHPHQW paradigm. These 
studies showed both an increase of food intake and enhancement brain self-stimulation, 
effects which were attributed to an enhancement of motivation (Bendotti and Samanin 
1986; Dourish et al. 1986; Montgomery and Grottick 1999; Montgomery et al. 1991). In 
agreement with this suggestion, Ho et al (2003) found that 8-OH-DPAT produced  a dose 
dependent increment of a. There was also an increase of į, suggesting that the increase of 
reinforcer value may have been accompanied by some impairment of motor functioning. 
Ho et al (2003) also found that the 5-HT1A  receptor antagonist WAY-100635 had no 
effect on any of the parameters of MPR; however, when 8-OH-DPAT and WAY-100635 
were administered together, the effect of 8-OH-DPAT was antagonized. Ho et al (2003) 
noted the similarity between the effects of 8-OH-DPAT and clozapine, and  suggested 
that the motivation enhancing effect produced by clozapine might be mediated by 5-HT1A 
receptors (see below). 
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The hypothesis that clozapine¶V motivational effect was mediated by the 5HT1A receptors 
was also investigated using MPR (Zhang et al. 2005b). In DJUHHPHQW ZLWK +R HW DO¶V
(2003) findings, clozapine and 8-OH-DPAT increased both a DQG į +RZHYHU ZKLOH 
WAY-100635 fully antagonized the effect of 8-OH-DPAT, it did not alter the effect of 
FOR]DSLQHLQGLFDWLQJWKDWFOR]DSLQH¶VHIIHFWZDVQRWPHGLDWHGE\-HT1A receptors.  
 
MPR has also been used to analyse the effects of brain lesions on progressive-ratio 
schedule performance. Kheramin et al (2005) compared the performance of a group of 
rats whose orbital prefrontal cortex (OPFC) had been lesioned with quinolinic acid and 
another group that had received sham lesions with the vehicle (saline).  After the animals 
recovered from surgery they were trained on the progressive-ratio schedule and the 
response rate data were used to fit Equation 1. The results showed that this lesion 
produced a reduction of the activation parameter a, suggesting that the lesion reduced the 
value of the food reinforcers. This result is consistent with previous findings by the same 
authors (Kheramin et al. 2002), based on an inter-temporal choice task, which indicated 
that lesions of the OPFC reduced the incentive value of food reinforcers.   
 
Bezzina et al. (2008b) used MPR to analyse the effect of quinolinic acid-induced lesions 
of the nucleus accumbens core (AcbC). According to Wise (1982) the AcbC and its 
dopaminergic afferents are crucial to the regulation of the values of both natural rewards 
and drugs (see section 1.3.4.4). Bezzina et al. (2008b) found that the breakpoint was 
significantly lower in the lesioned group in comparison with the sham-lesioned group. 
Application of Equation 1 revealed that the activation parameter a was not altered in the 
lesioned group. However, the response time parameter į was increased. In this 
experiment the magnitude of the reinforcers were manipulated. The value of a was higher 
in both groups when the reinforcer was two food pellets than when it was one pellet, 
consistHQWZLWK5LFNDUGHWDO¶VILQGLQJRIDPRQRWRQLFUHODWLRQEHWZHHQUHLQIRUFHU
size and the value of a %H]]LQD HW DO¶V E ILQGLQJ WKDW WKH $FE& OHVLRQ GLG QRW
affect a is consistent with the findings of Bezzina et al. (2007), based on an inter-
temporal choice task, which indicated that lesions of this structure did not affect the 
incentive value of food reinforcers.  
 
The findings reviewed in this section suggest that MPR may provide a useful framework 
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for analysing the effects of neurobiological interventions on reinforcement processes. 
Although only a limited range of interventions have been examined to date, the results 
obtained so far appear generally to support the claim that the application of Equation 1, 
derived from MPR, allows effects of interventions on performance that are mediated by 
changes in reinforcer value to be distinguished from effects that are mediated by changes 
in motor performance (Killeen 1994). 













EXPERIMENT 1: EFFECT OF OREXIN-B-SAPORIN INDUCED 
LESIONS OF THE LATERAL HYPOTHALAMUS ON 
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2.1.     Introduction 
 
The orexins are two neuropeptides which are synthesised in a small group of neurones 
localised in the hypothalamus and surrounding regions (see section 1.2.1). The orexin 
system has been implicated in several neurobehavioural functions, including reward 
processing and addictions (see section 1.2.3.4). According to the µdichotomy of orexin 
function¶ hypothesis  (Harris and Aston-Jones 2006), only the orexinergic neurones of 
the LHA are purported to be involved in reinforcement mechanisms (see section 1.2.3.4). 
Several experiments have studied the relationship between the orexin system and 
motivational processes using the progressive-ratio schedule of reinforcement (see section 
1.2.3.3). Traditionally the breakpoint has been used as a measure of the VXEMHFW¶V
motivational state. However, as reviewed in section 1.4.1. the breakpoint is subject to 
several problems, that can be overcome by using KilleHQ¶V (1994) MPR model (see 
section 1.4.3). 
 
According to MPR, the relationship between response rate (R) and ratio size (N) in ratio 






        [1] 
ZKHUHįµUHVSRQVHWLPH¶LVWKHPLQLPXPWLPHQHHGHGWRH[HFXWHDUHVSRQVHa µVSHFLILF
DFWLYDWLRQ¶LVWKHWLPHIRUZKLFKDVLQJOHUHLQIRUFHUGHOLYHU\LVDEOHWRDFWLYDWHEHKDYLRXU
DQGȕµFXUUHQF\¶ZKLFKUHIOHFWVWKHFRXSOLQJRIUHVSRQVHVWRUHLQIRUFers, expresses the 
weight given to the most recent response in the conditioning process (see section 1.4.3). 
A recent study of the effect of reinforcer size on progressive-ratio schedule performance 
(Rickard et al. 2009) revealed that while Equation 1 (see section 1.4.3.) provided a good 
description of overall response rate, iWV ILW WR WKH µUXQQLQJ¶ UHVSRQVH UDWH UHVSRQVH UDWH
calculated after exclusion of the post-reinforcement pause: Bizo et al 2001) was less 
satisfactory. Running response rate was, however, well described by the logistic function: 
  R = Ri /(1+[N/b]c)         [2] 
where Ri is a parameter expressing the initial (maximum) response rate, b expresses the 
rate of decay of the function, and the exponent c modulates the curvature of the function. 
Rickard et al. (2009) found that b was was monotonically related to reinforcer size, while 
Ri was unaffected by changes in reinforcer size. 
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The present experiment used a combination of quantitative analysis of operant behaviour 
maintained by positive reinforcement with neurochemical lesions of orexinergic neurones 
in the LHA. The lesion was inflicted using the OxSap neurotoxin (see section 1.2.2).  As 
the orexinergic system has been claimed to be involved in reward processing (see section 
1.2.3.3), it was expected that the OxSap-lesioned group would show a lower value of the 
motivational parameter of Equation 1, a (specific activation), and the decay parameter, b, 
of Equation 2, compared to the sham-lesioned group, and a decrease in these parameters 
compared to their own pre-surgical performance.  The effects of the lesion on locomotor 




The experiments were carried out in accordance with UK Home Office regulations 




Thirty experimentally naive female Wistar rats approximately 4 months old and weighing 
250±300 g at the start of the experiment were used. They were housed under a constant 
cycle of 12 h light and 12 h darkness (light on 06:00 - 18:00), and were maintained at 
80% of their initial free-feeding body weights throughout the operant behaviour 
experiment by providing a limited amount of standard rodent diet after each experimental 




The rats were divided into two groups. The first group received bilateral lesions of the 
LHA with the orexin-B-saporin conjugate (OxSap: Advanced Targeted Systems, USA) 
(n=14). The control group was divided into two sub-groups which received either 
bilateral intra-LHA injections of unconjugated saporin (Advanced Targeted Systems, 
USA) (n=8), or (ii) bilateral intra-LHA injections of the vehicle solution alone (0.9% 
sodium chloride solution) (n=8). Anaesthesia was induced with isoflurane (4% in 
oxygen), and the animals were placed in a stereotaxic instrument (David Kopf), with the 
upper incisor bar set 3.3 mm below the inter-aural line. Isoflurane was kept at 2% in 
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oxygen during the surgical procedure. A small hole was drilled through the skull 
overlying each cerebral hemisphere for microinjection of the solutions into the LHA.  
The following coordinates were used to locate the LHA: AP -3.3, L ± 1.6, V -9.1, 
measured from bregma (Paxinos and Watson 1998). 
 
0LFURLQMHFWLRQV ZHUH DGPLQLVWHUHG ZLWK D  ȝO +DPLOWRQ V\ULQJH FRQQHFWHG E\ D
polyethylene tube to a 0.3-mm diameter cannula. The solution administered to the first 
JURXS FRQWDLQHG  QJ 2[6DS GLVVROYHG LQ  ȝO of non-pyrogenic 0.9 % sodium 
chloride (Baxter Health Care, UK). (The dose used was based in preliminary studies 
carried out in this laboratory in which it was found that doses of 180 ng, 90 ng and 45 ng 
of OxSap produced substantial tissue damage in the LHA and surrounding areas. 
Furthermore these doses produced significant reductions of food intake and loss of body 
weight which necessitated euthanasia of most animals 2-3 weeks after surgery.) The 
cannula was slowly lowered to the target position, and the solution was injected during a 
60-s period. The cannula was left in position for 3 minutes after completion of the 
injection, and was then withdrawn. The procedure for the other two groups was identical 
H[FHSWWKDWWKHLQMHFWLRQVZHUHHLWKHUQJXQFRQMXJDWHGVDSRULQLQȝOVDOLQHQ RU




2.2.3.1. Operant behaviour chambers 
 
The rats were trained in custom built operant conditioning chambers of internal 
dimensions 20 cm × 23 cm × 22.5 cm. One wall of the chamber contained a recess into 
which a motor-operated dispenser could deliver 45-mg food pellets (TestDiet, MLab 
Rodent Tablet 45 mg; Sandown Scientific, UK). An aperture was situated 5 cm above 
and 2.5 cm to the left of the recess, through which a motor-operated retractable lever 
could be inserted into the chamber. The lever could be depressed by a force of 
approximately 0.2 N. The chamber was enclosed in a sound-attenuating chest; masking 
noise was provided by a rotary fan. An Acorn 5000 microcomputer and interface unit 
(Paul Fray Ltd.), programmed in ARACHNID BASIC and located in an adjoining room, 
controlled the schedules and recorded the behavioural data.  
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2.2.3.2. Locomotor behaviour chambers 
 
Locomotor behaviour was recorded in transparent Perspex boxes of internal dimensions 
42 cm × 32 cm × 29 cm, equipped with eight infrared photocell beams located at equal 
intervals along the long axis of the box, 4 cm above the floor. An Acorn microcomputer 
programmed in ARACHNID BASIC and located in an adjoining room recorded the data.  
 
2.2.4. Behavioural procedures 
  
2.2.4.1.  Progressive-ratio schedule 
 
Two weeks before the start of behavioural training, the food deprivation regimen was 
introduced and the rats were gradually reduced to 80% of their free-feeding body 
weights. Then they were trained to press the lever for a food-pellet reinforcer (45 mg) 
and were exposed to a fixed-ratio 1 schedule for 3 sessions, followed by fixed-ratio 5 for 
a further 3 sessions. Thereafter, they underwent daily training sessions under the 
progressive-ratio schedule. The progressive-ratio schedule was based on the following 
exponential progression: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, . . . , derived from the 
formula [(5×e0.2ní], rounded to the nearest integer, where n is the position in the 
sequence of ratios (Roberts and Richardson 1992). Sessions took place at the same time 
each day during the light phase of the daily cycle (between 07:00 and 14:00) 7 days a 
week for the duration of the experiment. At the start of each session, the lever was 
inserted into the chamber; the session was terminated by withdrawal of the lever 50 min 
later. The rats were trained under the progressive-ratio schedule until the estimated 
parameters of Equation 1 (see Data analysis, section 2.2.6) had attained stability 
according to the following criterion. Each parameter was deemed to be stable when the 
cumulated change in the group mean value of the parameter over three successive blocks 
RIVHVVLRQVZDV7KHYDOXHRISDUDPHWHUa increased steadily over 60 sessions 
and the formal criterion was not met until the 10th block. Surgery was carried out after 
110 training sessions. Training continued for 40 sessions after surgery.    
 
2.2.4.2.  Locomotor behaviour 
 
Each rat was tested at the same time of day, and under the same food restriction 
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conditions as in the operant behaviour experiment. Each session was 30 min in duration 
and the data were recorded in 6 successive epochs of 5 min. The tests took place 23 h 
after the last meal. The rats underwent the locomotor activity testing on 7 successive 
days: 5 habituation sessions and two recording sessions.  
 
2.2.4.3.  Food intake 
 
Food intake tests took place in the animal holding room. Each rat was placed in a cage 
similar to the home cage containing a pre-weighed dish containing approximately 25 g of 
the same 45-mg food pellets as were used in the operant behaviour experiment. The rats 
were left undisturbed for 60 min before being returned to their home cages. The dishes 
were re-weighed and the weight of food consumed was calculated. Three test sessions 
were carried out at intervals of 48 h while the rats were maintained under the same food 
deprivation conditions as in the operant behaviour experiment. In a second phase, the 
same procedure was carried out while the rats had free access to standard chow in their 




At the end of the behavioural experiment, the rats were deeply anaesthetised with sodium 
pentobarbitone, and perfused transcardially with phosphate-buffered sodium chloride 
solution (PBS), followed by 10% formol PBS. The brains were removed from the skull 
and fixed in formol PBS for 3 days. Coronal sections (60-ȝPZHUH WDNHQ WKURXJK WKH
LHA region using a freezing microtome. Alternate sections were selected for labelling of 
neurone-specific nuclear protein (NeuN) and orexin. 
 
NeuN was labelled as described by Jongen-Relo and Feldon (2002). The protocol 
followed was described by Bezzina et al. (2007). Three freshly sliced sections, taken at 
approximately 120-µm intervals between AP +3.0 and AP +3.6 were washed in 0.1 M 
PBS and placed in 0.5% H2O2 in PBS for 30 min at room temperature. Then they were 
washed twice in PBS and placed for 1 h in a blocking solution [10% normal horse serum 
(Vector Laboratories, Peterborough, UK), 1% bovine serum albumin (BSA, Sigma-
Aldrich, Gillingham, UK) and 0.3% Triton X-100 (Sigma-Aldrich) in PBS]. They were 
then incubated for 48 h at 4°C in the primary antibody [monoclonal mouse anti-NeuN 
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serum (1:5,000, Chemicon, Chandlers Ford, UK) in 1% normal horse serum, 1% BSA 
and 0.3% Triton X-100 in PBS], washed twice in PBS, and incubated for 2 h at room 
temperature in biotinylated horse antimouse serum (Vector Laboratories; 1:1,000 in 1% 
BSA and 0.3% Triton X-100 in PBS). After two washes in PBS, they were placed for 2 h 
in avidin±biotin±horseradish peroxidase complex (1:200, ABC-Elite, Vector 
Laboratories) in PBS. Following two further washes in PBS, they were placed in a 
chromagen solution [0.05% diaminobenzidine (Sigma-Aldrich) and 0.01% H2O2 (Sigma-
Aldrich)] for 5 min. The reaction was observed visually and stopped by washing in PBS. 
The sections were floated on to chrome-gelatine-coated slides and mounted with DPX.  
 
The procedure for orexin staining was the same as that described above, except that the 
primary antibody was goat anti-orexin diluted 1:5,000 in PBS (Santa Cruz 
Biotechnology, USA) and the secondary antibody was horse anti-goat serum 1:1000.  
 
NeuN-positive nuclei and orexin-positive neurones were counted blind from coded 
images of the sections using Image-J software (Wayne Rasband, National Institutes of 
Health, USA).  
 
2.2.6. Data analysis  
 
The data from one rat belonging to the sham-lesioned group were discarded, because this 
rat failed to complete a sufficient number of ratios in each session to permit curve fitting 
analysis to be performed. A preliminary analysis comparing the immunohistochemical 
data and post-surgical performances of the two control sub-groups (i.e. the rats that 
received intra-LHA injections of unconjugated saporin and the saline vehicle) revealed 
no significant differences between the numbers of orexin-positive neurones or NeuN-
positive nuclei or any of the performance measures, and therefore the data from the two 
sub-groups were pooled in all subsequent analyses. Analyses were thus based on the data 
from the OxSap-lesioned group (n=14) and the combined sham-lesioned group (n=15).  
 
2.2.6.1.  Operant behaviour data 
 
Data from the last block of 10 sessions before surgery and the four successive blocks of 
10 sessions following surgery were used in the analyses. 
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(i) Peak response rate. Differences between the highest overall response rate (see below) 
attained during performance of the progressive-ratio schedule during the final pre-
surgical block of sessions and the four post-surgical blocks were analysed by two-factor 
analysis of variance (group × block) with repeated measures on the latter factor. In the 
case of a significant main effect of group or a significant interaction term, comparisons 
were made between groups at each block using the least significance difference test. 
 
(ii) Highest completed ratio and breakpoint. The breakpoint was defined as the last ratio 
to be completed before 5 min elapsed without any responding (Hodos 1961; Hodos and 
Kalman 1963). In most cases, this was identical to the highest ratio completed in the 
session. However, in some cases, this criterion was not met within the 50-min session. 
Therefore, the highest completed ratio and the breakpoint were analysed separately. The 
data were analysed in the same way as the peak response rate. Analysis of the highest 
completed ratio incorporated the data from all sessions, whereas analysis of the 
breakpoint entailed exclusion of data from sessions in which the formal breakpoint 
criterion was not attained. 
 
(iii) Overall response rate. Overall response rate was calculated for each ratio using the 
total time taken to complete the ratio, including the post-reinforcement pause, measured 
from the end of the preceding reinforcer delivery until the emission of the last response 
of the ratio (Bizo and Killeen 1997). The first ratio (a single response) and any ratios that 
had not been completed at the end of the session were excluded from the analysis. The 
raw data from the final pre-surgical and the four post-surgical blocks of 10 sessions were 
analysed by three-factor analysis of variance (group × block × ratio) with repeated 
measures on the second and third factors. Equation 1 was fitted to the overall response 
rate data from each rat using an iterative least-squares method (SigmaPlot, Version 8.0), 
and the estimated values of the parameters ȕ, į and a were derived; goodness of fit was 
expressed as r2, the proportion of the data variance accounted for by the equation. In 
agreement with previous findings  (Bezzina et al. 2008b; Bezzina et al. 2008c; Ho et al. 
2003; Mobini et al. 2000; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b), 
examination of the data revealed that in some rats very low response rates were generated 
under the highest ratios, which did not conform to Equation 1. Therefore the equation 
ZDV ILWWHG WR HDFK UDW¶V GDWD DIWHU H[FOXVLRQ RI WKHVH ORZ UDWHV XVLQJ WKH IROORZLng 
operational criterion (Mobini et al. 2000). Points were removed successively, starting 
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from the highest ratio completed, when the curve-fitting routine generated an abscissa 
intersection point (a/į) which lay to the left of the rightmost empirical datum point; such 
an intersection implies a negative predicted response rate, which is impossible 
empirically and specifically precluded by the model (section 1.4.3). A fit was accepted 
when the predicted response rates for all the surviving data points had positive values. 
This procedure seldom eliminated more than one datum point from the data sets derived 
from individual rats. A preliminary analysis of the estimates of the three parameters of 
Equation 1 (aįDQGȕ LQVXFFHVVLYHEORFNVRIVHVVLRQVEHIRUHVXUJHU\ DQDO\VLVRI
variance: group × block) was carried out in order to check that there were no significant 
between-group differences in the pre-surgical data. Then the post-surgical changes of the 
estimates of the three parameters obtained during the final pre-surgical block of sessions 
and the four post-surgical blocks were analysed in the same way as the highest completed 
ratio and peak response rate.  
 
(iv) Running response rate. Running rate was calculated by dividing the number of 
UHVSRQVHVE\WKHµUXQ-WLPH¶i.e. the time taken to complete the ratio, excluding the post-
reinforcement pause: Bizo et al. 2001). The data were analysed as described above. 
Equation 2 was fitted to the data from the individual rats and post-surgical changes in the 
parameters were analysed in the same way as the parameters of Equation 1.  
 
Because the number of ratios completed within a session under a progressive-ratio 
schedule differs among individual subjects, analyses of variance of the raw response rates 
included only those ratios that were completed by at least 75% of the rats in each group 
in each phase of the experiment (ratios up to and including 62), missing values being 
filled using the value obtained in the highest ratio completed by the subject in question 
(Rickard et al. 2009). (Note that this limitation did not apply to the quantitative analysis 
of response rates using Equations 1 and 2, which entailed fitting functions to the data 
from individual rats.) 
 
2.2.6.2.  Locomotor activity data 
 
Data were averaged across the two test sessions. The total numbers of beam breaks 
recorded in successive 5-min epochs were analysed by two-factor analysis of variance 
(group × epoch) with repeated measures on the latter factor. 
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2.2.6.3.  Food intake data 
  
Comparisons between groups were made XVLQJ6WXGHQW¶Vt-test.  
 




2.3.1. Operant behaviour data 
 
2.3.1.1.  Peak response rate 
 
The mean (±SEM) post-/pre-surgical differences in peak response rate for the sham-
lesioned and the OxSap-lesioned group are shown in Fig. 2.1 (left-hand panel). Analysis 
of variance revealed no significant main effect of group [F(1,27) = 2.24,  NS] or block 
[F<1]. However there was a significant group × block interaction [F(3,81) = 4.26, 
p<0.01], reflecting a decrement of the maximum response rate in the OxSap-lesioned 
group in the last three blocks of sessions after surgery. 
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Figure 2.1. Left-hand panel. Changes in peak response rate following surgery in the 
sham-lesioned (open circles) and OxSap-lesioned (filled circles) groups. Ordinate: 
change in the peak response rate (responses min-1); abscissa: blocks of 10 sessions. 
Points are differences between the values obtained in the four post-surgical blocks and 
the final pre-surgical block (Pre) (mean ± SEM). Significant difference between groups: 
* p<0.05. Middle panel: Changes in highest completed ratio; right-hand panel: Changes 
in break point; conventions as in left-hand panel. 
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2.3.1.2.  Highest completed ratio and breakpoint  
 
Both the highest completed ratio (Fig. 2.1, middle panel) and the breakpoint (Fig. 2.1, 
right-hand panel) were somewhat reduced after surgery, the reduction appearing slightly 
greater in the OxSap-lesioned group than in the sham-lesioned group. However, analysis 
of variance of the highest completed ratio revealed no significant main effect of group 
[F<1] or block [F(3,81) = 1.05, NS] and no significant interaction [F<1]. In the case of 
the breakpoint, there was a significant effect of block [F(3,69) = 3.0, p<0.05], but no 
significant effect of group and no significant interaction [Fs<1]. 
 
2.3.1.3.  Overall response rate 
 
Fig. 2.2 shows the estimates of the parameters of Equation 1 in successive blocks of 10 
sessions in the pre-surgical phase of the experiment. The parameter a showed a 
progressive increase during training, and the formal stability criterion (see above: 
Method) was not attained until the 10th block of sessions. Analysis of variance revealed a 
significant main effect of block [F(10,270) = 10.9, p<0.001], but no significant effect of 
group and no significant interaction [Fs<1]; moreover there was no significant difference 
between the groups in the final pre-surgical block [t(27) = 0.6, NS]. The other two 
parameters (į and ȕ) remained relatively stable during the training phase, there being no 
significant differences between the two groups across the eleven blocks [all Fs<1.2, NS] 
nor any significant difference in the final pre-surgical block [į: t(27) = 0.8, NSȕ t(27) = 
0.5, NS].  
 
Fig. 2.3 shows the group mean overall response rate data for the sham-lesioned (left hand 
panel) and OxSap-lesioned groups (right hand panel) in the last pre- and post-surgical 
blocks of sessions.  In both groups, response rate increased rapidly to a peak, and then 
gradually declined as the response/reinforcer ratio was progressively increased. The 
maximum response rate was reduced in the Ox-Sap lesioned group following surgery.  
The fits of Equation 1 to the group mean data accounted for >90% of the total variance 
(sham lesion: pre-surgery, r2 = 0.93; post-surgery, r2 = 0.90; OxSap lesion: pre-surgery, 
r
2
 = 0.94; post-surgery, r2 = 0.92). There were significant main effects of block [F 
(4,108) = 6.2,  p<0.001] and ratio [F(11,297) = 20.1, p<0.001], but not of group [F<1]. 
There were significant group × block [F(4,108) = 4.5, p<0.01] and block × ratio 
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[F(44,1188) = 1.9, p<0.01] interactions; the group × ratio and three-way interactions 
were not significant [Fs<1]. 
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Figure 2.2. Values of the three parameters of Equation 1 (left-hand graph: a; middle 
graph: į; right-hand graph: ȕ) in successive blocks of 10 sessions during the pre-surgical 
training phase of the experiment. The filled symbols show the mean values for all rats; 
the open symbols show the mean values for the rats that were subsequently allocated to 
the sham-lesioned group (triangles) and the Ox-Sap lesioned group (circles). 
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Figure 2.3. Overall response rates in successive ratios of the progressive-ratio schedule. 
Left hand panel: data from the sham-lesioned group; right hand panel: data from the 
OxSap-lesioned group. Ordinates: response rate (responses min-1); abscisae: ratio, N. 
Points are group mean data. Circles: data from the last ten sessions before surgery; 
triangles: data from sessions 31-40 after surgery. The curves are fits of Equation 1 to the 
data (see text for details). Note the reduction of response rates in the OxSap-lesioned 
group, but not the sham-lesioned group, following surgery. 
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Fig. 2.4 shows the changes in the parameters of Equation 1 following surgery. 
 
(i) µ6SHFLILFDFWLYDWLRQ¶ a. 
 There was no significant main effect of group [F<1] or block [F(3,81) = 1.1, NS], and no 
significant group × block interaction [F<1]. 
 
(ii) µ5HVSRQVHWLPH¶į 
There was a significant main effect of group [F(1,27) = 5.6, p<0.05], but not of block 
[F(3,81) = 2.1, NS]. There was a significant group × block interaction [F(3,81) = 2.3, 
p<0.05]. Multiple comparisons indicated that there was a significant increase in į in the 
OxSap-lesioned group, compared to the sham-lesioned group in the second, third and 
fourth post-surgical blocks. 
 
(iii) µ&XUUHQF\¶ȕ  
There was no significant main effect of group [F<1] or block [F(3,81) = 1.5, NS], and no 
significant interaction [F (3,81) = 1.3, NS]. 
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PARAMETERS OF EQUATION 1
 
 
Figure 2.4  Changes in the parameters of Equation 1 following surgery in the sham-
lesioned (open circles) and OxSap-lesioned (filled circles) groups. Ordinates: change in 
parameter value; abscissa: blocks of 10 sessions. Points are differences between the 
values obtained in the four post-surgical blocks and the final pre-surgical block (Pre) 
(mean ± SEM). Significant difference between groups: * p<0.05. Left-hand graph: 
µDFWLYDWLRQ¶SDUDPHWHUa (s); middle graphµUHVSRQVHWLPH¶SDUDPHWHUį (s); right-hand 
graphµFXUUHQF\¶SDUDPHWHUȕ. 
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2.3.1.4.  Running response rate 
 
Fig. 2.5 shows the group mean running response rate data for the sham-lesioned (left-
hand panel) and OxSap-lesioned groups (right-hand panel) in the last pre- and post-
surgical blocks of 10 sessions. In both groups, running rate declined monotonically as a 
function of the ratio requirement. Running rates were reduced following surgery in the 
OxSap-lesioned group. The fits of Equation 2 to the group mean data accounted for about 
95% of the total variance. There were significant main effects of block [F (4,108) = 7.2,  
p<0.001] and ratio [F(11,297) = 115.2, p<0.001], but not of group [F<1]. There was a 
significant group × block [F(4,108) = 10.0, p<0.01] interaction; the block × ratio 




































































Figure 2.5. Running response rates in successive ratios of the progressive ratio schedule. 
Left hand panel: data from the sham-lesioned group; right hand panel: data from the 
OxSap-lesioned group. Ordinates: response rate (responses min-1); abscisae: ratio, N. 
Points are group mean data . Circles: data from the last ten sessions before surgery; 
triangles: data from sessions 31-40 after surgery. Note the reduction of response rates in 
the OxSap-lesioned group, but not the sham-lesioned group, following surgery. 
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Fig. 2.6 shows the changes in the parameters of Equation 2 following surgery. 
 
(i) µ,QLWLDOUXQQLQJUDWH¶5i.  
There was a significant main effect of group [F(1,27) = 4.9, p<0.05], reflecting a lower 
value of this parameter in the OxSap-lesioned group than in the sham-lesioned group. 




There was no significant main effect of group [F<1] or block [F<1], and no significant 
interaction [F(3,81) =1.2, NS]. 
 
(iii) µ([SRQHQW¶ c.  
There was no significant main effect of group [F(1,27) = 2.7, NS] or block [F<1], and no 
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PARAMETERS OF EQUATION 2
 
Figure 2.6 Changes in the parameters of Equation 2 following surgery in the sham-
lesioned (open circles) and OxSap-lesioned (filled circles) groups. Ordinates: change in 
parameter value; abscissa: blocks of 10 sessions. Points are differences between the 
values obtained in the four post-surgical blocks and the final pre-surgical block (Pre) 
(mean ± SEM). Significant difference between groups: * p<0.05. Left-hand graph: 
µLQLWLDOUHVSRQVHUDWH¶SDUDPHWHURi (responses min-1); middle graphµGHFD\¶SDUDPHWHUb 
(s); right-hand graphµH[SRQHQW¶c. 
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2.3.2. Locomotor activity data 
 
Fig. 2.7 shows the locomotor activity data in successive 5-minute epochs of the 30-min 
test sessions. There was a significant main effect of epoch [F(5,135) = 18.9, p<0.001], 
reflecting the decline in activity after the first epoch. There was no significant main effect 
of group or group × epoch interaction [Fs<1].  
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Figure 2.7. Locomotor activity in the sham-lesioned (open circles) and OxSap-lesioned 
(filled circles) groups in 30-minute sessions. Ordinate: total beam breaks per 5-min 
epoch; abscissa: epochs. Points are group mean data (± SEM).  
 
 
2.3.3. Food intake and body weight 
 
2.3.3.1. Feeding tests 
  
Table 2.1 shows the total weights of 45-mg food pellets consumed during the 60-min 
tests under the food-restricted and free-feeding conditions. In neither case did food 
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consumption differ between the two groups [t<1 in each case]. Consumption of standard 
chow during the 23 hours between feeding tests under the free-feeding condition did not 
differ between the groups [t(27) = 1.0, NS].  
 
2.3.1.2.  Body weight  
 
'XULQJWKHRSHUDQWEHKDYLRXUH[SHULPHQWWKHUDWV¶ERG\ZHLJKWVZHUHPDLQWDLQHGDW
of their initial free-feeding weights. There was no significant difference between the 
weights of the food rations needed to maintain the criterion weights in the two groups 
[group × blocks of sessions: all Fs<1]. On return to the free-feeding condition, the body 
weights of both groups rapidly increased to their free-feeding levels; there was no 
significant difference between the two groups  [t(27) = 1.5, NS; see Table 2.1]. 
 
Table 2.1. Results of food consumption tests and body weight 
 Sham-lesioned group  OxSap-lesioned group 
Consumption of food pellets (g per 60-min session) 
 Food-restricted condition 12.8 ± 0.4  13.2 ± 0.5 
 Free-feeding condition 5.6 ± 0.5  6.1 ± 0.4 
Home-cage chow consumption (g per 23 h) 
 Free-feeding condition 22.4 ± 0.6  23.7 ± 1.1 
Body weight (g) 





Fig. 2.8 shows representative photomicrographs of sections stained for orexin (upper 
panels) and NeuN (lower panels). OxSap resulted in a marked loss of orexin-positive 
neurones from the LHA with a smaller loss from the PFA. Numerical data are shown in 
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Fig. 2.9. There was a significant reduction of the number of orexin-positive neurones in 
the LHA [approximately 50% reduction: t(27) = 3.7, p<0.001], whereas the reduction fell 
short of statistical significance in the case of thePFA [t(27) = 1.5, NS]. There was a small 
reduction of the number of NeuN-positive nuclei in the LHA in the lesioned group 
[approximately 12% reduction: t(27) = 1.9, p = 0.06]; there was no significant difference 





Figure 2.8. Left-hand panel. Diagram of coronal section of the rat brain at AP -3.3 mm, 
measured from bregma (from Paxinos and Watson 1998). The filled rectangles indicate 
the areas used for counting orexin-positive neurones and NeuN-positive nuclei. LHA, 
lateral hypothalamic area; PFA, perifornical hypothalamic area; MTT, 
mammillothalamic tract. Representative coronal sections through the hypothalamus of a 
sham-lesioned and an OxSap-lesioned rat are shown in the middle and right-hand panels; 
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Figure 9. Left-hand panel. Density of orexin-positive neurones counted in the lateral 
hypothalamic area (LHA) and perifornical hypothalamic area (PFA). Ordinate: number 
of cells counted per mm2. Columns show the group mean data (+SEM) for the sham-
lesioned (white bars) and lesioned (black bars) groups. Significant difference from sham-
lesioned group: * p<0.05. Right-hand  panel. Density of NeuN-positive nuclei counted in 





Injection of the OxSap neurotoxin into the LHA produced a significant depletion of 
orexin-containing neurones from the LHA. The lesion was most pronounced in the LHA. 
Some loss of orexinergic neurones was evident in the perifornical region in some rats; 
however, this was not statistically significant in the group as a whole. The destruction of 
orexinergic neurones by local injection of OxSap into the LHA is consistent with 
previous reports (Anaclet et al. 2010; Blanco-Centurion et al. 2007; Di Sebastiano et al. 
2011a; Di Sebastiano et al. 2010b; Frederick-Duus et al. 2007; Furlong and Carrive 2007; 
Gerashchenko et al. 2003; Gerashchenko et al. 2001; Vetrivelan et al. 2009).  
 
It is well established that orexinergic neurones are susceptible to the neurotoxic effects of 
OxSap; however the relative vulnerability of other neurones bearing the OX2 receptor 
remains controversial (see also section 1.2.2.) In an early study employing OxSap, 
Gerashchenko et al. (2001) found that in addition to orexin-containing neurones, 
melanocortin concentrating hormone (MCH)-containing neurones were also destroyed by 
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OxSap, whereas neurones expressing a-melanocyte-stimulating hormone were resiliant. 
The susceptibility of MCH-containing neurones to destruction by OxSap has been 
confirmed in some subsequent studies (Furlong and Carrive 2007; Ocampo-Garces et al. 
2011). However, there is evidence that MCH-containing neurones may be less vulnerable 
than orexin-containing neurones (Frederick-Duus et al. 2007), and indeed some authors 
found that injections of OxSap into the LHA which produced profound loss of 
orexinergic neurones had no significant effect on the numbers of MCH-containing 
neurones in this area (Di Sebastiano et al. 2011a; Di Sebastiano et al. 2010b). It is 
generally agreed that hypothalamic histaminergic neurones are sensitive to OxSap 
(Blanco-Centurion et al. 2007; Luo and Leung 2010), as are cholinergic neurones on the 
lateral dorsal tegmentum (Blanco-Centurion et al. 2004). Interestingly, noradrenergic 
neurones of the locus coeruleus have been found to be resistant to OxSap, probably 
reflecting the fact that these orexin-sensitive neurones express OX1 rather than OX2 
receptors (Blanco-Centurion et al. 2004).   
 
The relative selectivity of OxSap for OX2 receptor-bearing neurones appears to be dose-
dependent. High doses of OxSap generally produce non-selective neuronal loss (Furlong 
and Carrive 2007; Gerashchenko et al. 2006; Mistlberger et al. 2003), whereas the effect 
of lower doses tends to be more selective (Anaclet et al. 2010; Gerashchenko et al. 2006; 
Vetrivelan et al. 2009). In the present experiment, the number of neurones destroyed by 
OxSap appears to have been a relatively small proportion of the total population of 
neurones in the affected region, as indicated by the modest reduction of the number of 
NeuN-positive nuclei seen in the OxSap-lesioned group compared to the sham-lesioned 
group (relative loss, 12%; p=0.06). This is consistent with the results of some previous 
studies which employed low doses of OxSap (Di Sebastiano et al. 2010a; Di Sebastiano 
et al. 2011b; Gerashchenko et al. 2006). Therefore, taking all these factors into account, it 
seems that while the lesion used in this experiment produced a substantial depletion of 
orexinergic neurones from the LHA and presumably induced a major disruption of 
orexinergic output from this area, it is not possible to quantify the contribution of a 
putative loss of other orexin (OX2) receptor-bearing neurones of the LHA to the 
behavioural effects of the lesion. 
 
The performance of both the sham-lesioned and OxSap-lesioned groups on the 
progressive-ratio schedule was similar to that seen in many previous studies (see section 
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1.1.4; Bezzina et al. 2008b; Bezzina et al. 2008c; Bizo and Killeen 1997; Ho et al. 2003; 
Kheramin et al. 2005b; Killeen et al. 2009; Mobini et al. 2000; Rickard et al. 2009; 
Zhang et al. 2005a; Zhang et al. 2005b).  
 
It has been proposed that orexinergic neurones of the LHA play an important role in 
reinforcement processes (see sections 1.2.3.3 and 1.2.3.4: Cason et al. 2010; Harris and 
Aston-Jones 2006; Harris et al. 2005; Sharf et al. 2010b). It was therefore expected that 
destruction of orexinergic neurones of the LHA would suppress responding on this 
VFKHGXOH +RZHYHU .LOOHHQ¶V  WKHRUHWLFDO DQDO\VLV RI UHLQIRUFHPHQW VFKHGXOHV
indicates that suppression of responding on ratio schedules may be caused not only by a 
reduction of the activation parameter a but also by an increase of the parameter į. 
Therefore a change in either or both of these parameters is expected to alter the 
traditional index of progressive-ratio schedule performance, the breakpoint (see section 
1.4).  
 
Additionally to the breakpoint, the highest completed ratio was also analysed (see section  
2.2.6.1(ii): Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). Although both 
measures showed a tendency to be reduced following the OxSap lesion, the change was 
not statistically significant in either case. 
 
Application of Equation 1 to the overall response rate data indicated that the OxSap 
lesion had no significant effect on a, suggesting that the lesion did not alter the intrinsic 
value of the reinforcer. This conclusion is supported by the analysis of the running rate 
data using Equation 2, which showed that the decay parameter, b, related to reinforcer 
value (Rickard et al. 2009), was not significantly altered.  
 
On the other hand, the OxSap lesion produced a substantial increment LQ WKH µUHVSRQVH
WLPH¶SDUDPHWHUį, of Equation 1, DUHGXFWLRQRIWKHµLQLWLDOUHVSRQVHUDWH¶SDUDPHWHURi, 
of Equation 2, and a reduction of the peak response rate. Since į specifies the minimum 
time required to execute an operant response, the increase of this parameter in the 
OxSap-lesioned group is consistent with an impairment of motor capacity. The reduction 
of Ri is also consistent with this interpretation, and it is noteworthy that, unlike į, Ri is 
not influenced by the duration of the post-reinforcement pause; therefore the reduction of 
this parameter cannot readily be attributed to subtle changes in post-prandial behaviour in 
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the lesioned group (see Bezzina et al., 2008a, 2008b; Rickard et al., 2009). Ri has been 
found to be impervious to changes in reinforcer magnitude (Rickard et al. 2009), which 
further argues against the possibility that the effect of the lesion might have been caused 
by a change in reinforcer value. 
 
An impairment of motor function induced by the OxSap lesion is consistent with 
previous reports that stimulation of orexinergic mechanisms increases, and suppression 
of orexinergic mechanisms reduces, postural muscle tone and motor output (Anaclet et 
al. 2010; Hara et al. 2001; Ida et al. 1999; Jones et al. 2001; Kiyashchenko et al. 2001; 
Torterolo et al. 2003; Wu et al. 2002). 
 
The lack of effect of the lesion on the parameters of Equations 1 and 2 that are related to 
the incentive value of reinforcers is in apparent disagreement with previous findings 
indicating that the LHA orexinergic projection is critically involved in determining 
reinforcer efficacy. Evidence consistent with this proposition derives from a range of 
pharmacological manipulations, for example, systemic or central administration of orexin 
receptor antagonists (Borgland et al. 2009; Choi et al. 2010; Clegg et al. 2002; Harris and 
Aston-Jones 2006; Harris et al. 2005; Zheng et al. 2007), central administration of orexin 
or its precursor (Choi et al. 2010; Thorpe et al. 2005a; Thorpe and Kotz 2005), and a 
variety of behavioural paradigms (e.g., conditioned place preference: Harris et al., 2005, 
2007; Narita et al., 2006; consumption of palatable diet: Borgland et al., 2009; Clegg et 
al., 2002; Sharf et al., 2010; Zheng et al., 2007;  performance on progressive-ratio 
schedules: Borgland et al., 2009; Choi et al., 2010; Thorpe et al., 2005). Several 
methodological factors may have contributed to the apparent discrepancy between the 
present findings and the results of previous experiments. Firstly, it may be noted that no 
previous investigation of the effect of manipulating orexinergic function on 
reinforcement processes has used the neurotoxin OxSap to destroy LHA orexinergic 
neurones. In the present experiment, OxSap injected into the LHA induced a 50% loss of 
orexin-containing neurones from this area. It is possible that a more extensive depletion 
may be required in order to reveal an effect on the incentive value of food reinforcers.  
 
Another potentially important factor is the level of food deprivation. The subjects of this 
experiment were maintained at 80% of their free-feeding body weights, whereas most 
previous studies of the effect of manipulating orexinergic function on motivated 
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behaviour have been carried out on non-deprived animals or under milder deprivation 
conditions than that used in this experiment (Borgland et al. 2009; Cason et al. 2010; 
Harris and Aston-Jones 2006; Sharf et al. 2010b; Thorpe et al. 2005a). It is not clear how 
this might have influenced the results, although the control of food intake is known to be 
different in non-deprived and deprived states (Rowland et al. 2001). It is known that in 
food-deprived subjects various pathways in addition to those involving orexinergic 
mechanisms modulate food intake. For example, food deprivation increases immediate-
early gene expression in neuropeptide-Y containing neurones of the arcuate nucleus 
(Cummings et al. 2001), and plasma ghrelin is elevated by food deprivation (Gerard et al. 
1990; Meister 2007). Conceivably, the operation of non-orexinergic mechanisms might 
have compensated for an effect of orexin depletion on reinforcer value in the food-
deprived animals used in the present study. In this context, it is of interest that Sharf et al. 
(2010) recently found that the performance of mice lacking the orexin precursor prepro-
orexin (orexin -/-) on a progressive-ratio schedule did not differ from that of normal 
mice. Sharf et al. (2010) suggested that non-orexinergic mechanisms may have 
compensated for the lack of orexin in the genetically modified animals. 
 
Yet another potentially relevant methodological factor is the length of training which the 
rats underwent before surgery. In most previous experiments in which the progressive-
ratio schedule has been used to evaluate the effects of manipulating orexinergic function, 
the initial training period has been in the order of 5-15 sessions (Borgland et al. 2009; 
Choi et al. 2010; Thorpe et al. 2005a). Although responding on the progressive-ratio 
schedule is generally well established within a few days of training, several previous 
studies have found that many sessions are required in order to attain stability of the 
parameters of Equation 1 (Bezzina et al. 2008b; Bezzina et al. 2008c; Kheramin et al. 
2005b; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). In the present 
experiment, attainment of the formal stability criterion based on the parameters of 
Equation 1 required approximately 100 training sessions; this was especially apparent in 
WKHFDVHRIWKHµVSHFLILFDFWLYDWLRQ¶SDUDPHWHUa (see Figure 2.2). It is not clear how such 
protracted training might have affected the results of this experiment. There is evidence 
WKDWDIWHUH[WHQGHG WUDLQLQJ OHDUQHGEHKDYLRXU WHQGV WREHFRPHµKDELWXDO¶DQGUHODWLYHO\
insensitive to reinforcer devaluation or changes in motivational level (de Wit et al.; 
Dickinson 1985; Miles et al. 2003). It is possible that, in the present experiment, the UDWV¶
extensive experience with the progressive-ratio schedule reduced the impact of an 
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OxSap-induced decrease in reinforcer value on schedule performance. Further 
experiments may be warranted to examine the impact of prior training on the sensitivity 
of operant behaviour to manipulation of orexinergic function.  
 
7KHµFXUUHQF\¶SDUDPHWHU ȕ, of Equation 1 did not differ significantly between the two 
groups. ȕ H[SUHVVHVWKHµFRXSOLQJ¶RIUHVSRQGLQJWRUeinforcers, which is purported to be 
determined, in part, by the working memory limitations of the organism (Killeen 1994). 
An effect of the OxSap lesion on this parameter might therefore have been expected, in 
view of evidence indicating that manipulation of orexinergic function in the medial 
septum,  hippocampus and dentate gyrus, whose orexinergic afferents emanate from the 
LHA, can alter mnemonic functions, including working memory (Akbari et al. 2008; 
Akbari et al. 2006; Smith and Pang 2005). However, it has yet to be demonstrated 
experimentally that the empirical value of ȕ derived from ratio schedule performance is 
sensitive to disruption of working memory.  
 
There was no significant difference between the spontaneous locomotor activity of the 
OxSap-lesioned and sham-lesioned rats in this experiment. Previous studies have shown 
that acute central administration of orexins increases spontaneous locomotor behaviour, 
whereas orexin receptor antagonists reduce it (Jones et al. 2001; Thorpe and Kotz 2005). 
However, orexin deficient rodents have been found to show normal levels of locomotor 
activity (Sharf et al. 2010a) or altered activity levels that are restricted to a brief period at 
the start of the dark phase of the daily cycle (Hara et al. 2001). It is possible that 
alteration of locomotor behaviour is not sustained on a chronic basis in the absence of 
orexinergic function. In this experiment the rats underwent locomotor testing 
approximately six weeks after the OxSap lesion had been inflicted. It would be of interest 
to examine whether locomotor behaviour is suppressed at an earlier stage following this 
lesion. 
 
Food intake was not affected by the OxSap lesion in this experiment. Previous reports 
have emphasised the preferential effect of orexinergic manipulations on the ingestion of 
especially palatable foods in non-deprived animals (Borgland et al. 2009; Farr et al. 
2005; Nair et al. 2008; Sakurai et al. 1998; Thorpe et al. 2005a; Thorpe et al. 2006; 
Thorpe and Kotz 2005). The food pellets used in the food intake tests in the present 
experiment were the same as those used in the operant behaviour tests. Although these 
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pellets are more palatable than standard laboratory chow, it is possible that they were not 
sufficiently appetizing to reveal an effect of the lesion on food intake.  
 
In conclusion, the results obtained in this experiment confirm that disruption of 
orexinergic mechanisms in the LHA results in a significant disruption of food-reinforced 
operant behaviour maintained under the progressive-ratio schedule. Quantitative analysis 
RI SHUIRUPDQFH EDVHG RQ .LOOHHQ¶V  PDWKHPDWLFDO PRGHO RI VFKHGXOH-controlled 
behaviour (MPR) indicated that this disruption was not brought about by a change in the 
incentive value of the food reinforcer, but by a change in non-motivational processes that 
DUHHQFDSVXODWHGLQWKHµUHVSRQVH-WLPH¶SDUDPHWHUįRI.LOOHHQ¶VPRGHO7KLVLV
consistent with the suggestion that motor effects may play a more important role in the 
effects of manipulating orexinergic function on reinforced behaviour than has previously 

































EXPERIMENT 2: EFFECT OF OREXIN-B-SAPORIN-INDUCED 
DISCONNECTION OF THE LATERAL HYPOTHALAMUS FROM 
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3.1.  Introduction 
 
As reviewed in Chapter 1 (section 1.2), the orexinergic projection from the hypothalamus 
is believed to play an important role in the modulation of reward processes, arousal and 
the regulation of the sleep/wakefulness cycle (see section 1.2.3). More specifically, there 
is a growing amount of evidence for the importance of the orexinergic pathway between 
the LHA and the VTA in reward processes, including both food and drug reinforcers (see 
section 1.2.3.3). For instance, the administration of orexin A directly into the VTA has 
been found to re-establish previously extinguished drug seeking behaviour (Harris et al. 
2005). More recently, it has been reported that the disconnection of the LHA from the 
VTA disrupts drug seeking behavior (Harris et al. 2007). In this study of Harris et al. 
(2007), the LHA was unilaterally lesioned using the excitatory amino-acid N-methyl-D-
aspartate (NMDA), and the OX1 receptor antagonist SB-334867 was microinjected in the 
contralateral or ipsilateral VTA. Since the LH-VTA pathway is principally ipsilateral, the 
contralateral treatment was assumed to produce an acute µfunctional disconnection¶ of the 
LHA from the VTA (for other examples of 'funcitonal disconnections' see Bezzina et al. 
2008a; Gaffan and Eacott 1995). Harris et al. (2007) found that a morphine-induced 
conditioned place preference (CPP) task was blocked in the disconnection group. The 
results led the authors to conclude that the orexinergic projections between LHA and 
VTA are important in drug reward processes. 
 
As previously described, the progressive-ratio schedule (Hodos 1961; Hodos and Kalman 
1963) has been used to evaluate the incentive value of reinforcers. However, there are 
several problems related with the traditional measure derived from this schedule, the 
breakpoint (see section 1.4.1). Some of these problems can be overcome by using 
Killeen¶s (1994) MPR model (see section 1.4.3). This model yields a quantitative index 
of reinforcer value (as denoted by changes in the parameter a) and dissociates effects of 
interventions on motor (expressed by the motor parameter į) and motivational processes 
(see section 1.4.3).  
 
In the present experiment the putative role of the orexinergic projections between LHA 
and VTA in relation to reward or motor processes was investigated. Three groups of rats 
underwent surgical interventions where the LHA was chronically disconnected from the 
VTA or control procedures (unilateral lesions of the LHA and VTA, or sham lesions). 
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Lesions were induced by intracerebral injections of the selective neurotoxin OxSap (see 
sections 1.2.2 and 2.4). The effects of the interventions were evaluated using .LOOHHQ¶V
(1994) MPR model (see section 1.4.3). Based on the putative role of the LHA/VTA 
orexinergic pathways in reward processes (Harris et al. 2007), it was predicted that this 
chronic VTA/LHA disconnection would produce a reduction of the incentive value 
parameter a. The disconnection lesion was not expected to change the response time 
parameter į or the currency parameter ȕ. In addition, food intake and body weight were 







Forty four experimentally naive female Wistar rats approximately 4 months old and 
weighing 250±300 g at the start of the experiment were used. They were housed under 




The rats were divided into three groups: disconnection (VTA lesion is contralateral to 
LHA lesion), unilateral (VTA lesion is ipsilateral to LHA lesion) and sham-lesioned 
groups. The first two groups received unilateral lesions of the LHA with the orexin-B-
saporin conjugate (OxSap: Advanced Targeted Systems, USA). In addition to the LHA 
lesion, the disconnection group (n=16) received an OxSap injection in the contralateral 
VTA. The unilateral group (n=14) received an OxSap injection in the ipsilateral VTA. 
Finally, the sham-lesioned group (n=14) received injections of the vehicle solution (0.9% 
sodium chloride solution) instead of OxSap into the same target regions. The injection 
was administered to the left LHA in half rats in each group, and to the right LHA in the 
remaining rats. The coordinates for the LHA lesion were the same as in the previous 
experiment (see section 2.2.2). The coordinates for the VTA lesion were AP -5.3, L 
+/-0.9, V -8.4, measured from bregma. The quantity of OxSap injected into the LHA and 
VTA was 30 QJLQȝO in each case. The rest of the surgical procedures were identical 
to those used  in Experiment 1 (see section 2.2.2). 




The same operant conditioning chambers, control apparatus and software were used as in 
Experiment 1 (see section 2.4.1.1). 
 
3.2.4. Behavioural procedures 
  
3.2.4.1.  Progressive ratio schedule 
 
The behavioural training was carried out exactly in the same way as in Experiment 1 (see 
section 2.2.4.1). 
 
3.2.4.2.  Food intake 
 





The procedures for fixing the tissue, taking frozen sections and staining for orexin and 
NeuN were identical to those used in Experiment 1 (see section 2.4.1). In addition to the 
LHA sections, three sections were taken  through the VTA for NeuN staining.  
 
3.2.6.   Data analysis  
 
The data from two rats were discarded (one from the disconnection group and the other 
from the unilateral group). These rats constituted µoutliers¶ as they had pre-surgical 
values of a over 900 seconds, well outside the range of values seen in the other rats. 
Analyses were thus based on the data from the disconnection (n=15), unilateral (n=13) 
and sham (n=14) lesioned groups.  The data were analysed in the same way as in 
Experiment 1 (see section 2.2.6). 
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3.2.6.1.  Operant behaviour data 
 
Data from the last block of 10 sessions before surgery and the four successive blocks of 
10 sessions following surgery were used in the analyses. Behavioural measures (see 
below) were analysed by analysis of variance, followed, in the case of significant F-
ratios, by post hoc comparisons of the two lesioned groups with the sham-lesioned group 
using DunnetW¶VWHVW The behavioural measures analysed were the same as those used in 
Experiment 1 (see section 2.2.6.1). 
 
3.2.6.2.  Food intake data 
 





3.3.1.  Operant behaviour data 
 
3.3.1.1.  Peak response rate 
 
The mean (±SEM) post-/pre-surgical differences in peak response rate for the sham-
lesioned, unilateral-lesioned and disconnection-lesioned groups are shown in Fig. 3.1 
(left-hand panel). Analysis of variance revealed no significant main effects of group 
[F(2,39) = 1.8,  NS]. However, there was a significant main effect of block [F(3,117) = 
12.4, p<0.001] and group × block interaction [F(6,117) = 2.6, p=0.05]. Post hoc 
comparisons indicated a decrement of the peak response rate in the disconnection group 
in the second block of 10 sessions after surgery.  
 
3.3.1.2.  Highest completed ratio and breakpoint 
 
Both the highest completed ratio (Fig. 3.1, middle panel) and the breakpoint (Fig. 3.1, 
right-hand panel) were reduced in the first post-surgical block in all three groups. 
Analysis of variance of the highest completed ratio revealed no significant effect of 
 - 85 - 
group [F<1]. However, there was a significant main effect of block [F(3,117) = 17.7 p< 
0.001] and a significant block × group interaction [F(6,117) = 5.2 p<0.001].  In the case 
of the breakpoint, there was a significant effect of block [F(3,117) = 15.3  p<0.001] and  
a significant interaction [F(6,117) = 4.4 p< 0.001]. No significant main effect of group 
was found [F<1]. Comparison of the three groups at each level of block with one way 
analysis of variance IROORZHG ZLWK 'XQQHWW¶V WHVW GLG QRW UHYHDO VLJQLILFDQW GLIIHrences 




Figure 3.1. Left-hand panel. Changes in peak response rate following surgery in the 
sham (open circles), unilateral (filled triangles) and disconnection (filled circles) lesioned 
groups. Ordinate: change in the peak response rate (responses min-1); abscissa: blocks of 
10 sessions. Points are differences between the values obtained in the four post-surgical 
blocks and the final pre-surgical block (Pre) (mean ± SEM). Significant difference 
between groups: * p<0.05. Middle panel: Changes in highest completed ratio; right-hand 
panel: Changes in break point; conventions as in left-hand panel. 
 
 
3.3.1.3.  Overall response rate 
 
As in the previous experiment (see section 2.3.1.2), the parameters of Equation 1 reached 
stability after approximately 100 sessions. The same stability criterion was adopted for 
the present experiment.  
 
The group mean data from the pre-surgical and third post-surgical block are shown in 
Fig. 3.2. In the three groups, response rate increased rapidly to a peak, and then gradually 
declined as the response/reinforcer ratio was progressively increased. The fits of 
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Equation 1 to the group mean data accounted for >90% of the total variance (sham-
lesioned group : pre-surgery, r2 = 0.96; post-surgery, r2 = 0.93; disconnection lesioned 
group: pre-surgery, r2 = 0.92; post-surgery, r2 = 0.94; unilateral lesioned group: pre-
surgery, r2 =   0.92 post surgery, r2 =  0.93). There was a significant main effect of block 
[F (1,39) = 8.3, p<0.01] and ratio [F(17,663) = 208.7, p<.001], but not of  group [F<1]. 
There was also a significant block × group interaction [F (2,39) = 8.3,  p<0.001]  and 
group ×  ratio × block  interaction [F(34,663) = 2.3, p<.001]. There were no significant 



















Figure 3.2. Overall response rates in successive ratios of the progressive-ratio schedule. 
Left hand panel: data from the sham-lesioned group; Middle panel: data from the 
disconnection-lesioned group; Right hand panel: data from the unilateral-lesioned group 
Ordinates: response rate (responses min-1); abscisae: ratio, N. Points are group mean 
data. Open symbols: data from the last ten sessions before surgery; filled symbols: data 
from sessions 21-30 after surgery. The curves are fits of Equation 1 to the data (see text 
for details).  
 
 
Fig. 3.3. shows the changes in the parameters of Equation 1 following surgery. 
 
(i) µ6SHFLILFDFWLYDWLRQ¶ a 
There was no significant main effect of block [F(3,117) = 1.2, NS] or group [F<1] and no 
significant group × block interaction [F(6,117) = 1.2, NS] 
 
(ii) µ5HVSRQVHWLPH¶į 
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There was an almost significant main effect of group [F(2,39) = 3.1, p =0.057], but not of 
block [F(3,117) = 1.5, NS]. There was no significant group × block interaction [F(6,117) 
= 1.0, NS]. Multiple comparisons indicated that there was a significant increment of the 
motor parameter į in the unilateral group in the first block and in the disconnection group 
in the third block compared with the sham-lesioned group. 
 
(iii) µ&XUUHQF\¶ȕ  
There was a significant main effect of block [F(3,117) = 3.6, p<0.05]. However, there 
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Figure 3.3. Changes in the parameters of Equation 1 following surgery in the sham-
lesioned (open circles) unilateral-lesioned (filled triangles)  and disconnection-lesioned 
(filled circles) groups. Ordinates: change in parameter value; abscissa: blocks of 10 
sessions. Points are differences between the values obtained in the four post-surgical 
blocks and the final pre-surgical block (Pre) (mean ± SEM). Significant difference 
between unilateral- (*) or disconnection- (#) lesioned group and the sham-lesioned 
group:  p<0.05. Left-hand graph: µDFWLYDWLRQ¶SDUDPHWHUa (s); middle graph µUHVSRQVH
WLPH¶SDUDmeter, į (s); right-hand graphµFXUUHQF\¶SDUDPHWHUȕ. 
 
 
3.3.1.4.  Running response rate 
 
Fig. 3.4. shows the group mean running response rate data for the sham- (left-hand panel) 
disconnection- (middle panel) and unilateral-lesioned groups (right-hand panel) in the 
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last pre- and post-surgical blocks of 10 sessions. In all three groups, running rate declined 
monotonically as a function of the ratio requirement. Running rates were reduced 
following surgery in both the disconnection- and unilateral-lesioned groups. The fit of 
Equation 2 to the group mean data accounted for over 95% of the total variance in each 
case. There was a significant main effect of ratio [F (17,663) = 203.6, p<0.001] but not 
of block [F(1,39) = 2.9, NS] or group [F<1]. There was a significant group × block 
interaction [F(2,39) = 7.2, p<0.01], but neither the block × ratio [F<1] nor the group × 
ratio [F<1] interaction was significant. Finally, the three-way block × ratio × group 
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Figure 3.4. Running response rates in successive ratios of the progressive ratio schedule. 
Left hand panel: data from the sham-lesioned group; middle panel: data from the 
disconnection-lesioned group and right hand panel unilateral-lesioned group. Ordinates: 
response rate (responses min-1); abscise: ratio, N. Points are group mean data. Open 
symbols: data from the last ten sessions before surgery; filled symbols: data from sessions 
31-40 after surgery. Note the reduction of response rates in the disconnection and 
unilateral groups, but not the sham-lesioned group, following surgery. 
 
Fig. 3.5. shows the changes in the parameters of Equation 2 following surgery. 
 
(i) µ,QLWLDOUXQQLQJUDWH¶5i  
There was a significant main effect of group [F(2,39) = 7.6, p<0.01], reflecting a lower 
value of this parameter in the unilateral- and disconnection-lesioned groups in 
comparison with the sham-lesioned group after surgery. The main effect of block [F<1] 
and the group × block interaction [F(6,117) = 1.1, NS] were not significant. Post hoc 
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comparison with Dunnett¶V test revealed a significant decrement in this parameter in 
blocks 1, 3 and 4 after surgery in the disconnection- and unilateral-lesioned groups 
following the surgical procedure. 
 
(ii) µ'HFD\SDUDPHWHU¶E 
There was a significant main effect of block [F(3,117) = 2.7, p=0.05]. However, the main 
effect of group [F<1] and the block × group interaction [F<1] were not significant.  
 
(iii) µ([SRQHQW¶F  
There was no significant main effect of group [F<1] or block [F<1], and no significant 
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Figure 3.5 Changes in the parameters of Equation 2 following surgery in the sham-
lesioned (open circles) unilateral-lesioned (filled triangles) and disconnection-lesioned 
(filled circle) groups. Ordinates: change in parameter value; abscissa: blocks of 10 
sessions. Points are differences between the values obtained in the four post-surgical 
blocks and the final pre-surgical block (Pre) (mean ± SEM). Significant differences 
between the sham- and unilateral-lesioned groups (*) and between the sham- and 
disconnection-lesioned groups (#): p<0.05. Left-hand graph: µLQLWLDO UHVSRQVH UDWH¶
parameter, Ri (responses min-1); middle graph µGHFD\¶ SDUDPHWHU b (s); right-hand 
graphµH[SRQHQW¶c. 
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3.3.2. Food intake and body weight 
 
3.3.2.1. Feeding tests 
 
Table 3.1. shows the total intake of 45 mg food pellets during 60-min test under food 
deprivation and free feeding conditions. ANOVA yielded a significant group effect 
[F(2,39) = 5.8, p<0.01] under food restricted conditions. Post hoc tests (least significant 
difference test) revealed higher consumption of food pellets in the unilateral-lesioned 
group in comparison with the disconnection- but not with the sham-lesioned group. There 
was also a significant higher consumption of pellets in the unilateral group [F(2,39) = 
5.3, p<0.01] in comparison with both the sham-lesioned and the disconnection-lesioned 
groups under the free-feeding condition.  
 
The total amount of chow intake during the free feeding condition did not show any 
significant differences among the groups [F(2,39) = 1.5, NS].  
 

















4.5 ± 0.3 5.6 ± 0.2*# 4.2 ± 0.4 




22.2 ± 0.3 23.7 ± 0.6 22.7 ± 0.8 




291.1 ± 2.5 294.0 ± 3.1 286.0 ± 3.1 
 
* significant difference from sham-lesioned group (p<0.05)  
# significant difference from disconnection-lesioned group (p<0.05) 
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3.3.2.2. Body weight and food ration  
 
As in the previous experiment (see section 2.3.3.2), the rats¶ body weights were 
maintained at 80% of their initial free-feeding body weights. The three groups¶ body 
weights were compared during the baseline and free-feeding conditions (Table 2.1). 
There were no significant time [F<1] or group effects [F(2,39) = 1.4, NS], and no 
significant  group × time interaction [F<1]. A significantly higher amount of food ration 
was needed in the disconnection group in order to maintain the criterion weight during 




Fig. 3.6 shows representative photomicrographs of sections taken through the 
hypothalamus, stained for orexin (upper panels) and NeuN (middle panels), and sections 
taken through the VTA, stained for NeuN (lower panels). OxSap resulted in a marked 
loss of orexin-positive neurones from the LHA with a much smaller loss from the 
perifornical region. There was some loss of NeuN-positive units in the LHA, the PFA 
and the VTA. 
 
Fig. 3.7 shows the numerical data for the counts of orexin-positive neurones in the LHA 
and PFA (left hand panel) and the NeuN-positive nuclei in the LHA, PFA and VTA 
(right hand panel). OxSap created a substantial reduction of the density of orexin-positive 
neurones in the LHA and a smaller reduction in the PFA. Analysis of variance revealed a 
significant reduction of the number of orexin-positive neurones in both OxSap-lesioned 
groups in the LHA [approximately 50%: F(2,34) = 5.7 p<0.01] when compared with the 
sham lesioned group. The effect of the lesion did not reach statistical significance in the 
case of the PFA [F<1]. 
 
OxSap produced a significant reduction [F(2,37) = 14.8, p<0.01] in the number of NeuN 
positive nuclei in the LHA in both the disconnection- and the unilateral-lesioned groups 
(approximately 40% and 30% respectively). In the case of the PFA the effect of OxSap 
was significant [F(2,37)= 9.3, p<0.001], but post hoc comparisons indicated that the only 
disconnection-lesioned group differed significantly from the sham-lesioned group. The 
number of NeuN positive nuclei was significantly reduced in the VTA [approximately 
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50%: F(2,41) = 6.4, p<0.01]  in both the unilateral- and disconnection-lesioned groups 




Figure 3.6. Left-hand panels. Diagrams of coronal sections of the rat brain at AP -3.3 
and -5.3 mm, measured from bregma (from Paxinos and Watson 1998). The filled 
rectangles indicate the areas used for counting orexin-positive neurones and NeuN-
positive nuclei in the hypothalamus (upper diagram) and the VTA (lower diagram). 
LHA, lateral hypothalamic area; PFA, perifornical hypothalamic area; MTT, 
mammillothalamic tract; ML, medial lemniscus; SN, substantia nigra; VTA, ventral 
tegmental area. Middle and right-hand panels. Representative coronal sections taken 
through sham-lesioned (middle panel) and OxSap-lesioned (right-hand panel) brains 
(each pair of sections is from the same rat); upper panels: sections through the 
hypothalamus stained for orexin; middle panels: sections through the hypothalamus 
















































Figure. 3.7. Left-hand panel. Density of orexin-positive neurones counted in the lateral 
hypothalamic area (LHA) and perifornical hypothalamic area (PFA). Ordinate: number 
of cells counted per mm2. Columns show the group mean data (+SEM) for the sham-
lesioned (white bars), unilateral-lesioned (grey bars) and disconnection-lesioned (black 
bars) groups. Significant difference from sham-lesioned group: * p<0.05. Right-hand  
panel. Density of NeuN-positive nuclei counted in the LHA, PFA and VTA (ventral 




3.4.  Discussion 
 
Injection of OxSap into the LHA induced a significant reduction of orexin-containing 
neurones in both the unilateral- and disconnection-lesioned groups when compared with 
the sham-lesioned group. The adjacent PFA was also affected in both OxSap-lesioned 
groups, the effect reaching statistic significance in the case of the disconnection-lesioned 
group. The effective depletion of orexin-containing neurones using OxSap is in 
agreement with previous reports (Anaclet et al. 2010; Blanco-Centurion et al. 2007; Di 
Sebastiano et al. 2011a; Frederick-Duus et al. 2007; Furlong and Carrive 2007; 
Gerashchenko et al. 2003; Gerashchenko et al. 2001; Vetrivelan et al. 2009) and with the 
results of Experiment 1 (see section 2.3). As discussed in section 2.4, other neurones 
bearing the OX2 receptor are also susceptible to OxSap. To evaluate the extent of the 
lesion on other populations of neurones, the number of NeuN-positive nuclei was 
quantified in the LHA, PFA and VTA. The results showed that both OxSap-lesioned 
groups had a reduction of NeuN-positive nuclei in the LHA, PFA and VTA in 
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comparison with the sham-lesioned group. This reduction reached statistical significance 
in both the LHA and the VTA when compared with the sham-lesioned group. 
 
The selectivity of OxSap is dose-dependent (see section 2.4). In this experiment the dose 
of OxSap was higher than in the previous experiment (30 ng vs 15 ng). The higher dose 
was adopted in this experiment in an attempt to produce a more profound depletion of 
orexinergic neurones in the target area. However, the effect of the higher dose on the 
density of orexin-containg neurones was very similar to that seen in Experiment 1 
(approximately 50% depletion in both cases). The higher dose of OxSap did, however, 
result in a greater loss of NeuN-positive nuclei in the LHA in the present experiment 
(35% ), than in the previous experiment (12%). This result is in agreement with previous 
reports of dose-dependent selectivity of the effect of OxSap (Di Sebastiano et al. 2010a; 
Di Sebastiano et al. 2011b; Frederick-Duus et al. 2007; Gerashchenko et al. 2006).  
 
It is not entirely clear why the higher dose of OxSap used in this experiment did not 
result in a more profound loss of orexin-containing neurones. One possibility is that a 
sub-population of orexinergic neurones in the LHA is relatively resistant to OxSap 
because they express OX1 receptors rather than OX2 receptors. OxSap is a conjugate of 
orexin-B and saporin; since orexin-B binds preferentially to OX2 receptors 
(Gerashchenko et al. 2001), any orexinergic neurones that do not express these receptors 
would be expected to be relatively resistant to the neurotoxin. It must be emphasised that 
this interpretation of the present findings is speculative, because there do not seem to be 
any published data on the proportion of hypothalamic neurones that exclusively express 
one or other of the two subtypes of orexin receptor. 
 
Since OX2 receptors are expressed in the VTA (Lu et al. 2000; Trivedi et al. 1998) (see 
section 1.2.1), it was expected that OxSap would produce some neuronal loss in the 
VTA. This expection was confirmed by the reduction of NeuN-positive nuclei in the 
OxSap-treated hemisphere (see Fig. 3.7).  
 
The performance of the disconnection-, unilateral- and sham-lesioned groups on the 
progressive-ratio schedule was similar to other studies (see section 1.4) (Bezzina et al. 
2008b; Bezzina et al. 2008c; Bizo and Killeen 1997; den Boon et al. 2011; Ho et al. 
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2003; Kheramin et al. 2005b; Killeen et al. 2009; Mobini et al. 2000; Rickard et al. 2009; 
Zhang et al. 2005a; Zhang et al. 2005b).  
 
As discussed earlier, the results of some previous studies have suggested that the 
orexinergic pathways emanating from the LHA may be involved in the regulation of 
reward value (see section 1.2.3.3 and 1.2.3.4)  (Cason et al. 2010; Harris and Aston-Jones 
2006; Harris et al. 2005; Harris et al. 2007; Sharf et al. 2010b). In particular, Harris et al. 
(2007) implicated the orexinergic projection from the LHA to the VTA in reinforcement 
processes. This experiment further investigated this hypothesis by disconnecting the 
orexinergic projection from the LHA to the VTA.   
 
It was expected that the disconnection-lesioned group would show a decrement in the 
value of the activation parameter a (Equation 1), which has been proposed as a 
quantitative measure of reinforcer value (Reilly 2003; Rickard et al. 2009). Several 
previous studies have examined the effect of orexins or orexin receptor antagonists on 
progressive-ratio schedule performance, and it has been observed that these treatments 
have increased or decreased the breakpoint, respectively (Borgland et al. 2009; Choi et 
al. 2010; Nair et al. 2008; Sharf et al. 2010a). However, apart from the experiment 
described in Chapter 2, no previous studies have examined the effects of orexinergic 
treatments on the parameters of Equation 1. The present results show that a did not 
change significantly in any of the groups during the 4 blocks of 10 sessions after surgery. 
This finding is also supported from the analysis of the running rate (Equation 2). In this 
case, the decay parameter b, which has been shown to be sensitive to the magnitude of 
the reinforcer (Rickard et al. 2009), was not altered following the surgical intervention.  
 
In addition, the traditional breakpoint and the highest completed ratio were also analysed. 
As can be seen from Fig. 3.1, there was a trend for both measures to be reduced in the 
second postsurgical block of 10 sessions. This apparent reduction could be explained as a 
postsurgical debilitating effect, due to the fact that in the following 3rd and 4th post- 
surgical blocks, the parameters recovered to similar values to those seen presurgically. It 
should also be noted that this reduction of the breakpoint and highest completed ratio was 
accompanied by a significant reduction of the peak response rate in the same block of 
sessions. In other words, the reduction of the breakpoint could have been due to motor 
rather than motivational factors. Furthermore, any conclusions based on the breakpoint, 
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which is based on a single data point, have to be taken cautiously, as there are several 
problems associated with this measure (see section 1.4). Moreover, methodological 
differences from previous studies, such as the food deprivation level, the length of 
training and the kind of reinforcers used, may have contributed to the lack of effect on 
the activation parameter (see section 2.4).  
 
Although no reduction was found in either of the parameters that express the incentive 
value of  food reinforcers a (Equation 1) or b (Equation 2), a significant effect was found 
on the two parameters which are related to motor performance, į (Equation 1) and Ri 
(Equation 2) (see section 2.1). The increment of į in the disconnection-lesioned group is 
consistent with the previous experiment (see Chapter 2), where a bilateral lesion of 
orexinergic neurones in the LHA produced an increment of į and a reduction of Ri.. This 
increment of the response time parameter į was significant in the third block of sessions 
in the disconnection group. The significant effect seen in the unilateral-lesioned group in 
the second block was unexpected. It is possible that it reflects a slower postsurgical 
recovery in this group, because the effect gradually subsided, and by block 4 the value of 
įLQthis group had returned to a value  similar to the presurgical value. Another possible 
explanation is that this group had slightly greater loss of orexin-containing neurones from 
the LHA, and NeuN-positive nuclei in the VTA, than the disconnection-lesioned group 
(see Fig 3.9).  
 
Another factor that may have contributed to the lack of a clear dissociation between the 
disconnection-and unilateral-lesioned groups in this experiment is the presence of 
contralaterally projecting fibres from the LHA to the VTA. The logic of the 
disconnection lesion is based on the supposition that connections between the two 
component structures are exclusively unilateral (see Gaffan and Eacott 1995; Bezzina et 
al. 2008). However, Fadel et al. (2002) reported that although the predominant  
projections from the LHA to the VTA are ipsilateral, there is a small number of fibres 
that cross to the contralateral hemisphere. It is not clear whether these contralaterally 
projecting fibres make a significant contribution to the functional connection between the 
LHA and the VTA.  
 
,W VKRXOG EH QRWHG WKDW ERWK į Equation 1) and Ri (Equation 2) were affected by the 
OxSap lesion. $VGLVFXVVHGHDUOLHUVHHVHFWLRQįLVEDVHGRQRYHUDOOUHVSRQVHUDWHV
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which incorporates the post-reinforcement pause. Therefore, the effect of the OxSap 
OHVLRQRQįPLJKWLQWKHRU\KDYHEHHQEURXJKWDERXWE\DVHOHFWLYHHIIHFWRQWKHSRVW-
reinforcement pause. However, this interpretation cannot account for the effect of the 
lesion on Ri, since this parameter is based on running response rates and is therefore not 
influenced by the post reinforcement pause. Furthermore, there is evidence that Ri  is not 
influenced by the magnitude of the reinforcer (Rickard et al. 2009). Therefore, the 
OxSap-induced decrement of this parameter is unlikely to have been affected by any 
change in reinforcer value, providing further circumstantial evidence that effect of the 
lesion on performance reflected a genuine alteration of motor performance. 
 
Harris et al. (2007) disconnected the VTA acutely from the LHA by lesioning the LHA 
in one hemisphere and injecting the OX1 receptor antagonist SB-334867-A into the 
contralateral VTA (see section 3.1). They found a disruption of drug seeking behaviour 
in the conditioned place preference paradigm. There are many differences between the 
behavioural techniques used in +DUULVHWDO¶Vexperiment and the present one, which may 
have contributed to the differing results obtained. However, there are also differences 
between the disconnection procedures employed, which have potentially interesting 
implications for the role of orexinergic mechanisms in reinforcement processes. In Harris 
et al.¶V (2007) experiment, N-methyl-D-aspartate (NMDA) was used to produce 
excitotoxic lesions of the LHA. Since NMDA receptors are present on most neurones, it 
is likely that the lesion was not restricted to neurones bearing OX2 receptors. The acute 
treatment with the OX1 receptor antagonist SB-334867-A, injected into the contralateral 
VTA, probably produced a quite specific interruption of synaptic transmission mediated 
by these receptors.  Moreover, previous experiments that have purported to demonstrate 
an involvement of LHA orexinergic mechanisms in reward processes have mainly used 
treatments that preferentially target OX1 receptors (e.g. intracerebral treatment with 
orexin-A or OX1 receptor antagonists) (Borgland et al. 2009; Farr et al. 2005; James et 
al. 2011; Nair et al. 2008; Thorpe et al. 2005a; Thorpe et al. 2006; Thorpe and Kotz 
2005; Thorpe et al. 2003; Thorpe et al. 2005b). In contrast, the use of OxSap in the 
present experiment probably had a preferential destructive effect on OX2 receptor- 
mediated transmission (see above). This raises the interesting possibility that OX2 
receptor-mediated mechanisms play a predominant role in motor processes, whereas 
OX1 receptor-mediated mechanisms may be more important in the regulation of 
reinforcement processes. Indeed there is a growing body of evidence consistent with this 
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suggestion (Akanmu and Honda 2005; Chemelli et al. 1999; Hondo et al. 2009; 
Thompson and Borgland 2011). For instance Wang et al. (2009) trained rats to lever-
press in a cocaine self-administration paradigm. They found that the injection of orexin A 
into the VTA produced an increment of cocaine-seeking behaviour This effect was 
blocked by an OX1 receptor antagonist. Furthermore this effect was not replicated when 
orexin B was injected into the VTA under the same conditions (Wang et al. 2009). In 
another cocaine self-administration experiment in rats, Smith et al. (2009) found that the 
OX1 receptor antagonist SB-334867-A, administered systemically, induced a dose-
dependent decrement of cocaine-seeking behaviour. This effect was not found when the 
OX2 receptor antagonist 4PT (4-pyridylmethyl (S)-tert-leucyl 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline) was injected. In addition, the same group tested these orexin 
receptor antagonists in a locomotor activity experiment. They found that 4PT but not SB-
334867-A produced a significant reduction of the total distance travelled. Consistent with 
these findings, it has recently been reported that systemically-administered SB-334867-A 
reduces the breakpoint for highly salient positive reinforcers (Borgland et al. 2009), and 
that injection of this antagonist into the VTA attenuates cocaine seeking behaviour but 
has no effect on locomotor activity (James et al. 2011).  All these experiments appear to 
support the hypothesis of differential involvement of the two types of orexin receptor in 
motivational and motor functions.   
 
In conclusion, it can be said that this experiment demonstrated that OxSap-induced 
disconnection of the LHA from the VTA resulted in a significant alteration of food-
reinforced operant behaviour under a progressive-ratio schedule of reinforcement. 
Quantitative analysis of behaviour based RQ .LOOHHQ¶V 035  DQG Equation 2 
(Rickard et al. 2009) indicated that this alteration was caused by alteration of the 
response time parameter į DQG WKH LQLWLDO UXQQLQJ UDWH SDUDPHWHU 5L 7KHVH UHVults are 
consistent with previous experiments that have found motor output alterations following 
manipulation of orexinergic function. Consideration of recent literature suggests that the 
motor consequences of manipulating orexinergic function may be mediated mainly by 
OX2 receptors, whereas changes on reinforcer value may be mediated mainly by OX1 
receptors. Further experiments investigating the effect of OX1 receptor antagonists on 
the parameters of .LOOHHQ¶V (1994) MPR and Rickard et al.¶V (2009) equation could 
provide useful evidence for or against this suggestion. The experiment described in the 
following chapter is an initial effort in provide such evidence.  















EXPERIMENT 3: EFFECT OF µACUTE FUNCTIONAL 
DISCONNECTION¶ OF THE LATERAL HYPOTHALAMUS FROM 














The orexinergic neurones of the LHA project to the nucleus accumbens (see section 
1.2.1), which is an area that highly expresses OX1 and OX2 receptors (Martin et al. 
2002). The nucleus accumbens is also a major projection region of the mesolimbic 
dopaminergic pathways that emanate from the VTA. Dopaminergic neurotransmission in 
the nucleus accumbens is believed to play an important role in the regulation of the 
reinforcing value of drugs of abuse and natural rewards such as water, food and sex 
(Hoebel 1997; Koob 1998; Koob and Nestler 1997; Salamone 2009; Salamone et al. 
2005; Stratford and Kelley 1997; Wise 1998). Furthermore, the function of the 
dopaminergic system is believed to be modulated by the orexinergic system; for instance, 
VTA dopaminergic neurones are activated by orexin A (Martin et al. 2002; Nakamura et 
al. 2000), and the intra-VTA administration of orexin A has been found to elevate 
extracellular levels of dopamine in the AcbS and the prefrontal cortex (Narita et al. 2006; 
Narita et al. 2007; Vittoz et al. 2008). 
 
Manipulation of the orexinergic system in the AcbS has produced conflicting results in 
different studies. On one hand, Baldo and Kelly (2001) found no effect on locomotor 
activity or food intake when they injected orexin A in the AcbS. On the other hand 
Thorpe and Kotz (2005) found an increment in both food intake and locomotor activity 
with intra-AcbS administration of orexin A. Unexpectedly, Thorpe and Kotz (2005) 
found that intra-AcbS injection of the OX1 receptor antagonist SB-334867-A produced 
an attenuation of food intake induced by orexin A, but had no effect on orexin A-induced 
locomotor activity. This led the authors to conclude that the effects of orexins on 
locomotion and feeding behavior may be meditated by different orexin receptors. 
 
In the first experiment of this thesis, a major site of origin of the orexinergic projection, 
the LHA, was bilaterally lesioned with the neurotoxin OxSap (see Chapter 2). This was 
followed by an experiment where the site of origin of the mesolimbic dopaminergic 
pathway (the VTA) was disconnected from the LHA orexinergic neurones by unilateral 
injection of OxSap into the LHA and injection of OxSap into the VTA of the 
contralateral hemisphere (see Chapter 3). In both of theses experiments, a motor 
impairment was revealed, as expressed by an increment in the motor parameter įderived 
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IURP .LOOHHQ¶V 035 (Killeen 1994) and Ri (Rickard et al. 2009). In neither of these 
experiments was an effect on reward related measures found.  
 
As reviewed in previous chapters, a number of studies have obtained evidence consistent 
with the hypothesis that disruption of the LHA orexinergic projection reduces the 
incentive value of positive reinforcers (for review, see Aston-Jones et al. 2009; see also 
section 1.2.3). A possible explantion for the apparent discrepancy between the results 
obtained in previous studies and those described in Chapters 2 and 3 is that in many 
previous studies that have reported effects on reinforcement processes, disruption of 
orexinergic function was achieved using the OX1 receptor antagonist SB-334867-A, 
whereas disruption of orexinergic function in the experiments described in Chapters 2 
and 3 was achieved using the neurotoxin OxSap, a conjugate of orexin B and saporin. 
Although the selectivity of OxSap is not absolute (see section 1.2.2), it does show a 
greater destructive effect on neurones expressing the OX2 rceptor than on neurones that 
exclusively express the OX1 receptor, due to the fact that orexin-B has greater affinity 
for OX2 than OX1 receptors (Gerashchenko et al. 2001). Recently it has been suggested 
that the role of orexins in reinforcement processes may be mediated mainly by OX1 
receptors, whereas their role in arousal and motor function may be mediated mainly by 
OX2 receptors (Hondo et al. 2009; Wang et al. 2009; Thompson and Borgland 2011). 
Therefore in the present experiment intracerebral injection of the OX1 receptor 
antagonist SB-334867-A was used to induce an acute disruption of orexinergic function 
of the AcbS. 
 
In the present experiment the orexinergic neurones of the LHA were unilaterally lesioned 
with OxSap (see section 1.2.2) and SB-334867-A was microinjected into the ipsilateral 
or contralateral AcbS. The LHA-AcbS pathway is principally intra-hemispheric, the 
contralateral treatment was assumed to produce an acute µIXQFWLRQDOGLVFRQQHFWLRQ¶RIWKH
LHA from the AcbS (Bezzina et al. 2008a; Gaffan and Eacott 1995). The effect of this 
LQWHUYHQWLRQZDVHYDOXDWHGZLWK.LOOHHQ¶V035model (1994) (see section 1.4.3). It was 
hypothesised that the µdisconnection¶ group would show a decrement in the µincentive-
value¶ parameter a (Killeen 1994), but would not differ from the control (ipsilaterally-
treated) group with respect to the µmotor¶ SDUDPHWHUį.LOOHHQ) (see section 1.4.3). 
Additionally locomotor activity was evaluated; no change was expected as a consequence 
of the treatment. 







Twenty-six experimentally naive female Wistar rats approximately 4 months old and 
weighing 250±300 g at the start of the experiment were used. They were housed under 




All the rats underwent two surgical procedures. In the first, each rat received a unilateral 
OxSap lesion of the LHA, the side of the lesion (left or right) being counterbalanced 
across subjects. This procedure was carried out in the same way as in Experiment 1 (see 
section 2.2.2). The only exception was that the dose of OxSap injected was 30 ng instead 
of 15 ng.  
 
Approximately six weeks later the animals underwent a second surgical procedure for the 
microcannula implantation. The same anaesthetic and surgical preparation conditions 
were used as in Experiment 1 (see section 2.2.2). Bilateral 26-gauge guide cannula with a 
separation distance of 1.5 mm, mounted on a plastic pedestal (Bilaney Consultants Ltd, 
Sevenoaks, UK), were introduced into the brain via 1-mm holes drilled in the skull, 
symmetrically on either side of the midline. The assembly was lowered into position 
using the following stereotaxic coordinates to position the tips of the guide cannulae just 
above the medial shell: AP+1.3 mm, /PP9íPP, measured from bregma. 
(Paxinos and Watson, 1998). Three stainless steel anchor screws were placed in the skull, 
the cannula assembly was fixed to the skull with dental cement, and the wound was 
closed around the cannula assembly. Stylets were introduced into the guide cannulae, and 
the assembly was covered by a plastic screw cap. Fluid replacement (5 ml 0.9% saline 
solution, intraperitoneally) and wet mash diet were provided after the surgery. The rats 
were returned to the food-deprivation regimen and the daily training routine on the day 
following surgery. 
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4.2.3. Apparatus 
 
4.2.3.1. Operant behaviour chambers  
 
The same apparatus and software was used as in Experiment 1 (see section 2.2.3.1). 
 
4.2.3.2.  Locomotor behaviour chambers 
 
The same apparatus and software was used as in Experiment 1 (see section 2.2.3.2). 
 
 
4.2.4. Behavioural procedures 
  
4.2.4.1.  Progressive ratio schedule 
 
The behavioural training was carried out exactly in the same way as in Experiment 1 (see 
section 2.2.4.1). 
 
4.2.4.2.  Locomotor activity 
  
This experiment was done in the same way as in Experiment 1 (see section 2.2.4.2), the 
only exception being that the rats were placed in the locomotor activity boxes each day 




4.2.5. Drug treatment 
 
One week after surgery, the rats were acclimatized to manual restraint and the 
intracerebral injection procedure over a number of sessions before starting the drug 
treatment regimen; the total number of training sessions that occurred before the start of 
the intracerebral injection regimen was >165. Intracerebral injections were given via 
bilateral 33-gauge injection cannulae which protruded 2 mm below the tip of the guide 
cannulae. Sterile SB-334867-A solution was injected into the AcbS on one side of the 
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brain and vehicle in the other side. The rats that received SB-334867-A in the AcbS that 
was contralateral to the LHA lesioned side were designated the µdisconnection¶ group 
(n=14), and the rats that received SB-334867-A into the same side as the lesion were 
designated thH µunilateral¶ JURXS Q 7KHVROXWLRQVZHUH LQIXVHGDW D UDWHRIȝO
min-1 via polyethylene tubes connected to 100-ȝO +DPLOWRQ V\ULQJHV GULYHQ E\ D GXDO
syringe pump (Linton Instrumentation, Diss, UK). The dose of SB-334867-A was based 
on previous studies (Thorpe and Kotz 2005): 6 QJLQDYROXPHRIȝOWRWDOLQMHFWLRQ
time, 2.5 min). The injection cannulae remained in place for one minute after the 
completion of the injection to allow for diffusion within the tissue. The cannulae were 
then removed and the stylets replaced, and the rats were returned to their home cages for 
12 min before being placed in the operant conditioning chambers. The experimental 
session began 15 minutes after completion of the injection. The data shown correspond to 
one injection per rat. 
 
4.2.6. Immunohistochemistry and histology 
 
After completion of the behavioural experiment, the animals were deeply anaesthetized 
with pentobarbitone and perfused with phosphate buffered saline (PBS) followed by 
formol PBS using the same methods as in Experiment 1 (see section 2.2.5). The same 
immunohistochemical procedures as those used in Experiment 1 (see section 2.2.5) were 
used to prepare sections of brain tissue for the detection of orexin-positive neurones and 
NeuN-positive nuclei in the LHA.  
 
Cannula placement was verified from coronal sections (60 ȝm) taken through the nucleus 
accumbens and stained using cresyl violet. These sections were mounted on gelatine-
coated slides, dried overnight in formaldehyde vapour, and immersed in the following 
series of solutions: 95% ethanol (15 min), 70% ethanol (1 min), 50% ethanol (1 min), 
distilled water (2 min), 0.25% cresyl violet (2 min), distilled water (1 min), 50% ethanol 
(1 min), 70% ethanol (2 min), 95% ethanol (2 min), 100% ethanol (1 min), xylene (5 
min). The slides were mounted with DPX and coverslipped. An investigator who was 
blind to the behavioural results performed the microscopic examination. Drawings of the 
locations of the cannula tips were superimposed on the appropriate pages of the 
stereotaxic atlas of Paxinos and Watson (1998). 
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4.2.7. Data analysis 
 
The data from 5 five rats were discarded (4 rats from the disconnection group and 1 from 
the unilateral group), because meaningful parameter estimates were not obtained in the 
drug-treatment session. Analysis were thus based on the data from the disconnection 
group (n=10) and unilateral group (n=11).  
 
 
4.2.7.1.   Operant behaviour data 
 
Data from the session in which SB-334867-A was injected into the AcbS were compared 
with the data obtained in the final 10-session block before drug treatment. 
 
(i) Peak response rate 
Peak response rate was analysed in the same way as in Experiment 1 (see section 
2.2.6.1(i)), with the exception that comparisons were made between the intra-cerebral 
treatment session and the final 10-session pre-treatment block, as described above, rather 
than between the pre- and post-surgical data.  
 
(ii) Highest completed ratio and breakpoint 
These measures were analysed in the same way as in Experiment 1 (see section 
2.2.6.1(ii)), with the same exception as above. 
 
(iii) Overall response rate 
Overall response rate was analysed in the same way as in Experiment 1 (see section 
2.2.6.1(iii)) with the same exception as above. 
 
(iv) Running response rate 
Running response rate was analysed in the same way as in Experiment 1 (see section 
2.2.6.1(iv)) with the same exception as above. 
 
4.2.7.2. Locomotor activity data.  
 
The numbers of beam breaks in successive 5-minute epochs of the 30-min sessions were 
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analysed by three-factor analysis of variance : group [disconnection, unilateral] × 
treatment-day [SB-334867-A, no treatment] × epoch [1-6]) with repeated measures on 




4.3.1. Operant behaviour data 
 
4.3.1.1.  Peak response rate 
 
The mean (±SEM) post-/pre-treatment differences in peak response rate for the 
disconnection and the unilateral groups are shown in Fig. 4.1 (left-KDQGSDQHO6WXGHQW¶V
t-tests revealed no significant differences between the two groups [t(19) = 1.1, NS]. 
 
4.3.1.2.  Highest completed ratio and breakpoint 
 
Although both groups showed slightly increased values of the highest completed ratio 
(Fig 4.1 middle panel) as a consequence of the drug treatment, this failed to reach 
statistical significance [t(19) = 1.2, NS]. The breakpoint increased in the unilateral group 
and decreased in the disconnection group (Fig 4.1 right-hand panel). However, these 



























































Figure 4.1. Changes in the peak response rate (left panel), highest completed ratio 
(middle panel) and breakpoint (right panel) following intra-AcbS SB-334867-A 
treatment in the unilateral (white bars) and the disconnection (black bars) groups. The 
data shown correspond to the differences (mean ± SEM) between the data obtained 
during the SB-334867-A treatment and the last 10 sessions before treatment commenced.  
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4.3.1.3.  Overall response rate 
 
Fig 4.2 shows the group mean overall response rate data for the unilateral (left-hand 
panel) and disconnection groups (right-hand panel) in the last pre-treatment block and on 
the treatment day. In both groups response rate increased to a peak, and then gradually 
declined as the response/reinforcer ratio was progressively increased. Analysis of the raw 
data revealed a significant main effect of ratio [F(17,23) = 19.6, p<0.001], but not of 
treatment [F(1,19) = 2.5, NS] or group [F<1]. There was a significant treatment × ratio 
interaction [F(17,323) = 2.4,  p<0.05], but no significant ratio × group [F(17,323) = 1.1, 
NS], treatment × group [F<1] or treatment × ratio × group interaction [F(17,323) = 1.2, 
NS]. 
 
The fits of Equation 1 to the group mean data accounted for >84% of the total variance 
(unilateral group: pre-treatment, r2 = 0.97; SB-334867-A treatment, r2 = 0.90; 
disconnection group: pre treatment, r2 = 0.85;  SB-334867-A treatment,  r2  = 0.84). The 
activation parameter a was reduced in the disconnection group as a consequence of intra-
AcbS SB-334867-A treatment (see below). This is reflected in the steeper descending 
limb of thLVJURXS¶V curve in the treatment session compared to the no-treatment sessions.  
UNILATERAL GROUP
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Figure 4.2 Overall response rates in successive ratios of the progressive-ratio schedule. 
Left hand panel: data from the unilateral group; right hand panel: data from the 
disconnection group. Ordinates: response rate (responses min-1); abscisae: ratio, N. 
Points are group mean data. Circles: data from the last ten sessions before drug 
treatment; triangles: data from intra AcbS SB-334867-A treatment. The curves are fits of 
Equation 1 to the data. Note the reduction in a, indicated by the steeper decline in 
response rate as a function of ratio size in the disconnection group following drug 
treatment. 
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Fig 4.3 shows the estimates of the parameters of Equation 1 in successive blocks of 10 
sessions before the unilateral LHA lesion, before the implantation of the cannulae, and 
before the drug treatment session. The first surgical intervention was performed after 90 
sessions when all the parameters were stable (see section 2.3.1.3). The two groups were 
compared before the intra-AcbS injections started, and no significant differences were 


























































































Figure 4.3. Values of parameters of Equation 1 (left-hand graphs: a; middle graph: į; 
right-hand graph: ȕ) in the final block of 10 sessions before the unilateral LHA lesion, 
the block before the intracerebral cannulation, and the final block of sessions before 
intracerebral drug treatment The filled symbols show the mean values for all the rats; the 
open symbols show the mean values for the rats that were subsequently allocated to the 
unilateral group (triangles) and the disconnection group (circles). 
 
 
Fig. 4.4 shows the differences the differences between the values of the parameters of 
Equation 1 obtained in the pre-treatment block and in the treatment session.  
 
(i) µ6SHFLILFDFWLYDWLRQ¶D 
There was a significant reduction of the activation parameter a [t(19) = 2.2, p <0.05] in 
the disconnection group following the AcbS SB-334867-A treatment, compared to the 
unilateral group. 
 
(ii) µResponse time¶, į 
In both groups į decreased after the drug treatment. However, this decrement did not 
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differ significantly [t(19) = 1.2, NS] between the disconnection and the unilateral groups. 
 
(iii) µ&XUUHQF\¶ȕ 
This parameter was reduced in both groups after the administration of the drug. However, 


























































Figure 4.4. Changes in the parameters of Equation 1 following the intra AcbS SB-
334867-A treatment in the unilateral (white bars) and disconnection (black bars) groups. 
Ordinates: differences between the values obtained in the pre-treatment blocks and on 
the treatment day (mean ± SEM). Left-hand graph: µDFWLYDWLRQ¶SDUDPHWHUa (s); middle 
graphµUHVSRQVHWLPH¶SDUDPHWHUį (s); right-hand graphµFXUUHQF\¶SDUDPHWHUȕ. Intra-
AcbS SB-334867-A treatment resulted in a significant reduction of a in the disconnection 
group, in comparison to the change seen in the unilateral group (difference between 
groups: * p<0.05). 
 
 
4.3.1.4.  Running response rate 
 
Fig 4.5 shows the group mean running response rate data for the unilateral (left-hand 
panel) and the disconnection (right-hand panel) groups before SB-334867-A treatment 
and on the day of treatment. In both groups the running response rate was highest at the 
lowest ratios, decreasing monotonically as a function of increasing ratio size. Analysis of 
the raw data revealed no significant main effect of treatment [F(1,19) = 3.1, NS] or group 
[F<1], and no significant treatment × group [F(1,19) = 2.4, NS], treatment × ratio [F<1] 
or ratio × group [F(11,209) = 1.6, NS] interaction. There was a significant main effect of 
ratio [F(11,209) = 57.0, p<0.001], and the three-way treatment × ratio × group interaction 
was significant [F(11,209) = 5.6,  p<0.001].  
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Figure 4.5. Running response rates in successive ratios of the progressive ratio schedule. 
Left hand panel: data from the unilateral group; right hand panel: data from the 
disconnection group. Ordinates: response rate (responses min-1); abscissae: ratio, N. 
Points are group mean data. Circles: data from the last ten sessions before treatment; 
triangles: data from the session in which intra-AcbS injection of SB-334867-A was 
administered.  
 
The fits of Equation 2 to the group mean data accounted for over 95% of the total 
variance. The effects of treatment on the parameters of Equation 2 are shown in Fig 4.6. 
 
(i) µ,QLWLDOUXQQLQJUDWH¶ Ri  
There was a (non-significant) tendency for this parameter to be increased following 
treatment with SB-334867-A. There was no significant difference between the changes 
of this parameter seen in the two groups [t<1] (Fig.  4.6, left-hand graph). 
 
(ii) µ'HFD\SDUDPHWHU¶ b 
This parameter showed a non-significant increase in the unilateral group, and a non-
significant reduction in the disconnection group, following treatment with SB-334867-A. 
However the between-groups difference failed to reach statistical significance [t(19) = 
1.2, NS] (Fig. 4.6, middle graph). 
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(iii) µ([SRQHQW¶ c 
As was the case with the other parameters, there was no significant between-group 
difference in the change in this parameter [t(19) = 1.4, NS]. 
 
























































Figure 4.6. Changes in the parameters of Equation 2 following SB-334867-A treatment. 
Unilateral group (white bars) and disconnection group (black bars). Ordinates: change in 
parameter value; abscissa: differences between the values obtained during the treatment 
and the final pre-treatment block (mean ± SEM). Left-hand graph: µLQLWLDOUHVSRQVHUDWH¶




4.3.2. Locomotor activity data 
 
Fig 4.7 shows the locomotor activity data in successive 5-minute epochs of the 30- 
minute test sessions on the days that the animals received the SB-334867-A treatment 
and no treatment. Analysis of variance revealed a significant main effect of treatment 
[F(1,19) = 12.9,  p=0.002] and epoch [F(5,95) = 11.0,  p<0.001], but not of group 
[F(1,19) = 2.2,  NS]. The two-way treatment × group [F (1,19), NS], treatment × epoch 
[F<1] and epoch × group [F<1] interactions and the three-way treatment × epoch × group 
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Figure 4.7. Locomotor activity in the unilateral (open circles) and disconnection (filled 
circles) groups in 30-minute sessions. Left hand panel corresponds to the no-treatment 
days and right hand panel to the SB-334867-A treatment day. Ordinate: total beam 




4.3.3. Immunohistochemistry and histology 
 
Fig 4.8 shows representative photomicrographs of sections stained for orexin and NeuN 
in the OxSap and sham-lesioned hemispheres The numerical data for the densities of 
orexin-positive neurones and NeuN-positive nuclei detected in the LHA and PFA are 
shown in Fig. 4.9.  OxSap resulted in a significant depletion of orexin-positive neurones 
from the LHA of the lesioned side [t(25) = 5.5, p<0.001] and PFA [t(25) = 5.7, p<0.001] 
in comparison with the sham-lesioned side. There was also a significant reduction of the 
the number of NeuN-positive nuclei in both the LHA [t(43) = 8.5, p<0.001] and the PFA 
[t(43) = 8.5,  p<0.001]. 
 
Fig 4.10 is a representative photomicrograph showing the cannula placement. In each rat 
the tracks of the internal cannulae terminated in the medial area of the AcbS. 
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Figure 4.8. Left-hand panel. Diagram of coronal section of the rat brain at AP -3.3 mm, 
measured from bregma (from Paxinos and Watson 1998), The filled rectangles indicate 
the areas used for counting orexin-positive neurones and NeuN-positive nuclei in the 
hypothalamus. LHA, lateral hypothalamic area; PFA, perifornical hypothalamic area; 
MTT, mammillothalamic tract. Middle and right-hand panels. Representative coronal 
sections taken through sham-lesioned (middle panel) and OxSap-lesioned (right-hand 
panel) hemispheres; upper panels: sections through the hypothalamus stained for orexin; 








































Figure 4.9 Left-hand panel. Density of orexin-positive neurones counted in the lateral 
hypothalamic area (LHA) and perifornical hypothalamic area (PFA). Ordinate: number 
of cells counted per mm2. Columns show the group mean data (+SEM) for the unilateral 
(white bars), and disconnection (black bars) groups. Significant difference between the 
two groups: * p<0.05. Right-hand  panel. Density of NeuN-positive nuclei counted in the 
LHA and PFA (conventions as in the left-hand panel). 
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Figure 4.10. Placement of the bilateral cannulae in the nucleus accumbens shell. Left-
hand diagram: map of coronal section of the rat brain 1.44 mm anterior to bregma 
(modified from Paxinos and Watson 1998); the rectangle indicates the area of the 
photomicrograph. Right-hand panel: Representative photomicrograph showing the 
cannula placement; the tracks of the internal cannulae (indicated by white arrows) 
terminate in the medial area of the AcbS. LV: lateral ventricle; AcbC: nucleus 





Unilateral OxSap injections into the LHA caused a significant reduction of the number of 
orexin-containing neurones in the lesioned side, when compared with the non-lesioned 
side, in both the disconnection and the unilateral groups. The lesion extended to the 
adjacent PFA, the reduction of orexin-containing neurones in the PFA reaching statistical 
significance when compared with the non-lesioned side. The successful depletion is in 
agreement with previous studies (Anaclet et al. 2010; Blanco-Centurion et al. 2007; Di 
Sebastiano et al. 2011a; Frederick-Duus et al. 2007; Furlong and Carrive 2007; 
Gerashchenko et al. 2003; Gerashchenko et al. 2001; Vetrivelan et al. 2009) and with the 
results of  Experiments 1 and 2 (see sections  2.3.3 and 3.3.3). Other neurones containing 
the OX2 receptors are also vulnerable to effect of OxSap (see section 2.4). To evaluate 
the effect on other population of neurones affected by the Ox-Sap infusion, NeuN-
positive nuclei were quantified in the LHA. The Ox-Sap lesioned side showed a 
significant reduction of the number of NeuN-positive nuclei in both the LHA and PFA. 
The extent of the depletion of orexin-containing neurones in the LHA in this experiment 
was similar to that seen in Experiments 1 and 2. The reduction of NeuN-positive nuclei 








 - 115 - 
The performance of the two groups on the progressive-ratio schedule was similar to that 
seen in previous studies (see section 2.4) (Bezzina et al. 2008b; Bezzina et al. 2008c; 
Bizo and Killeen 1997; den Boon et al. 2011; Ho et al. 2003; Kheramin et al. 2005b; 
Killeen et al. 2009; Mobini et al. 2000; Rickard et al. 2009; Zhang et al. 2005a; Zhang et 
al. 2005b) and in Experiments 1 and 2. Baseline performance was well described by 
Equation 1, and the unilateral OxSap lesion of the LHA and the stereotaxic placement of 
the indwelling guide cannulae had no significant effect on the parameters of the equation 
(see Fig. 4.3). 
 
The principal aim of the experiment ZDV WR H[DPLQH WKH HIIHFW RI µDFXWH IXQFWLRQDO
disconnection¶ of the orexinergic pathway from the LHA to the AcbS. As LHA-AcbS 
connections are predominantly ipsilateral (Stratford 2005), a contralateral disconnection 
method was used (Gaffan and Eacott 2995; Bezzina et al. 2008), in which the orexinergic 
projection emanating from the LHA on one side of the brain was permanently inactivated 
using the neurotoxin OxSap, and OX1 receptors in the AcbS on the other side were 
blocked acutely by intra-AcbS injection of the OX1 receptor antagonist SB-334867-A. 
 
Injection of SB-334867-A into the AcbS affected performance on the progressive-ratio 
schedule. The motivational parameter a derived IURP .LOOHHQ¶V (1994) mathematical 
model was reduced by intra-AcbS injection of SB-334867-A in the disconnection group 
in comparison with the unilateral group. (A similar trend was seen in the case of the 
µPRWLYDWLRQDO SDUDPHWHU b, derived from the running response rates [Equation 2; see 
Rickard et al. 2009]; however the reduction of this parameter in the disconnection group 
fell short of statistical significance.) The reduction of a is in accord with predictions 
based on the notion that functional connections between the LHA and the AcbS mediated 
by OX1 receptors may contribute to the regulation of the incentive value of food 
reinforcers (see section 4.1). Previous findings have implicated OX1 receptors in 
reinforcement processes (Hondo et al. 2009; Wang et al. 2009; Thompson and Borgland 
2011), and there is abundant evidence for the importance of the AcbS in feeding 
behaviour and food reward (see Stratford and Kelley 1999; Baldo and Kelley 2007). The 
present results suggest that OX1 receptor-mediated neurotransmission in the AcbS may 
make a significant contribution to the role of LHA-AcbS connections in regulating 
reinforcer value.  
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As reviewed earlier (see section 1.2.3), central administration of orexin A increased the 
breakpoint and SB-334867-A injected into the AcbS decreased it (Borgland et al. 2009; 
Choi et al. 2010; Nair et al. 2008; Sharf et al. 2010a; Thorpe et al. 2005a). These effects 
on the breakpoint have been interpreted as changes in the motivational state of the 
organism as a consequence of manipulating orexinergic function. The present results also 
suggest that a decrement of motivated behaviour occured when SB-334867-A was 
centrally administered. However, despite the fact that this experiment found a modest 
reduction of the breakpoint (and the highest completed ratio), this was not statistically 
significant. Several factors mentioned before may account for these discrepancies, for 
example the type of reinforcer, the food deprivation level and the criterion used to define 
the breakpoint (see sections 1.4 and 2.4). An additional factor is the length of the 
experimental sessions. The sessions in this experiment lasted for 50 minutes, whereas  in 
other studies sessions lasted for up to three hours (Borgland et al. 2009; Nair et al. 2008). 
It is possible that longer sessions might have revealed a reduction of the breakpoint in 
this experiment. However, as discussed earlier (section 1.4.1), very long sessions carry 
the disadvantage that the effects of acutely administered drugs may dissipate before the 
session finishes (see section 1.4).  
 
The putative rewarding properties of the orexin system in the AcbS have been evaluated 
with feeding experiments, and have yielded contradictory results. On one hand Thorpe 
and Kotz (2005) showed that unilateral microinjections of orexin A increased food 
intake, and this effect was blocked by the administration of  SB-334867-A. On the other 
hand Baldo and Kelly (2007) injected orexin A bilaterally and did not find any 
significant differences in food or water intake  More evidence about the rewarding 
properties of the orexin system and their projections to the AcbS came from a study that 
showed that SB-334867-A reduced amphetamine-evoked dopamine release in the AcbS. 
This effect was not found when SB-334867-A was injected without amphetamine 
(Quarta et al. 2010).  Sharf et al (2008) examined naloxone-induced morphine 
withdrawal symptoms in mice, and found that the administration of SB-334867-A 
decreased both withdrawal symptons and c-Fos expression in the AcbS (Sharf et al. 
2008). 
 
As expected, no significant changes were found in the response time parameter į or in 
the peak response rate (two measures derived from the overall response rate). To exclude 
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the possibility that the post reinforcement pause (PRP) was masking any possible motor 
deficit, Equation 2 was applied to the running rate (see section 2.1). The results showed 
that Ri, was not significantly affected as a consequence of the disconnection treatment 
with SB-334867-A.  
 
As predicted, the disconnection and the unilateral groups did not differ significantly 
during their performance in the spontaneous locomotor activity task. This is in agreement 
with previous reports of the effect of intra-AcbS-administered SB-334867-A (Thorpe and 
Kotz 2005). However, when orexin A has been injected in the AcbS it has caused 
contradictory results. For instance, Thorpe and Kotz  (2005) found a significant 
increment in locomotor activity and Baldo and Kelley (2001) did not. The authors 
attributed these discrepancies to the doses used, which were considerably lower in Baldo 
DQG .HOOH\¶V experiment. The results from feeding and locomotor activity experiments 
led Thorpe and Kotz (2005) to conclude that motor processes are partially mediated by 
OX2 receptors and reward processes are modulated by OX1 receptors.  
 
In the present experiment the orexinergic neurones in the LHA were depleted unilaterally 
and the OX1 receptor antagonist SB-334867-A was microinjected into the AcbS. This 
acute treatment in the AcbS resulted in a reduction in the motivational parameter a 
GHULYHGIURP.LOOHHQ¶V035$VGLVFXVVHGEHIRUHVHHVHFWLRQ3.1) it is thought 
that the OX1 receptor is involved in reward-related processes and the OX2 receptor is 
more involved with motor processes (Borgland et al. 2009; Farr et al. 2005; James et al. 
2011; Nair et al. 2008; Smith et al. 2009; Thorpe et al. 2005a; Thorpe et al. 2006; Thorpe 
and Kotz 2005; Thorpe et al. 2003; Thorpe et al. 2005b). The results from this 
experiment add more evidence in support of this theory, as the reduction on a occurred 
under the SB-334867-A-induced disconnection treatment and not under the unilateral 
treatment condition.  
 
To summarise, it can be said that the acute orexinergic disconnection between the LHA 
and AcbS resulted in a significant alteration of food-reinforced operant behaviour under a 
progressive-ratio schedule of reinforcement. Quantitative analysis of behaviour based on 
.LOOHHQ¶V 035  LQGLFDWHG WKDW WKLV DOWHUDWLRQ ZDV FDXVHG E\ D UHGXFWLRQ RI the 
incentive value of the reinforcer (as indicated by a reduction of the µVSHFLfic activation¶ 
parameter a). These results are in contrast with the results of Experiments 1 and 2 (see 
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Chapters 2 and 3), where a significant motor impairment was found (as indicated by an 
increase in WKH µUHVSRQVH WLPH¶SDUDPHWHU į ZLWKRXW DQ\ DSSDUHQW FKDQJH LQ incentive 
value. It was suggested that in Experiments 1 and 2 the disruption of orexinergic function 
was mainly focused on OX2 receptor-mediated neurotransmission, whereas changes in 
reinforcer value seen in the present experiment may have been caused by disruption of 
OX1 receptor-mediated neurotransmission. More research is needed using MPR and 
manipulating the two subtypes of orexin receptor to add more evidence against or in 

























EXPERIMENT 4: A CLOZAPINE-LIKE EFFECT OF 
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5.1 Introduction 
 
As reviewed in Chapter 1 (section 1.3), iW LV JHQHUDOO\ DJUHHG WKDW µFRQYHQWLRQDO¶
antipsychotic drugs, including the phenothiazines and butyrophenones, are less effective 
in combating the negative symptoms of schizophrenia (anhedonia, avolition, flattened 
affect) than they are in suppressing positive psychotic symptoms (hallucinations, 
delusions). Indeed, there is evidence that conventional antipsychotics may have an 
adverse effect on motivation in man, as they are known to do in animals (King and 
Waddington 2004; Wise 1982; Wise 2006). ,QFRQWUDVWµDW\SLFDO¶DQWLSV\FKRWLFVVXFKDV
clozapine are less liable to induce negative symptoms, and in some cases may even help 
to alleviate these symptoms by enhancing motivation (Corrigan et al. 2003; Müller-
Spahn 2002).  
 
An adverse effect of conventional antipsychotics on motivation in animals has been 
recognized for many years (Wise 1982). For example, operant behaviour maintained by 
food or psychostimulant self-administration is suppressed by conventional 
antipsychotics, and it has been proposed that this effect is caused by a reduction of the 
incentive value of primary reinforcers (Wise 1982; Wise 2006). Less is known about the 
effects of atypical antipsychotics on motivation and reinforcement processes; however 
there is evidence that these drugs enhance appetite in rodents (Hartfield et al. 2003) as 
they do in humans (Meltzer et al. 2003), and that they may increase the incentive value of 
food in operant behaviour paradigms (Cilia et al. 2001; Mobini et al. 2000; Zhang et al. 
2005a; Zhang et al. 2005b; see below). 
 
The principal pharmacological action of conventional antipsychotics is the blockade of 
D2 dopamine receptors (Kapur et al. 2000; Seeman et al. 1976), and it has been proposed 
that the adverse effects of these drugs on motivation reflects their ability to disrupt 
dopaminergic mechanisms in limbic structures (Wise 1982; Wise 2006; see section 1.3). 
Atypical antipsychotics, however, have complex and varied pharmacological profiles, 
and their principal mode of action remains in dispute. Clozapine, the most extensively 
studied drug of this class, has a relatively low affinity for D2 dopamine receptors, but a 
high affinity for several subtypes of 5-hydroxytryptamine (5-HT) receptor, most notably 
5-HT2A receptors (Bymaster et al. 1996). The combination of D2 and 5-HT2A receptor 
DQWDJRQLVPKDVEHHQSURSRVHGDVWKHEDVLVRIFOR]DSLQH¶VIDYRXUDEOHWKHUDSHXWLFSURILOH
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(Ichikawa et al. 2001; Meltzer et al. 2003), leading to the suggestion that the combination 
of a conventional antipsychotic with a 5-HT2 receptor antagonist might offer some 
therapeutic advantages over treatment with a conventional antipsychotic alone in the 
management of the negative symptoms of schizophrenia (Meltzer 1995). Clinical 
investigations of this proposal have yielded mixed results: some studies found that the 5-
HT receptor antagonist cyproheptadine produced an improvement of negative 
symptomatology in schizophrenic patients (Akhondzadeh et al. 1999; Bacher et al. 1994; 
Silver et al. 1989), whereas others found no significant effect (Chaudhry et al. 2002; Lee 
et al. 1995; Silver et al. 1991).  
 
There have been several preclinical studies comparing the behavioural effects of atypical 
antispychotics and 5-HT2 receptor antagonists. Comparisons of clozapine and 
cyproheptadine are of particular interest because these drugs have similar profiles of 
affinity for different subtypes of 5-HT receptor, both drugs having particularly high 
affinity for 5-HT2A receptors (Bymaster et al. 1996; Goudie et al. 2007; Young et al. 
2005). These drugs share many behavioural effects. Both drugs stimulate appetite and 
induce weight gain, have sedative effects, and reverse the suppressant effect of 
punishment on operant responding in rats (Hartfield et al. 2003; Ketelaars and Bruinvels 
1989; Moore et al. 1992) Recently it has been found that the two drugs show 
generalization and mutual cross-tolerance in a drug discrimination paradigm (Goudie et 
al. 2007). The present experiment extended these observations by comparing the effects 
of clozapine and cyproheptadine on operant behaviour in rats, with the aim of 
establishing whether these drugs share the ability to enhance the incentive value of a food 
reinforcer. .LOOHHQ¶VMPR model (Killeen 1994) was used to assess the effects of these 
drugs on the incentive value of reinforcers (see section 1.4. and Chapters 2, 3 and 4).  
 
Atypical antipsychotics have a profile of action on the parameters of Equation 1 (see 
sections 1.4 and 2.1) which distinguishes them from conventional antipsychotics. 
Clozapine and other atypical antipsychotics increase both a and į (Mobini et al. 2000; 
Zhang et al. 2005a; Zhang et al. 2005b) consistent with an increase in the incentive value 
of the reinforcer and an impairment of motor function. Conventional antipsychotics also 
increase į, but unlike the atypical antipsychotics they either have no effect on a or reduce 
the value of this parameter (Mobini et al. 2000; Zhang et al. 2005a).  
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The present experiment compared the effects of cyproheptadine and clozapine on the 
parameters of Equations 1 and 2 (see section 2.1). Based on the similarity oIWKHVHGUXJV¶
effects on appetite and the finding that these two drugs display behavioural cross-
tolerance and generalization in drug discrimination studies (see above), it was predicted 
that cyproheptadine, like clozapine, would increase the values of a and į. For 
comparison, the effects of the conventional antipsychotic haloperidol and two drugs with 
well documented appetite-enhancing effects, chlordiazepoxide (Berridge and Treit 1986; 
Freet et al. 2006) DQG ǻ9-tetrahydrocannabinol (THC) (Abel 1975; Kirkham and 
Williams 2001; Koch 2001; Williams and Kirkham 2002), were also examined.  
 
 
5.2  Methods 
 
The experiment was carried out in accordance with UK Home Office regulations 




Female Wistar rats approximately 4 months old and weighing 250±300 g at the start of 
the experiment were used. They were housed under the same conditions as in Experiment 




The same operant conditioning chambers, control apparatus and software were used as in 
Experiment 1 (see section 2.2.3). 
 
5.2.3.  Behavioural procedures 
  
Training under the progressive-ratio schedule was carried out in the same way as in 
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5.2.4 Drug treatment 
 
The drug treatment regimen started after 90 sessions of preliminary training under the 
progressive-ratio schedule. Injections of drugs were given on Tuesdays and Fridays, and 
injections of the vehicle alone on Mondays and Thursdays; no injections were given on 
Wednesdays, Saturdays or Sundays. Different groups of rats were used to test the various 
drugs (see below); each rat was tested five times with each dose of the drug, the order of 
doses being counterbalanced across animals according to a Latin square design. Drugs 
were injected intraperitoneally (2.5 ml kg-1; 25-gauge needle) 30 min before the start of 
the experimental session. Doses were calculated from the weights of the salts. 
Cyproheptadine hydrochloride (1 and 5 mg kg-1; n = 12) and chlordiazepoxide 
hydrochloride (3 and 10 mg kg-1; n = 12) were dissolved in sterile 0.9% sodium chloride 
solution. Clozapine (3.75 and 7.5 mg kg-1; n = 15) and haloperidol (0.05 and 0.1 mg kg-1; 
n = 11) were dissolved in 0.1 M tartaric acid, buffered to pH 5.5 and diluted with sterile 
0.9% sodium chloride WRJLYHWKHGHVLUHGFRQFHQWUDWLRQǻ9-tetahydrocannabinol (THC, 1 
and 3 mg kg-1; n = 12) was dissolved in a mixture of ethanol and Tween (1:1) and diluted 
with strerile water to give the desired concentration. Cyproheptadine and THC were 
obtained from Tocris Bioscience, Bristol, UK; clozapine, haloperidol and 
chlordiazepoxide were obtained from Sigma Chemical Company, Poole, UK. The doses 
of clozapine and haloperidol were chosen on the basis of previous findings of the effects 
of these drugs on progressive-ratio schedule performance (Mobini et al. 2000; Zhang et 
al. 2005a), the dose of cyproheptadine was chosen on the basis of previous findings with 
the drug discrimination paradigm (Goudie et al. 2007), and the doses of chlordiazepoxide 
and THC were chosen on the basis of their effects on feeding behaviour (Berridge and 
Treit 1986; Freet et al. 2006; Koch 2001; Williams and Kirkham 2002). 
 
5.2.5 Data analysis 
 
The data obtained with each drug were analyzed separately. Only the data obtained from 
the sessions in which injections had been given were used in the analysis.  
 
(i) Peak response rate  
The highest overall response rate (see below) attained during performance on the 
progressive-ratio schedule was compared between treatments by repeated-measures one-
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way analysis of variance, followed, in the case of a significant effect of treatment, by 
comparison of each dose of the drug with the vehicle-aloQH WUHDWPHQW XVLQJ 'XQQHWW¶V
test. 
 
(ii) Highest completed ratio and breakpoint  
The highest completed ratio and breakpoint (see section 2.2.6.1) were compared between 
treatment conditions in the same way as the peak response rate.  
 
(iii) Overall response rate 
 Overall response rate data were analysed by two-factor analysis of variance (treatment 
condition × ratio) with repeated measures on both factors. The parameters were derived 
and analysed as in Experiment 2 (see section 2.2.6.1). 
 
(iv) Running response rate  
The data were analysed as described above. All the calculations were carried in the same 







5.3.1.1  Peak response rate 
 
The mean (± SEM) data are shown in Table 5.1. There was a significant effect of 
treatment [F(2,22) = 19.7, p<0.001], peak response rate being significantly reduced by 
the higher dose of cyproheptadine. 
 
5.3.1.2.  Highest completed ratio and breakpoint  
 
The mean (± SEM) data are shown in Table 5.1. There was a significant effect of 
treatment [F(2,22) = 10.7, p<0.01], the ratio being significantly increased by both doses 
of the drug. The breakpoint was also affected [F(2,22) = 4.0, p<0.05], the effect of the 
higher dose being statistically significant. 
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Table 5.1 Peak response rate, breakpoint and highest completed ratio under each 
treatment condition (mean ± SEM) 
 
* Significance of difference from vehicle control, p<0.05 (see text for details) 
 
 
5.3.1.3.  Overall response rate  
 
The group mean data under each treatment condition are shown in Fig. 5.1 (left-hand 
 
Treatment 




Highest  completed 
ratio 
Cyproheptadine          
   vehicle 129.1 ± 5.2  116.8 ± 13.8 135.7 ± 16.9 
   1 mg kg-1 132.0 ± 6.1  140.6 ± 16.0 186.3 ± 20.5* 
   5 mg kg-1 102.1 ± 6.6*  189.0 ± 33.3* 226.5 ± 29.3* 
Clozapine           
   vehicle 92.4 ± 6.7  125.9 ± 10.7 134.5 ± 10.6 
   3.75 mg kg-1 82.6 ± 7.7  135.5 ± 16.4 163.6 ± 19.8 
   7.5 mg kg-1 70.4 ± 5.5*  137.7 ± 16.8 159.8 ± 18.1 
Haloperidol           
   vehicle 108.1 ± 9.5  126.8 ± 18.9 208.0 ± 39.6 
   0.05 mg kg-1 97.7 ± 7.1  59.8 ± 7.4* 112.2 ± 27.0* 
   0.1 mg kg-1 78.8 ± 7.4*  20.1 ± 2.5* 28.7 ± 5.9* 
Chlordiazepoxide          
   vehicle 126.0 ± 6.1  105.2 ± 13.5 120.4 ± 16.2 
   3 mg kg-1 145.4 ± 8.7*  151.4 ± 18.8* 178.7 ± 20.8* 
   10 mg kg-1 127.5 ± 9.6  116.9 ± 15.3 161.3 ± 21.7* 
THC           
   vehicle 134.5 ± 7.8  105.8 ± 14.3 127.4 ± 18.2 
   1 mg kg-1 131.4 ± 7.4  112.5 ± 15.5 134.0 ± 19.9 
   3 mg kg-1 133.6 ± 7.0  108.9 ± 13.1 127.4 ± 17.5 
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panel). Response rate tended to be reduced in the case of lower ratios and increased in the 
case of higher ratios by the higher dose of cyproheptadine. Analysis of variance revealed 
significant main effects of treatment [F(2,22) = 11.6, p<0.001] and ratio [F(15,165) = 
16.1, p<0.001] and a significant treatment × ratio interaction [F(30,330) = 2.9, p<0.001]. 
The fits of Equation 1 to the group mean data accounted for >85% of the total variance 
(vehicle: r2 = 0.98; cyproheptadine 1 mg kg-1: r2 = 0.95; 5 mg kg-1: r2 = 0.86). The 
parameters of Equation 1 are shown in Table 5.2. Cyproheptadine significantly increased 
WKH µVSHFLILF DFWLYDWLRQ¶ SDUDPHWHU a [F(2,22) = 9.1, p@ DQG WKH µUHVSRQVH WLPH¶
parameter, į [F(2,22) = 12.7, p<0.001], the effect of the higher dose being significant in 
HDFKFDVH7KHUHZDVQRVLJQLILFDQWHIIHFWRIF\SURKHSWDGLQHRQWKHµFXUUHQF\¶SDUDPHWHU
ȕ [F(2,22) = 1.3, p>0.2]. 
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Figure 5.1. Effects of cyproheptadine (CYPRO) on progressive-ratio schedule 
performance. Left-hand graph: relation between overall response rate and the 
response/reinforcer ratio, N. Unfilled circles: vehicle-alone treatment; upright filled 
triangles: cyproheptadine 1 mg kg-1; inverted filled triangles: cyproheptadine 5 mg kg-1 
(see inset). Curves are fits of Equation 1 to the data. Right-hand graph: relation between 
running response rate and N. The curves are fits of Equation 2 to the data; other 
conventions are as in the left-hand graph. 
 
5.3.1.4.  Running response rate  
 
The group mean data under each treatment condition are shown in Fig. 5.1 (right-hand 
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Table 5.2.  Parameters of Equation 1 (group mean data ± SEM)  
 
* Significance of difference from vehicle control, P<0.05 (see text for details) 
 
panel). Running rate tended to be reduced in the case of lower ratios by both doses of 
cyproheptadine. Analysis of variance revealed significant main effects of treatment 
[F(2,22) = 14.7, p<0.001] and ratio [F(15,165) = 81.3, p<0.001] and a significant 
treatment × ratio interaction [F(30,330) = 1.5, p<0.05]. The fits of Equation 2 to the 
group mean data accounted for >90% of the total variance (vehicle: r2 = 0.97; 
cyproheptadine 1 mg kg-1: r2 = 0.98; 5 mg kg-1: r2 = 0.96). The parameters of Equation 2 
Treatment a (s)  įV  ȕ 
Cyproheptadine            
   vehicle 116.6 ± 12.2  0.69 ± 0.06  0.57 ± 0.09 
   1 mg kg-1 151.0 ± 20.8  0.65 ± 0.08  0.45 ± 0.08 
   5 mg kg-1 315.2 ± 64.3*  0.88 ± 0.07*  0.46 ± 0.08 
Clozapine            
   vehicle 174.7 ± 22.8  0.92 ± 0.09  0.37 ± 0.09 
   3.75 mg kg-1 303.7 ± 39.3*  1.19 ± 0.10  0.53 ± 0.10 
   7.5 mg kg-1 470.9 ± 84.5*  1.41 ± 0.24*  0.57 ± 0.10* 
Haloperidol            
   vehicle 252.7 ± 65.0  0.97 ± 0.10  0.36 ± 0.09 
   0.05 mg kg-1 156.4 ± 53.6*  1.11 ± 0.12  0.51 ± 0.09 
   0.1 mg kg-1 40.2 ± 6.7*  1.20 ± 0.16*  0.63 ± 0.12 
Chlordiazepoxide            
   vehicle 101.6 ± 13.0  0.67 ± 0.06  0.42 ± 0.09 
   3 mg kg-1 124.9 ± 15.1  0.56 ± 0.03*  0.56 ± 0.07 
   10 mg kg-1 135.6 ± 15.4*  0.70 ± 0.06  0.67 ± 0.08 
THC            
   vehicle 106.9 ± 13.1  0.72 ± 0.11  0.57 ± 0.08 
   1 mg kg-1 122.0 ± 16.6  0.68 ± 0.08  0.48 ± 0.07 
   3 mg kg-1 101.7 ± 10.3  0.73 ± 0.13  0.52 ± 0.08 
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are shown in Table 5.3. Cyproheptadine significantly reduFHGWKHµLQLWLDO UHVSRQVHUDWH¶
parameter, Ri [F(2,22) = 5.4, p<0.05], the effect of the higher dose being statistically 
VLJQLILFDQW7KHUHZDVQRVLJQLILFDQWHIIHFWRIF\SURKHSWDGLQHRQWKHµGHFD\¶SDUDPHWHUb  
[F 16@RUWKHµH[SRQHQW¶SDUDmeter, c [F(2,22) = 1.8, NS]. 
 
 Table 5.3.  Parameters of Equation 2 (group mean data ± SEM) 
 
* Significance of difference from vehicle control, P<0.05 (see text for details) 
 
 
Treatment Ri (responses min-1)  b  c 
Cyproheptadine            
   vehicle 222.0 ± 19.1  30.0 ± 13.1  1.43 ± 0.20 
   1 mg kg-1 191.7 ± 15.9  66.9 ± 12.9  1.40 ± 0.11 
   5 mg kg-1 151.9 ± 19.2*  85.0 ± 27.0  2.47 ± 0.84 
Clozapine            
   vehicle 154.5 ± 10.8  59.4 ± 8.8  1.61 ± 0.21 
   3.75 mg kg-1 138.7 ± 14.1  66.5 ± 12.3  1.40 ± 0.16 
   7.5 mg kg-1 107.3 ± 11.4*  72.3 ± 14.4  2.21 ± 0.72 
Haloperidol            
   vehicle 158.1 ± 15.9  59.5 ± 9.6  1.31 ± 0.12 
   0.05 mg kg-1 148.1 ± 13.1  37.3 ± 9.4  1.78 ± 0.20 
   0.1 mg kg-1 133.4 ± 17.4  14.5 ± 2.3*  3.88 ± 0.75* 
Chlordiazepoxide            
   vehicle 208.1 ± 20.2  51.6 ± 13.7  1.84 ± 0.40 
   3 mg kg-1 210.7 ± 17.7  57.7 ± 10.8  1.44 ± 0.21 
   10 mg kg-1 186.5 ± 15.0  53.4 ± 12.4  1.36 ± 0.15 
THC            
   vehicle 207.2 ± 20.1  48.2 ± 7.9  1.73 ± 0.19 
   1 mg kg-1 201.8 ± 16.0  53.8 ± 11.4  1.82 ± 0.23 
   3 mg kg-1 189.5 ± 9.5  57.0 ± 9.7  1.87 ± 0.11 
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5.3.2. Clozapine. 
 
5.3.2.1.  Peak response rate  
 
There was a significant effect of treatment [F(2,28) = 10.2, p<0.001], peak response rate 
being significantly reduced by the higher dose of clozapine (Table 5.1). 
 
5.3.2.2.  Highest completed ratio and breakpoint  
 
Clozapine had no significant effect on either measure [highest completed ratio: F(2,28) = 
2.6, NS; breakpoint: F<1] (Table 5.1). 
 
5.3.2.3. Overall response rate 
 
Clozapine tended to reduce overall response rate under the lower ratios and increase it 
under the higher ratios (Fig. 5.2, left-hand panel). Analysis of variance revealed 
significant main effects of treatment [F(2,28) = 10.3, p<0.001] and ratio [F(15,210) = 
7.3, p<0.001] and a significant treatment × ratio interaction [F(30,420) = 3.1, p<0.001]. 
Equation 1 accounted for >85% of the total variance (vehicle: r2 = 0.88; clozapine 3.75 
mg kg-1: r2 = 0.93; 7.5mg kg-1: r2 = 0.92). Analysis of the parameters of Equation 1 
(Table 5.2) showed that a was increased by clozapine [F(2,28) = 10.9, p<0.001], the 
effects of ERWKGRVHVEHLQJVWDWLVWLFDOO\VLJQLILFDQWįZDVLQFUHDVHGE\FOR]DSLQH>F(2,28) 
= 3.4, p<0.05], the effect of 7.5 mg kg-1 EHLQJ VWDWLVWLFDOO\ VLJQLILFDQW ȕ ZDV DOVR
increased by clozapine [F(2,28) = 3.4, p<0.05], the effect of 7.5 mg kg-1 being 
statistically significant. 
 
5.3.2.4. Running response rate  
 
The group mean data are shown in Fig. 5.2 (right-hand panel). The higher dose of 
clozapine reduced response rates in the case of lower ratios. Analysis of variance 
revealed significant main effects of treatment [F(2,28) = 6.9, p<0.01] and ratio 
[F(15,210) = 74.8, p<0.001] and a significant treatment × ratio interaction [F(30,420) = 
1.8, p<0.05]. Equation 2 accounted for >90% of the total variance (vehicle: r2 = 0.98; 
clozapine 3.75 mg kg-1: r2 = 0.97; 7.5mg kg-1: r2 = 0.97). Analysis of the parameters of 
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Equation 2 (Table 5.3) showed that clozapine significantly reduced Ri [F(2,22) = 5.2, 
p<0.05], the effect of the higher dose being statistically significant. There was no 
significant effect of clozapine on b  [F<1] or c [F<1]. 
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Figure 5.2. Effects of clozapine (CLOZ) on progressive-ratio schedule performance. 
Unfilled circles: vehicle-alone treatment; upright filled triangles: clozapine 3.75 mg kg-1; 




5.3.3.  Haloperidol 
 
5.3.3.1.  Peak response rate 
 
There was a significant effect of treatment [F(2,20) = 13.0, p<0.001], peak response rate 
being significantly reduced by the higher dose of haloperidol (Table 5.1). 
 
5.3.3.2.  Highest completed ratio and breakpoint  
 
Haloperidol reduced the highest completed ratio [F(2,20) = 23.4, p<0.001], the effects of 
both doses being statistically significant. The breakpoint was also reduced [F(2,20) = 
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29.8, p<0.001], the effect of the both doses being statistically significant (Table 5.1). 
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Figure 5.3. Effects of haloperidol (HAL) on progressive-ratio schedule performance. 
Unfilled circles: vehicle-alone treatment; upright filled triangles: haloperidol 0.05 mg 
kg-1; inverted filled triangles: haloperidol 0.1 mg kg-1 (see inset). Other conventions are 
as in Fig. 5.1. 
 
5.3.3.3.  Overall response rate  
 
There was a dose-dependent suppression of overall response rate (Fig. 5.3, left-hand 
panel). There were significant main effects of treatment [F(2,20) = 70.5, p<0.001] and 
ratio [F(11,110) = 14.4, p<0.001] and a significant treatment × ratio interaction 
[F(22,220) = 8.2, p<0.001]. Equation 1 accounted for >90% of the total variance 
(vehicle: r2 = 0.97; haloperidol 0.05 mg kg-1: r2 = 0.93; 0.1mg kg-1: r2 = 0.92). Analysis 
of the parameters of Equation 1 (Table 5.2) showed that haloperidol significantly reduced 
the value of a [F(2,20) = 9.2, P<0.001] and incUHDVHG WKH YDOXH RI į >F(2,20) = 5.2, 
p@ȕZDVQRWVLJQLILFDQWO\DIIHFWHG>F(2,20) = 2.9, p>0.05]. 
 
5.3.3.4.  Running response rate 
 
The group mean data are shown in Fig. 5.3 (right-hand panel). There was a dose 
dependent reduction of response rates. Analysis of variance revealed significant main 
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effects of treatment [F(2,20) = 27.4, p<0.001] and ratio [F(11,110) = 52.0, p<0.001]; the 
interaction term was not significant [F(22,220) = 81.2, NS]. Equation 2 accounted for 
>90% of the total variance (vehicle: r2 = 0.98; haloperidol 0.05 mg kg-1: r2 = 0.99; 0.1mg 
kg-1: r2 = 0.99). Analysis of the parameters of Equation 2 (Table 5.2) showed that 
haloperidol did not significantly affect Ri [F(2,20) = 1.3, NS]. There was a significant 
reduction of b [F(2,20) = 10.4, P<0.01] and an increase of c [F(2,20) = 8.2, p<0.01] 
produced by the higher dose.  
 
  
5.3.4.  Chlordiazepoxide 
 
5.3.4.1  Peak response rate 
 
There was a significant effect of treatment [F(2,22) = 6.2, P<0.01], peak response rate 
being significantly increased by the lower dose of chlordiazepoxide (Table 5.1). 
 
5.3.4.2.  Highest completed ratio and breakpoint 
 
Chlordiazepoxide increased the highest completed ratio [F(2,22) = 7.7, p<0.001], the 
effects of both doses being statistically significant. The breakpoint was also increased 
[F(2,22) = 6.3, p<0.01], the effect of the lower dose being statistically significant (Table 
5.1). 
 
5.3.4.3.  Overall response rate  
 
Chlordiazepoxide tended to increase overall response rates, this being somewhat more 
apparent in the case of the smaller dose (3 mg kg-1) (Fig. 5.4, left-hand panel). There 
were significant main effects of treatment [F(2,22) = 11.6, p<0.001] and ratio [F(15,165) 
= 22.2, p<0.001] and a significant treatment × ratio interaction [F(30,330) = 1.8, p<0.01]. 
Equation 1 accounted for >90% of the total variance (vehicle: r2 = 0.97; chlordiazepoxide 
3 mg kg-1: r2 = 0.97; 10 mg kg-1: r2 = 0.97). Analysis of the parameters of Equation 1 
(Table 5.2) revealed a significant effect of treatment on a [F(2,22) = 5.2, p<0.05], the 
increase produced by 10 mg kg-1 being statistically significant. There was also a 
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significant effect on į [F(2,22) = 5.2, P<0.05], reflecting a reduction of this parameter 
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Figure 5.4. Effects of chlordiazepoxide (CDP) on progressive-ratio schedule 
performance. Unfilled circles: vehicle-alone treatment; upright filled triangles: 
chlordiadepoxide 3 mg kg-1; inverted filled triangles: chlordiazepoxide 10 mg kg-1 (see 
inset). Other conventions are as in Fig. 5.1. 
 
 
5.3.4.4.  Running response rate 
 
The group mean data are shown in Fig. 5.4 (right-hand panel). The lower dose of 
chlordiazepoxide produced a modest increase in running response rate. There were 
significant main effects of treatment [F(2,22) = 10.3, p<0.001] and ratio [F(15,165) = 
66.6, p<0.001]; the interaction was not significant [F(30,330) = 1.1, NS]. Equation 2 
accounted for >90% of the total variance (vehicle: r2 = 0.97; chlordiazepoxide 3 mg kg-1: 
r2 = 0.98; 10 mg kg-1: r2 = 0.99). Analysis of the parameters of Equation 2 (Table 5.3) 
showed that chlordiazepoxide had no significant effect on Ri [F<1], b [F<1] or c [F(2,22) 
= 1.3, NS]. 
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5.3.5.  ǻ9-tetrahydrocannabinol (THC) 
 
5.3.5.1.  Peak response rate 
  
THC had no significant effect on the peak response rate [F<1] (Table 5.1). 
 
5.3.5.2.  Highest completed ratio and breakpoint 
 
THC had no significant effect on the highest completed ratio [F(2,22) = 1.1, NS] or the 
breakpoint [F<1].  
 
5.3.5.3.  Overall response rate  
 
THC had no apparent effect on overall response rate (Fig. 5.5, left-hand panel). Analysis 
of variance revealed a significant main effect of ratio [F(15,165) = 15.5, p<0.001], but no 
significant main effect of treatment [F(2,22) = 2.6, NS] and no significant interaction 
[F<1]. Equation 1 accounted for >90% of the total variance (vehicle: r2 = 0.97; THC 1 
mg kg-1: r2 = 0.97; 3 mg kg-1: r2 = 0.97). None of the parameters of Equation 1 was 
significantly affected by the drug [a: F(2,22) = 2.2, p>0.05; į: F(2,22) = 1.6, p>0.1; ȕ: 
F<1] (Table 5.2). 
 
5.3.5.4. Running response rate 
 
THC had no significant effect on running response rate (Fig. 5.5, right-hand panel). 
There was a significant main effect of ratio [F(15,165) = 93.3, p<0.001], but no 
significant main effect of treatment [F<1] and no significant interaction [F(30,330) = 1.1, 
NS]. Equation 2 accounted for >90% of the total variance (vehicle: r2 = 0.98; THC 1 mg 
kg-1: r2 = 0.98; 3 mg kg-1: r2 = 0.99). None of the parameters of Equation 2 was 
significantly affected by THC [Ri, b, c:  all Fs<] (Table 5.3). 
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Figure 5.5 (IIHFWV RI ǻ9-tetrahydrocannabinol (THC) on progressive-ratio schedule 
performance. Unfilled circles: vehicle-alone treatment; upright filled triangles: THC 1 






Performance on the progressive-ratio schedule was similar to that seen in many previous 
studies (Bezzina et al. 2008b; Bezzina et al. 2008c; Bizo and Killeen 1997; den Boon et 
al. 2011; Ho et al. 2003; Kheramin et al. 2005; Mobini et al. 2000; Rickard et al. 2009; 
Zhang et al. 2005a; Zhang et al. 2005b) and in Experiments 2,3, and 4 (see section 2.4 for 
discussion). 
 
Previous comparisons of the effects of conventional and atypical antipsychotics on 
progressive-ratio schedule performance found that the two classes of drugs exerted 
different patterns of effect on the parameters of Equation 1 (Mobini et al. 2000; Zhang et 
al. 2005a). Atypical antipsychotics iQFUHDVHGWKHYDOXHVRIERWKWKHµVSHFLILFDFWLYDWLRQ¶
parameter, a DQG WKH µUHVSRQVH WLPH¶ SDUDPHWHU į; in contrast, conventional 
DQWLSV\FKRWLFVLQFUHDVHGįEXWHLWKHUUHGXFHGRUKDGQRHIIHFWRQa. The present results 
are consistent with these previous findings, in that clozapine increased both a and į, 
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ZKHUHDVKDORSHULGROLQFUHDVHGįDQGUHGXFHGa.   
 
The parameter a is believed to provide a quantitative measure of the efficacy or value of 
reinforcers (Bezzina et al. 2008b; Bezzina et al. 2008c; Bizo and Killeen 1997; den Boon 
et al. 2011; Kheramin et al. 2005b; Killeen 1994; Killeen 2009; Killeen and Sitomer 
2003; Reilly 2003; Rickard et al. 2009). Thus the opposite effects of clozapine and 
haloperidol on this parameter are consistent with the notion that clozapine increased and 
haloperidol reduced the incentive value of the food reinforcer. The decay parameter, b, of 
Equation 2 is also related to incentive value (Rickard et al. 2009). Clozapine tended to 
increase this parameter, although the effect was not statistically significant, whereas 
haloperidol significantly reduced it.  
 
The apparent enhancement of the incentive value of food reinforcers by clozapine may be 
UHODWHGWRWKLVGUXJ¶VNQRZQDSSHWLWH-enhancing effect (Comer et al. 1997; Goudie et al. 
2007; Hartfield et al. 2003). The mechanism underlying this effect is uncertain. 
Clozapine has a complex receptor binding profile which includes notably high affinities 
for 5-HT2A, histamine H1 and muscarinic M1 receptors (Bymaster et al. 1996); it has been 
suggested that the combined blockade of these receptors is responsible for the 
hyperphagic effects of this drug (Hartfield et al. 2003).  
 
A reduction of the incentive value of food reinforcers by haloperidol is consistent with 
WKHZHOONQRZQµDQKHGRQLDWKHRU\¶ZKLFKposits that conventional antipsychotics reduce 
the rewarding value of food and other reinforcers by blocking dopamine D2 receptors in 
limbic structures (Wise 1982; Wise 2006). Evidence consistent with an antihedonic effect 
of conventional antipsychotics derives from a wide variety of behavioural approaches, 
including operant response rate measures (Heyman 1983; Morley et al. 1984; Salamone 
1987; Salamone et al. 2001), conditioned reinforcement paradigms (Cador et al. 1991), 
and the rate of extinction of operant responses (Salamone 1986; Wise et al. 1978a). In 
some cases, these observations may be susceptible to an alternative interpretation in 
terms of a motor debilitating effect of the drugs (see Salamone et al. 1994, 1997). 
Quantitative analysis of schedule-FRQWUROOHGEHKDYLRXUEDVHGRQ.LOOHHQ¶V 035
model enables these two processes to be separated mathematically. Previous applications 
of this method indicated a predominant effect of haloperidol on motor capacity (Mobini 
et al. 2000; Zhang et al. 2005a). However, the present results indicate that haloperidol 
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also produced a substantial reduction of the incentive value of the food reinforcer. 
 
Since į is believed to be inversely related to the motor capacity of the organism     
(Bezzina et al. 2008a; Bezzina et al. 2008b; Bizo and Killeen 1997; Kheramin et al. 
2005; Killeen 1994; Killeen 2009; Killeen and Sitomer 2003; Reilly 2003; Rickard et al. 
2009), the increase in this parameter produced by both clozapine and haloperidol is 
consistent with an adverse effect of both drugs on motor functioning. The parameter Ri of 
Equation 2 may also be related to motor functioning, since it expresses the maximum rate 
of emission of trains of operant responses; however, unlike į, it is not influenced by the 
post-reinforcement pause, which may in part reflect post-prandial effects of the reinforcer 
(Rickard et al. 2009). Both clozapine and haloperidol tended to reduce this parameter, the 
effect being statistically significant only in the case of clozapine.  
 
The apparent motor debilitating effects of clozapine and haloperidol are unlikely to 
UHIOHFW WKH VDPH XQGHUO\LQJ SURFHVV ,Q FOR]DSLQH¶V FDVH WKH HIIHFW PD\ EH UHODWHG WR
sedation, a known side-effect of this drug which is generally attributed to the blockade of 
central H1 receptors (King and Waddington 2004). +DORSHULGRO¶V HIIHFW RQ WKH PRWRU
parameters of Equations 1 and 2 is more likely to reflect blockade of D2 receptors in the 
basal ganglia, the basis of the ubiquitous extrapyrimidal motor side-effects of 
conventional antipsychotics (Cunningham Owens 1999). 
 
Both clozapine and haloperidol produced modest increases in the value of the currency 
parameter, ȕ, although this effect only reached statistical significance in the case of 
clozapine. The interpretation of this finding is unclear. Increases in this parameter have 
been found to occur following increases in reinforcer size (Bizo et al. 2001; Bezzina et al. 
2008a; Rickard et al. 2009), possibly reflecting the propensity of larger reinforcers to 
induce more effective response-reinforcer coupling (Killeen 1994; Bizo et al. 2001; 
Rickard et al. 2009). This might suggest that clozapine increased the efficiency of 
response-reinforcer coupling in this experiment. However, it may be premature to 
attribute theoretical significance to the present finding, because previous experiments 
have not generally found reliable effects of clozapine and other antipsychotics on this 
parameter (Mobini et al. 2000; Zhang et al. 2005a, 2005b). 
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The main purpose of this experiment was to compare the effects of cyproheptadine and 
clozapine on progressive-ratio schedule performance. The results indicate that the two 
drugs had similar profiles of effect on the parameters of Equations 1 and 2. On the basis 
of the theoretical interpretation of these parameters discussed above, the present results 
are thus consistent with the notion that cyproheptadine, like clozapine, increased the 
incentive value of the food reinforcer and induced a degree of motor debilitation. An 
increase in the incentive value of food reinforcers by cyproheptadine may be related to 
the known appetite-enhancing effect of this drug, an effect that it shares with clozapine 
(Goudie et al. 2007; Hartfield et al. 2003). It has been proposed that the hyperphagic 
effects of both drugs reflect the combined blockade of central 5-HT2A, H1 and M1 
receptors (Goudie et al. 2007; Hartfield et al. 2003). The apparent motor debilitating 
effects of both drugs (increase in į and reduction of Ri) may reflect sedation which may 
be attributable to H1 receptor blockade in both cases.  
 
The similar pharmacological profiles of cyproheptadine and clozapine has led to the 
suggestion that cyproheptadine may be of value in the management of schizophrenia, 
particularly in the case of patients for whom negative symptoms are especially 
troublesome. Although attempts to verify this proposal in clinical studies have so far 
yielded mixed results (see section 5.1), the finding that cyproheptadine, like clozapine, 
may enhance incentive reinforcer value suggests that further clinical studies may be 
worthwhile (see Goudie et al. 2007). It must be emphasized, however, that the present 
results were obtained exclusively with food reinforcers, and it remains to be established 
ZKHWKHUF\SURKHSWDGLQH¶VDQGFOR]DSLQH¶VHIIHFWVUHIOHFWLQWHUDFWLRQVZLWKJHQHUDOUHZDUG
processes, rather than with mechanisms specific to food reinforcement. Further 
experimental work is needed in order to address this matter. 
 
Combined treatment with cyproheptadine and haloperidol was not tested in these 
experiments. It would be of interest, in future experiments, to examine the effect of this 
treatment combination on different behavioural paradigms, in view of the suggestion that 
combined treatment with cyproheptadine and a conventional antipsychotic may confer 
some advantages in the management of schizophrenia (see above). However, it is 
questionable whether the progressive-ratio schedule would be the ideal model for 
assessing the utility of this treatment. The putative clinical value of this treatment 
approach resides in the combination of a drug that may alleviate anhedonia and other 
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negative symptoms (i.e cyproheptadine) and a drug with known ability to suppress 
positive symptoms (i.e. haloperidol). The quantitative analysis of progressive-ratio 
schedule performance adopted here provides a means of assessing the incentive value of 
positive reinforcers, and may therefore provide a useful measure of the propensity of 
drugs to alleviate negative symptoms; however it offers no insights into ability of drugs 
to suppress positive psychotic symptoms 
 
ChlordiazepoxLGH¶VHIIHFWRQ WKHSDUDPHWHUVRI(TXDWLRQVDQG LVFRQVLVWHQWZLWKDQ
increase in the incentive value of the reinforcer (increase in a and b). However, unlike 
clozapine and cyproheptadine, its effect is not suggestive of motor impairment; indeed 
the lower dose actually reduced į and increased Ri, suggesting a modest facilitation of 
RSHUDQWUHVSRQGLQJ7KHLQFUHDVHLQUHLQIRUFHUYDOXHPD\EHUHODWHGWRFKORUGLD]HSR[LGH¶V
known ability to facilitate feeding in rodents (Berridge and Treit 1986; Freet et al. 2006) 
7KH PHFKDQLVP XQGHUO\LQJ EHQ]RGLD]HSLQHV¶ DSSHWLWH-enhancing effect is uncertain. 
+RZHYHU VLQFH WKH PDLQ SKDUPDFRORJLFDO DFWLRQ RI WKHVH GUXJV LV WR IDFLOLWDWH Ȗ-
aminobutyric acid (GABA)-mediated functions, and they do not interact directly with 5-




THC had no significant effect on performance on the progressive-ratio schedule. This 
QHJDWLYH UHVXOW ZDV XQH[SHFWHG LQ YLHZ RI 7+&¶V NQRZQ DSSHWLWH-stimulating effect 
(Abel 1975; Williams and Kirkham 1999; Williams et al. 1998) and previous reports of 
its ability to increase the breakpoint in progressive-ratio schedules (Higgs et al. 2005). It 
is possible that the doses used in this experiment were inadequate to alter the incentive 
value of the food reinforcer. However, these doses were selected on the basis of previous 
studies that reported increases in food intake (Higgs et al. 2005; Jarrett et al. 2005). The 
effect of cannabinoids on food reinforcement is known to differ between different 
foodstuffs, being especially pronounced in the case of sweet foods (Ward and Dykstra 
2005). The reinforcer pellets used in these experiments are more palatable and have a 
higher fat content than standard laboratory chow, but have no sucrose or other 
carbohydrate content (TestDiet published data). It may be of interest, therefore, to 
compare the effects of THC on the parameters of Equation 1 using progressive-ratio 
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schedules employing both fat and carbohydrohydrate reinforcers; this issue is addressed 
in the final experiment of the present project (see Chapter 7). 
 
7KHSUHVHQWILQGLQJVSURYLGHDIXUWKHULOOXVWUDWLRQRIWKHLPSOLFDWLRQVRI.LOOHHQ¶V
MPR model for interpreting the effects of neuropharmacological interventions on 
progressive-ratio schedule performance (for review, see Killeen et al. 2009; Rickard et al. 
2009). According to MPR, the traditional index of performance on this schedule (the 
breakpoint) is a hybrid measure, being jointly determined by the incentive value of the 
reinforcer, represented by a, and the motor limitations of the organism, represented by į. 
The estimated value of the breakpoint, derived by extrapolation of the descending limb of 
the response rate function, is defined as a/į. In the case of interventions that have little 
impact on motor performance, changes in the breakpoint may provide a reliable 
indication of changes of incentive value. However, an effect on motor performance may 
augment, attenuate or even completely override the impact of a change of incentive value 
on the breakpoint. In the present experiments, there was a general tendency for changes 
in a to coincide with changes in the breakpoint. For example both doses of 
cyproheptadine and the lower dose of chlordiazepoxide increased a and the breakpoint, 
whereas haloperidol produced dose-dependent reductions of  both these measures. 
Clozapine, however, did not significantly alter the breakpoint, evidently because the 
effects of the drug on a and į exerted opposing influences on the breakpoint.  
 
The breakpoint also presents practical difficulties for the behavioural pharmacologist. It 
is usual to describe the breakpoint as the response/reinforcer ratio at which responding 
ceases. However, the operational definition of  the cessation of responding is arbitrary, 
and different criteria have been adopted by different workers (see Killeen et al. 2009). 
Moreover, allowing the experimental session to become extended for an indefinite period 
until the breakpoint is reached can result in test periods that differ in length between 
subjects and conditions, clearly a complicating factor when the effects of acute drug 
treatments are compared. In the present experiments, as in many previous studies (e.g. 
Aberman et al. 1998; Zhang et al. 2005a, 2005b), time-constrained sessions were used. 
Although this avoids the problem of variable session length, it results in the formal 
breakpoint criterion (in the present case, 5 minutes without responding) not being 
attained by all subjects in all sessions, and necessitates either the elimination of data from 
sessions in which the criterion was not reached or the use of some other measure, such as 
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the highest ratio completed within the time-constrained session. As argued elsewhere 
(Killeen et al. 2009; Rickard et al. 2009), the mathematical approach exemplified by 
MPR, by deriving parameter estimates for individual subjects, avoids many of the 
practical, as well as the theoretical difficulties associated with the use of  the breakpoint. 
 
In summary, the present results confirm the differing effects of haloperidol and clozapine 
on progressive-UDWLR VFKHGXOH SHUIRUPDQFH DQG LQGLFDWH WKDW F\SURKHSWDGLQH¶V HIIHFW
resembled that of clozapine. Quantitative DQDO\VLVEDVHGRQ.LOOHHQ¶VWKHRUHWLFDO
model of schedule-controlled behaviour, MPR, indicated that both clozapine and 
cyproheptadine enhanced the incentive value of the food reinforcer and induced some 
degree of motor impairment. The results further confirm the utility of quantitative 
analysis of progressive-ratio schedule performance based on MPR for investigations of 
the effects of drugs on motivational processes (Killeen 2009; Rickard et al. 2009). 














EXPERIMENT 5: DIFFERENTIAL EFFECTS OF D1 AND D2 
DOPAMINE RECEPTOR ANTAGONISTS ON  PROGRESSIVE-
RATIO SCHEDULE PERFORMANCE OF RATS REINFORCED 
WITH SUCROSE OR CORN OIL 
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6.1. Introduction  
 
The rewarding properties of food have been extensively studied in animals and humans 
and it is thought that the sugar and fat content are primarily responsible for the rewarding 
effects of most foodstuffs (Levin and Dunn-Meynell 2002; Levine et al. 2003; Sclafani 
2004). The overconsumption of food together with the lack of exercise are thought to be 
the major factors responsible for the world-wide increase of obesity. Although it is 
generally accepted that foods with high fat content are very rewarding for humans and 
animals (Drewnowski and Greenwood 1983; Mattes 1993; Takeda et al. 2000), only a 
few studies have analysed the reinforcing properties of fat (Hayward et al. 2002; 
Imaizumi et al. 2000; Imaizumi et al. 2001; Yoneda et al. 2007b). Understanding the 
neurobehavioral mechanisms that lead to the overconsumption of fat may contribute to 
the treatment of obesity. However, despite the importance of understanding how these 
mechanisms work, little is known about why animals and humans are so attracted to fat 
(Yoneda et al. 2007a). 
 
The progressive-ratio schedule has been traditionally used to evaluate the efficacy of 
reinforcers under different experimental situations (Bezzina et al. 2008b; Bezzina et al. 
2008c; Bizo and Killeen 1997; den Boon et al. 2011; Ho et al. 2003; Hodos 1961; Hodos 
and Kalman 1963; Kheramin et al. 2005b; Killeen et al. 2009; Mobini et al. 2000; 
Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b). Hodos et al (1961) found 
that the breakpoint increased with the volume and concentration of a sweet solution, a 
finding that has been corroborated by subsequent experiments (Cheeta et al. 1995; Hodos 
and Kalman 1963; Naleid et al. 2008). Recently Rickard et al. (2009) carried out an 
experiment with rats reinforced with different volumes of a sucrose solution. Their 
results showed that the motivation to work for sucrose, as indicated by the parameter a in 
Killeen¶s (1994) MPR model, was directly proportional to the quantity of sucrose 
received (see section 1.4). Covarrubias and Aparicio (2008), in another experiment using 
progressive-ratio schedules, found higher breakpoints and a trend for a to be higher when 
rats were reinforced with saccharin in comparison with a sucrose reinforced condition. 
Other food reinforcers, including standard food pellets, which combined different kinds 
of nutrients and flavours, have been also used as reinforcers in progressive-ratio 
schedules (Bezzina et al. 2008b; Bezzina et al. 2008c; Borgland et al. 2009; Ho et al. 
2003; Maccioni et al. 2008).   
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The advantage of using pure nutrients (e.g. sucrose solution or fat) is that the effects of 
pharmacological manipulation on operant performance may provide insights into the 
brain mechanisms involved in the rewarding properties of those particular nutrients. For 
example, it has been suggested that D1 and D2 dopamine receptors are differentially 
involved in regulating the rewarding qualities of carbohydrate and fatty foodstuffs (see 
below). It might therefore be expected that antagonism of these receptors would have 
different effects on WKHµLQFHQWLYHYDOXH¶RUµVSHFLILFDFWLYDWLRQ¶SDUDPHWHUa, in MPR, 
when carbohydrates or fat are used as the reinforcer. This possibility was explored in the 
experiments described in this chapter. 
 
As reviewed in section 1.3, the mesolimbic dopaminergic system has been proposed to 
regulate the rewarding properties of food and other reinforcers. Much of the evidence 
supporting this suggestion came from studies using conventional antipsychotic drugs (see 
section 1.3). For example, in the case of progressive-ratio schedules, it has been found 
that these drugs decreased both the breakpoint (Cheeta et al. 1995; Mobini et al. 2000; 
Zhang et al. 2005a) and the activation parameter a (Mobini et al. 2000; see also chapter 
5) when the reinforcer was sucrose. The putative mechanism of action of conventional 
antipsychotics is the antagonism of D2 dopamine receptors (Kapur et al. 2000; Seeman et 
al. 1976), and  the anhedonic effects produced by these drugs are thought to be caused by 
the blockade of D2 dopamine receptors in the limbic system (Wise 1982; Wise 2006) (see 
section 1.3). 
 
However, although there have been numerous studies that have used sucrose-based 
reinforcers (see above), there have been relatively few studies that have used pure fat 
reinforcers in progressive-ratio schedules (Naleid et al. 2008; Ward and Dykstra 2005; 
Yoneda et al. 2007). Recently Naleid et al. (2008) tested the motivational properties of 
different concentrations of sucrose, oil or a mixture of the two on performance on 
progressive-ratio and fixed-ratio schedules. They found that the most effective 
reinforcers were sucrose solutions, and that the reinforcing efficacy of sucrose increased 
as a function of the concentration of the solution.  
 
Yoneda et al. (2007b) examined the role of dopamine receptors in the reinforcing 
efficacy of corn oil in mice. They found that mice responded for corn oil under a 
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progressive-ratio schedule, and that the breakpoint was decreased by systemic treatment 
with the D2 receptor antagonist sulpiride, but not by treatment with  the D1 receptor 
antagonist  SCH-23390 (7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-
ol). Further evidence in favour of the involvement of D2 receptors in the rewarding 
properties of corn oil came from sham feeding experiments (Schneider et al. 1990; 
Schneider et al. 1986; Schneider et al. 1998; Weatherford et al. 1990; Weatherford et al. 
1988). In this technique, animals are able to taste and swallow the foodstuff; however it 
is drained, via a gastric fistula, before reaching the intestine. Thus, the animals are 
exposed to the orosensory properties of food but the post-ingestive effects are minimized. 
Therefore, it is thought that the oromotor acts of licking and ingestion are due to the 
(sensory) reinforcing properties of food and not WR WKH VDWLVIDFWLRQ RI D µKXQJHU GULYH¶ 
(Weatherford et al. 1990). In WeatKHUIRUGHWDO¶V experiment rats were sham fed 
with either corn oil or sucrose. The authors found that the D1 receptor antagonist SCH-
23390 reduced both sucrose and corn oil intake; however, while sucrose intake was 
reduced by SCH-23390 in a dose-dependent manner, corn oil intake was reduced only 
with the highest dose tested, which also produced a sedative effect. In contrast, the D2 
receptor antagonist raclopride was found to suppress both corn oil and sucrose sham 
feeding at doses that did not induce any sedative effect. These results suggest that D1 
dopamine receptor plays a less important role than D2 dopamine receptors in the 
reinforcing effect of corn oil. 
 
The role of D1 dopamine receptors in the rewarding properties of corn oil have also been 
evaluated with the conditioned place preference test. Imaizumi et al. (2000) reported that 
acquisition of a place preference by corn oil intake was blocked by systemic treatment 
with either SCH-23390 (0.03 mg/kg) or haloperidol (0.1 mg/kg). The authors concluded 
that the positive reinforcing effects of corn oil were at least partially mediated by D1 
receptors (Imaizumi et al. 2000). In contrast, in the µone bottle test¶ neither D1 nor D2 
receptor antagonist drugs affected oil consumption, which led to Yoneda et al (2007a) to 
conclude that the dopamine system is involved in the reinforcing effect of corn oil but not 
on its consumption.  
 
Although there is a general agreement about the involvement of the dopaminergic system 
in regulating the rewarding properties of reinforcers, it is not clear from the evidence 
outlined above which subtype(s) of dopamine receptors are involved in controlling the 
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reinforcing efficacy of sucrose or fat.  
 
The first objective of this experiment was to test whether rats reinforced with corn oil 
would respond on the progressive-ratio schedule in a similar manner as they do with 
other reinforcers. In particular, it was of interest to establish whether meaningful data 
would be generated that could be used to fit Equations 1 and 2 for the derivation of 
estimates of the parameters of MPR. To address this objective, two groups of rats were 
trained on the progressive-ratio schedule WRUHVSRQGIRUHLWKHUȝORI(0.2 kcal) 
FRUQRLORUȝO of a 0.6M (approximately 20%) sucrose solution (0.04 kcal).  
 
The other objective of this experiment was to examine the effects of a D2 receptor 
antagonist, haloperidol, and a D1 receptor antagonist SKF-83566 on performance on the 
progressive-ratio schedule maintained by the two types of reinforcer, to see whether the 
effect of these drugV RQ .LOOHHQ¶V MPR model (1994) and Rickard et al¶V (2009) 
equation would differ between the two types of reinforcer. Based on the research outlined 
above (Yoneda et al. 2007b), it was predicted that in the group that received corn oil as 
the reinforcer, both motivational measures (a and b) would be reduced by the D2 receptor 
antagonist, but not by the D1 receptor antagonist. In contrast, it was expected that the 
sucrose-reinforced group would show a reduction of a and b when treated with either the 





The experiments were carried out in accordance with the UK Home Office regulations 




Twenty-four experimentally naive female Wistar rats approximately 4 months old and 
weighing 250±300 g at the start of the experiment were used. They were housed under 
the same conditions as in Experiment 1 (see section 2.2.1). 
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6.2.2. Apparatus 
 
The rats were trained in standard operant conditioning chambers (CeNeS Ltd, 
Cambridge, UK) of internal dimensions 25cm×25cm×22 cm. One wall of the chamber 
contained a central recess covered by a hinged clear Perspex (plexiglas) flap, into which 
a peristal peristaltic pump could deliver 50 µl of a 0.6 M (20%) sucrose solution or 25 µl 
of 100% corn oil. An aperture situated 5 cm above and 2.5 cm to one side of the recess 
(left for half the rats and right for the other half) allowed the insertion of a motorized 
retractable lever (CeNeS Ltd, Cambridge, UK) into the chamber. The lever could be 
depressed by a force of approximately 0.2 N. The operant chamber was enclosed in a 
sound-attenuating chest with additional masking noise generated by a rotary fan. No 
houselight was present during the sessions. An Acorn microcomputer programmed in 
Arachnid BASIC (CeNeS Ltd, Cambridge, UK), located in an adjoining room, controlled 
the schedules and recorded the behavioural data. 
 
6.2.3. Progressive-ratio schedule 
 
The behavioural training procedure was carried out in the same way as in Experiment 1 
(see section 2.2.4.1), with the exception that the session duration was 40 minutes rather 
than 50 minutes. Twelve rats were trained using the sucrose reinforcer, and twelve using 
the corn oil reinforcer. 
 
6.2.4. Drug treatment 
 
The drug treatment regimen started after 120 sessions of preliminary training under the 
progressive-ratio schedule. Injections of drugs were given on Tuesdays and Fridays, and 
injections of the vehicle alone on Mondays and Thursdays; no injections were given on 
Wednesdays, Saturdays or Sundays. The same rats were used to test the two drugs and 
each drug was tested five times with each dose of the drug, the order of drugs and doses 
being counterbalanced across animals according to a Latin square design. Drugs were 
injected intraperitoneally (2.5 ml kg-1; 25-gauge needle) 30 min before the start of the 
experimental session. Doses were calculated from the weights of the salts. Haloperidol 
(0.05 and 0.1 mg kg-1) was dissolved in 0.1 M tartaric acid, buffered to pH 5.5 and diluted 
with sterile 0.9% sodium chloride to give the desired concentration. SKF-83566 (8-
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bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide) 
(0.015 and 0.03 mg kg-1) was dissolved in 0.9% sodium chloride solution. Haloperidol 
was obtained from Sigma Chemical Company, Poole, UK; SKF-83566 was obtained 
from Tocris Bioscience, Bristol, UK. The doses of haloperidol were chosen on the basis 
of previous findings of the effects of this drug on progressive-ratio schedule performance 
(Mobini et al. 2000; Zhang et al. 2005a; see also Chapter 5). SKF-83566 has not been 
tested previously in this paradigm; the doses were chosen on the basis of recent findings 
of the effects of this drug on operant behaviour in free-operant timing schedules (Cheung 
et al. 2006; Cheung et al. 2007).  
 
6.2.5. Data analysis 
 
The data from the two groups (sucrose reinforcer, corn oil reinforcer) were analysed as 
separate experiments. In each case, the same behavioural measures were used as in the 
previous experiment (see section 5.2.5). In the case of each measure, the values obtained 
in the presence of the two active doses of each drug were compared with the values 
obtained in the sessions in which the corresponding vehicle treatment was administered 
(see section 5.2.5). 
 
6.3. Results  
 




6.3.1.1.1. Peak response rate 
 
The group mean (± SEM) data are shown in Table 6.1. Haloperidol had no significant 
effect [F(2,22) = 2.1,  NS]. 
 
6.3.1.1.2. Highest completed ratio and breakpoint 
 
The group mean (± SEM) data are shown in Table 6.1. In the case of the highest 
completed ratio, there was a significant effect of treatment [F(2,22) = 8.7, p<0.05], the 
 - 149 - 
highest completed ratio being significantly reduced by both doses of haloperidol. In the 
case of the BP, there was also a significant treatment effect [F(2,22) = 9.0, p<0.001], the 
effect being significant only in the case of the higher dose. 
 
Table 6.1. Progressive-ratio schedule performance: sucrose reinforcer. Effect of 
haloperidol on the highest completed ratio, breakpoint and peak response rate (responses 
min-1) (group mean values ± SEM) 
 
* significant difference from vehicle-alone treatment: p<0.05  
 
6.3.1.1.3. Overall response rate 
 
Figure 6.1 (left-hand panel) shows the group mean overall response rate for each 
treatment condition. The response rate tended to be reduced by the higher dose of 
haloperidol. Haloperidol produced a dose-dependent reduction of response rate. Analysis 
of variance revealed significant main effects of treatment [F(2,22) = 8.9, p<0.001] and 
ratio [F(14,154) = 43.1, p<0.001] and a significant treatment × ratio interaction 
[F(28,308) = 1.9, p<0.05]. The fits of Equation 1 to the group mean data accounted for 
>90% of the total variance (vehicle, r2 = 0.92; haloperidol 0.05mg kg-1, r2 = 0.93; 
haloperidol 0.1mg kg-1, r2 = 0.90). Table 6.2 shows the parameters of Equation 1. Both 
doses of haloperidol significantly reduced the activation parameter a [F(2,22) = 3.5, 
p<0.05]. There was a significant effect of treatment on the response time parameter į
[F(2,22) = 3.8, p<0.05] KRZHYHU 'XQQHWW¶V WHVW VKRZHG WKDW QHLWKHU GRVH GLIIHUHG
significantly from the vehicle-alone condition. The currency parameter ȕ [F<1] was not 
significantly affected. 
 
6.3.1.1.4. Running response rate 
 






0.05 mg kg-1 
haloperidol 
0.1 mg kg-1 
Highest completed 
ratio 130.2 ± 23.1 109.8 ± 17.3 *  93.6 ± 18.8 * 
Breakpoint 122.8 ± 21.9 106.1 ± 16.8 88.6 ± 17.3 * 
Peak response rate 161.2 ± 15.0 157.3 ± 14.4 149.0 ± 10.7 
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Running response rate tended to be reduced by the higher dose of haloperidol. Analysis 
of variance yielded a significant main effect of ratio [F(14,154) = 90.5, p<0.001], and 
there was a borderline main effect of treatment [F(2,22) = 3.0, p=0.06]; the  treatment × 
ratio interaction effect was not significant [F(28,308) = 1.42, NS]. The fits of Equation 2 
to the group mean data accounted for >90% of the total variance (vehicle: r2 = 0.92; 
haloperidol 0.05mg kg-1:  r2 = 0.95; 0.1mg kg-1 haloperidol 0.1 mg kg-1: r2 = 0.93). The 
parameters of Equation 2 are shown in Table 6.2. Neither dose of haloperidol 
significantly reduced Ri [F(2,22) = 3.3, NS@ KRZHYHU WKH µGHFD\¶ SDUDPHWHU, b, was 
significantly reduced [F(2,22) = 4.3, p<0.05], the effect of the higher dose being 
statistically significant 7KH µH[SRQHQW¶ SDUDPHWHU c was not affected by the treatment 
[F(2,22) = 1.7, NS]. 
 
 
OVERALL RESPONSE RATE RUNNING RESPONSE RATE









HALOPERIDOL 0.05 mg kg-1
HALOPERIDOL O.1 mg kg-1
    20%SUCROSE REINFORCER (0.6 M, 50 Pl)





















HALOPERIDOL 0.05 mg kg-1
HALOPERIDOL 0.1 mg kg-1
                  RATIO, N                                                   RATIO,  N 
 
Figure 6.1. Effects of haloperidol on progressive-ratio schedule performance reinforced 
with sucrose. Left-hand graph: relation between overall response rate and the 
response/reinforcer ratio, N (see inset for treatment conditions). Curves are fits of 
Equation 1 to the data. Right-hand graph: relation between running response rate and N. 
The curves are fits of Equation 2 to the data; other conventions are as in the left-hand 
graph. 
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Table 6.2. Progressive-ratio schedule performance: sucrose reinforcer. Effect of 
haloperidol on the parameters of Equations 1 and 2 (group mean values ± SEM) 
 
 
* significant difference from vehicle control (P <0.05) 
 
 
6.3.1.2.  SKF-83566 
 
6.3.1.2.1. Peak response rate 
 
As can be seen from Table 6.3, the peak reponse rate was not affected by any either dose 
of SKF-83566 [F(2,22) = 1.8, NS]. 
 
6.3.1.2.2. Highest completed ratio and breakpoint 
 
Table 6.3 shows the group mean (± SEM) data. There was a significant reduction of the 
highest completed ratio [F(2,22) = 8.0, p<0.01] and the breakpoint [F(2,22) = 4.3, 






0.05 mg kg-1 
haloperidol 
0.1 mg kg-1 
Equation 1 (overall response rate)     
a (s) 59.2 ± 9.1 44.9 ± 6.3 * 45.8 ± 8.9 * 
į (s) 0.55 ± 0.06 0.52 ± 0.02 0.59 ± 0.06 
ȕ 0.55 ± 0.06 0.63 ± 0.05 0.58 ± 0.06 
r2 0.83 ± 0.03 0.81 ± 0.02 0.78 ± 0.03 
Equation 2 (running response rate)     
Ri (responses min-1) 315.5 ± 24.4 274.5 ± 20.0 345.4 ± 18.0 
b 25.2 ± 8.2 24.4 ± 6.2 11.5 ± 4.1 * 
c 1.4 ± 0.1 1.4 ± 0.1 1.1 ± 0.1 
r
2 0.92 ± 0.01 0.95 ± 0.01 0.93 ± 0.01 
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Table 6.3. Progressive-ratio schedule performance: sucrose reinforcer. Effect of SKF-
83566 on the highest completed ratio, breakpoint and peak response rate (responses 











* significant difference from vehicle control (P <0.05) 
 
 
6.3.1.2.3. Overall response rate 
 
The group mean data (left-hand panel) for the two treatment conditions are shown in 
Figure 6.2. The higher dose of SKF-83566 produced an apparent reduction of response 
rate. However, analysis of the variance revealed a significant main effect of ratio 
[F(15,165) = 40.3, p<0.001] but not of treatment [F(2,22) = 1.3, NS], and there was no 
significant treatment × ratio interaction [F<1]. The fits of Equation 1 to the overall mean 
data accounted for >90% of the total variance (vehicle, r2 = 0.91; SKF-83566, 0.015mg 
kg-1, r2 = 0.91; SKF-83566 0.03 mg kg-1, r2
 
= 0.93). Table 6.4 shows the parameters of 
Equation 1. Analysis of the variance revealed a borderline significant effect of treatment 
on the activation parameter, a [F(2,22) = 3.4, p=0.05]; multiple comparisons indicated 
that the higher dose of SKF-835666 differed significantly from the vehicle condition. The 
response time parameter, į, was significantly affected [F(2,22) = 6.8, p<0.01], a 
significant reduction being produced by the higher dose. The currency parameter was not 









0.15 mg kg-1 
SKF-83566 
0.03 mg kg-1 
Highest completed 
ratio 140.5 ± 23.6 129.9 ± 23.7 120.0 ± 19.6 * 
Breakpoint  137.3 ± 22.9 132.4 ± 22.0 116.0 ± 18.5 * 
Peak response rate 164.6 ± 17.6 164.6 ± 17.6 165.9 ± 15.5 
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   20% SUCROSE REINFORCER (0.6 M, 50 Pl)
RATIO, N





















SKF-83566 0.015 mg kg-1
SKF-38566 0.03 mg kg-1
RATIO, N









SKF-38566 0.015 mg kg-1
SKF-38566 0.03 mg kg-1
 
Figure 6.2. Effects of SKF-83566 on progressive-ratio schedule performance reinforced 
with sucrose. Left-hand graph: relation between overall response rate and the 
response/reinforcer ratio, N (see inset for treatment conditions). Curves are fits of 
Equation 1 to the data. Right-hand graph: relation between running response rate and N. 
The curves are fits of Equation 2 to the data; other conventions as in the left-hand graph. 
 
 
Table 6.4. Progressive-ratio schedule performance: sucrose reinforcer. Effects of SKF-






0.15 mg kg-1 
SKF-83566 
0.03 mg kg-1 
Equation 1 (overall response rate)      
a (s) 68.5 ± 10.1 60.8 ± 10.6 49.0 ± 7.4 * 
į (s) 0.57 ± 0.06 0.55 ± 0.06 0.54 ± 0.06 * 
ȕ 0.63 ± 0.05 0.61 ± 0.06 0.58 ± 0.06 
r
2 0.83 ± 0.03 0.79 ± 0.03 0.83 ± 0.04 
Equation 2 (running response rate)      
Ri (responses min-1) 312.6 ± 21.1 291.6 ± 21.5 311.8 ± 21.8 
b 25.1 ± 7.6 25.8 ± 6.3 19.8 ± 5.2 
c 1.1 ± 0.1 1.4 ± 0.2 1.3 ± 0.2 
r2 0.93 ± 0.02 0.91 ± 0.02 0.91 ± 0.02 
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6.3.1.2.4. Running response rate. 
 
Fig 6.2 (right-hand panel) shows the group mean data. Running rate was higher in the 
lowest ratios and declined monotonically as a function of ratio size. There was no 
significant effect of treatment [F(2,22) = 3.0, NS]; however the main effect of ratio 
[F(14,154) = 76.5, p<0.001] and the ratio × treatment interaction [F(28,308) = 2.0, 
p<0.01] were significant. The fits of Equation 2 to the group mean data accounted for 
over 90% of the total variance (vehicle, r2 = 0.93; SKF-83566 0.015mg kg-1, r2 = 0.91; 
SKF-83566 0.03mg kg-1, r2 = 0.91). Table 6.4 shows the parameter values of Equation 2. 
None of the parameters of Equation 2 was significantly affected by SKF-83566 [Ri: F<1; 
b: F<1; c: F(2,22) = 1.5, NS].  
 




6.3.2.1.1.  Peak response rate 
 
As can be seen from Table 6.5, the peak response rate was not significantly affected 
[F(2,22) = 2.1, NS]. 
 
6.3.2.1.2.  Highest completed ratio and breakpoint 
 
Both the highest completed ratio [F(2,22) = 8.7, p<0.01] and the breakpoint [F(2,22) = 
9.0, p<0.01] were significantly affected by haloperidol, both measures being reduced by 
the higher dose of haloperidol (Table 6.5). 
 
6.3.2.1.3. Overall response rate 
 
Figure 6.3 (left-hand panel) shows the group mean data. The response rate was reduced 
by the higher treatment dose. Analysis of the variance revealed a significant main effect 
of treatment [F(2,22) = 6.9, p<0.01], ratio  [F(15,265) = 9.2, p<0.001] and  the treatment 
× ratio interaction [F(30,330) = 2.9, p<0.01]. The fits of Equation 1 to the group mean 
data accounted for 88% of the total variance (vehicle, r2 = 0.90; haloperidol 0.05mg kg-1, 
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r
2
 = 0.90; haloperidol 0.1mg kg-1, r2 = 0.88). Table 6.6 shows the parameters of Equation 
1. Analysis of the variance revealed a borderline significant effect on the activation 
parameter, a [F(2,22) = 3.2, p=0.06]; multiple comparisons indicated that a was 
significantly reduced by the higher dose of haloperidol. However the other two 
parameters, ȕ and  į, were not significantly affected [F< 1 in both cases].  
 
Table 6.5. Progressive-ratio schedule performance: corn oil reinforcer. Effects of 
haloperidol on the highest completed ratio, breakpoint and peak response rate (responses 
min-1) (group mean values ± SEM). 
 
 
* significant difference from vehicle condition: p<0.05 
 
   100% CORN OIL REINFORCER (25 Pl)


















HALOPERIDOL 0.05 mg kg-1
HALOPERIDOL 0.1 mg kg-1
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HALOPERIDOL 0.05 mg kg-1
HALOPERIDOL 0.1 mg kg-1
 
Figure 6.3. Effects of haloperidol on progressive-ratio schedule performance reinforced 
with corn oil. Left-hand graph: relation between overall response rate and 
response/reinforcer ratio, N (see inset for treatment conditions). Curves are fits of 
Equation 1 to the data. Right-hand graph: relation between running response rate and N. 
The curves are fits of Equation 2 to the data; other conventions as in the left-hand graph. 
HALOPERIDOL vehicle haloperidol 0.05 mg kg-1 
haloperidol0.1 mg 
kg-1 
Highest completed ratio 170.6 ± 44.6 160.5 ± 39.8  90.0 ± 24.8 * 
Breakpoint 170.6 ± 44.6 160.4 ± 39.8 88.7 ± 24.7 * 
Peak response rate 111.9 ± 11.0 113.9 ± 11.2 102.6 ± 10.3 
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Table 6.6. Progressive-ratio schedule performance: corn oil reinforcer. Effects of 


















* significant difference from vehicle control (p<0.05) 
 
6.3.2.1.4.   Running response rate 
 
The running response rates are shown in Figure 6.3 (right-hand panel). Running rate was 
reduced in the higher ratios by the higher dose of haloperidol. Analysis of the variance 
revealed a significant main effect of treatment [F(2,22) = 5.9, p<0.01], ratio [F(14,154) = 
31.2, p<0.001] and a significant treatment × ratio interaction [F(28,308) = 1.6, p<0.05]. 
The fit of Equation 2 to the group mean data accounted for over 95% of the total variance 
(vehicle, r2  = 0.96; haloperidol 0.05mg kg-1, r2 = 0.98; haloperidol 0.1 mg kg-1, r2 = 
0.96). Table 6.6 shows the values of the parameters of Equation 2. Analysis of the 
variance showed that none of the parameters was significantly affected [Ri: F(2,22) = 








0.05 mg kg-1 
haloperidol 
0.1 mg kg-1 
Equation 1 (overall response rate)     
a (s) 285.0 ± 84.0 300.3 ± 81.4  215.7 ± 86.5 *  
į (s) 0.95 ± 0.12 1.04 ± 0.15 1.09 ± 0.14 
ȕ 0.37 ± 0.08 0.52 ± 0.11 0.45 ± 0.09 
r
2 0.79 ± 0.05 0.66 ± 0.03 0.66 ± 0.06 
Equation 2 (running response rate)     
Ri (responses min-1) 256.7 ± 31.2 332.9 ± 38.1 304.0 ± 31.8 
b 19.2 ± 4.8 12.3 ± 3.4 9.6 ± 2.7 
c 1.5 ± 0.6 1.2 ± 0.3 1.1 ± 0.2 
r2 0.84 ± 0.03 0.82 ± 0.03 0.87 ± 0.02 
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6.3.2.2. SKF-83566  
 
6.3.2.2.1. Peak response rate 
 
Table 6.7 shows the group mean data (± SEM) for the peak response rate. Analysis of 
variance revealed no significant effect of treatment [F<1]. 
 
6.3.2.2.2. Highest completed ratio and breakpoint 
 
As can be seen from Table 6.7, neither the highest completed ratio [F<1] nor the 
breakpoint [F(2,22) = 1.4 NS] was significantly affected by SKF-83566. 
 
 
Table 6.7. Progressive-ratio schedule performance: corn oil reinforcer. Effects of SKF-
83566 on the highest completed ratio, breakpoint and peak response rate (responses 




6.3.2.2.3. Overall response rate 
 
Figure 6.4 (left-hand panel) shows the group mean data. The response rate was slightly 
reduced in the highest ratios with the higher dose of SKF-83566. Analysis of the variance 
revealed a significant main effect of ratio [F(14,165) = 7.5, p<0.001], however the main 
effect of treatment [F(2,22) = 1.0, NS] and the interaction  [F(30,330) = 1.0, NS] were 
not statistically significant. The fits of Equation 1 to the group mean data accounted for 
>87% of the total variance (vehicle, r2 = 0.87; SKF-83566 0.015 mg kg-1, r2 = 0.94; SKF-






0.15 mg kg-1 
SKF-83566 
0.03 mg kg-1 
Highest completed 
ratio 
170.6 ± 44.6 172.9 ± 45.8 157.6 ± 37.3 
Breakpoint  174.5 ± 44.1 172.9 ± 45.8 156.7 ± 37.5 
Peak response rate 113.6 ± 12.2 113.7 ± 13.4 109.4 ± 10.2 
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statistical analysis showed that none of the three parameters changed as a consequence of 
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   100% CORN OIL REINFORCER (25 Pl)
OVERALL RESPONSE RATE RUNNING RESPONSE RATE
 
 
Figure 6.4. Effects of SKF-83566 on progressive-ratio schedule performance reinforced 
with corn oil. Left-hand graph: relation between overall response rate and the 
response/reinforcer ratio, N (see inset for treatment conditions). Curves are fits of 
Equation 1 to the data. Right-hand graph: relation between running response rate and N. 




6.3.2.2.4. Running response rate 
 
SKF-83566 had no significant effect on running response rate (Fig. 6.4, right-hand 
panel). There was a significant main effect of ratio [F(14,154) = 41.8,  p<0.001], but no 
significant main effect of treatment [F(2,22) = 1.8, NS] and no significant interaction 
[F<1]. Equation 2 accounted for >95% of the total variance of the group mean data 
(vehicle, r2 = 0.97; SKF-83566 0.015mg kg-1,  r2 = 0.99; SKF-83566 0.03mg kg-1, r2 = 
0.98). As can be seen from Table 6.8, none of the parameters of Equation 2 were 
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significantly affected by SKF-83566 [Ri, b, c: all Fs<1].  
 
 
Table 6.8. Progressive-ratio schedule performance: corn oil reinforcer. Effects of SKF-







In this experiment one of the groups was reinforced with corn oil and the other with 
sucrose. The first objective of this experiment was to test whether the data derived from 
rats reinforced with corn oil could be adequately accommodated by .LOOHHQ¶V (1994) 
MPR model. The performance on the progressive-ratio schedule with both reinforcers 
was similar to that seen in previous studies using MPR (Bezzina et al. 2008b; Bezzina et 
al. 2008c; Bizo and Killeen 1997; den Boon et al. 2011; Ho et al. 2003; Kheramin et al. 






0.15 mg kg-1 
SKF-83566 
0.03 mg kg-1 
 
Equation 1 (overall response rate)      
a (s) 311.6 ± 103.6 297.6 ± 95.0 275.4 ± 78.1 
į (s) 0.95 ± 0.12 1.04 ± 0.16 1.01 ± 0.13 
ȕ 0.34 ± 0.09 0.41 ± 0.09 0.42 ± 0.10 
r2 0.77 ± 0.04 0.69 ± 0.04 0.73 ± 0.05 
 
Equation 2 (running response rate)      
Ri (responses min-1) 319.0 ± 29.8 326.5 ± 28.2 311.5 ± 28.2 
b 15.0 ± 5.1 17.7 ± 6.6 14.6 ± 5.4 
c 1.1 ± 0.2 1.2 ± 0.2 1.0 ± 0.2 
r2 0.86 ± 0.03 0.86 ± 0.02 0.84 ± 0.03 
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and in the other experiments described in this thesis (see section 2.4. for discussion). The 
performance maintained by the corn oil reinforcer appeared comparable to that 
maintained by the sucrose reinforcer used in this experiment. However quantitative 
comparison between the parameter values obtained using the two reinforcers would not 
be meaningful, because the sucrose and corn oil reinforcers used in these experiments 
were not matched according to any criteria such as volume, density or calorific content 
(see Chapter 7 for further discussion). 
 
The effects of haloperidol on progressive-ratio schedule performance in the sucrose-
reinforcement group are similar to previous studies using sucrose or food-pellet 
reinforcers (den Boon et al. 2011; Mobini et al. 2000; Zhang et al. 2005a) (see Chapter 
5). In those studies, the application of Equation 1 to the overall response rate data 
revealed that a was either reduced or not affected and į was increased. In the present 
study a was reduced and there was a trend for įto be increased, although the latter effect 
fell short of statistical significance in the present experiment. Furthermore, in agreement 
with previous research on the effects of D2 dopamine receptor antagonists, the highest 
completed ratio and the breakpoint were significantly reduced by haloperidol (den Boon 
et al. 2011; Mobini et al. 2000; Yoneda et al. 2007b; Zhang et al. 2005a). It is unclear 
why the effect of haloperidol on į was less pronounced in this experiment than in 
previous studies, since the same same volume (50 µl) and concentration (0.6 M) of the 
sucrose solution and the same doses of haloperidol (0.05 and 0.1 mg kg-1) were used as in 
previous studies (Mobini et al. 2000; Zhang et al. 2005a). The only obvious difference 
from previous studies is that the session time in the present experiment was shorter (40 
min) than in Mobini et al. (2000) and Zhang et al. (2005a) (75 min and 50 min 
respectively). It is not clear how this could have influenced the effect of haloperidol on į. 
Further research is needed in order to address how the session duration may affect the 
parameters of Equation 1. The currency parameter ȕ was not affected by haloperidol; this 
parameter has not been affected consistently by haloperidol in previous experiments (see 
section 5.4 for discussion).  
 
The running response rate data were analysed with Equation 2 (Rickard et al. 2009). 
Haloperidol reduced WKH µGHFD\ SDUDPHWHU¶, b, which is purported to be related to the 
incentive value of reinforcers (Rickard et al. 2009). These data are in agreement with 
results of the previous experiment (see section 5.4), where haloperidol reduced this 
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parameter significantly. However, the ILQGLQJ WKDW WKH µLQLWLDO UHVSRQVH UDWH¶ parameter, 
Ri, was not affected is in disagreement with the previous experiment, where this 
parameter was significantly reduced. As mentioned previously in the context of į, which 
is conceptually related to Ri (Rickard et al. 2009), the shorter session time may have an 
impact on this parameter.  
 
In agreement with the predictions outlined in the Introduction to this chapter (section 
6.1), the D1 receptor antagonist SKF-83566 reduced the activation parameter, a, in the 
sucrose reinforced group. Unexpectedly, the motor parameter į was significantly reduced 
in a dose-dependent manner, indicating that the drug produced a facilitatory effect on 
responding on the progressive-ratio schedule. As expected, ȕ did not change as a 
consequence of the treatment. None of the parameters of Equation 2 was significantly 
affected by SKF-83566. However there was D WUHQG IRU WKH µGHFD\ SDUDPHWHU¶ b to be 
reduced by the drug, which is consistent with the significant decrease of the motivational 
parameter of Equation 1 (a). The breakpoint and highest completed ratio were reduced, 
which is also consistent with a reduction of the incentive value of sucrose reinforcers 
when the D1 dopamine receptors are antagonized.  
 
Another aim of this experiment was to examine the differential effect of the D1 and D2 
dopamine receptor antagonists on the performance of rats reinforced with corn oil. In 
agreement with expectations (see above, section 6.1),  WKHµLQFHQWLYHYDOXH¶ parameter of 
Equation 1, a, was significantly reduced by the higher dose of haloperidol, and in 
addition the traditional measures of progressive-ratio schedule performance, the 
breakpoint and the highest completed ratio, were also reduced. This is in agreement with 
a study of progressive-ratio schedule performance by mice that were reinforced with corn 
oil. In this study the administration of the D2 receptor antagonist sulpiride reduced the 
breakpoint (Yoneda et al. 2007b). Similarly to the sucrose-reinforced group (see above), 
WKHµUHVSRQVHWLPH¶ parameter, į, was increased, although the effect of haloperidol on this 
parameter did not reach statistical significance, DQGWKHµFXUUHQF\¶ parameter, ȕ, was not 
affected by haloperidol. The application of Equation 2 to the running response rate data 
did not yield any significant results, although WKHUHZDVDWUHQGIRUWKHµGHFD\SDUDPHWHU¶
b to be reduced, which is in accordance with the effect of the drug on a. Taken together, 
these results are consistent with the notion that blockade of D2 dopamine receptors 
reduces the incentive value of oily/fatty reinforcers. 
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SKF-83566 had no significant effect on the performance of the corn oil reinforced group, 
although there was a non-significant trend for a to be reduced and for į to be increased. 
This trend may be analogous to the finding of Weatherford et al. (1990) who found that a 
high dose of a D1 receptor antagonist produced both a sedative effect and a reduction of 
the rewarding properties of corn oil. 
 
More research is needed on the differential effects of D1 and D2 receptor antagonists on 
progressive-ratio schedule performance maintained by different reinforcers. Although the 
present results are suggestive of an involvement of both receptor subtypes in the 
reinforcing property of sucrose, and a preferential involvement of D2 receptors in the 
reinforcing property of corn oil, it must be emphasised that only two doses of each drug 
were tested, and only one magnitude of each reinforcer was used. In future experiments it 
will be important not only to examine a range of compounds using a broader range of 
doses, but also to systematically manipulate the concentrations of both reinforcers. 
Another interesting question to be addressed in future experiments is whether selective 
D1 and D2 receptor agonists are able to enhance the values of sucrose and corn oil 
reinforcers, and if so whether the effects of the agonists can be selectively reversed by 
the appropriate antagonists. 
 
To summarize, it can be said that corn oil is a potent reinforcer on progressive-ratio 
schedule performance. The qXDQWLWDWLYH DQDO\VLV EDVHG RQ .LOOHHQ¶V  WKHRUHWLFDO
model of schedule-controlled behaviour, MPR, indicated that both haloperidol and SKF-
83566 reduced the incentive value of a sucrose reinforcer. Interestingly, while 
haloperidol tended to increase į, SKF-83566 reduced this parameter. This suggests that 
both D1 and D2 dopamine receptors may be involved in determining the incentive value 
of sucrose reinforcement, and that the two receptor subtypes may exert opposing 
influences on the motor aspects of progressive-ratio schedule performance. However, 
haloperidol but not SKF-83566, in the doses used in this experiment, affected 
performance maintained by the corn oil reinforcer, suggesting that, while D2 dopamine 
receptors contribute to the regulation of the incentive value of this reinforcer, D1 
dopamine receptors may not play a significant role in this process. The results from this 
experiment yield more evidence about the utility of quantitative analysis of progressive-
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ratio schedule performance based on MPR for investigations of the effects of drugs on 
motivational processes (Killeen 2009; Rickard et al. 2009). 















EXPERIMENT 6: EF)(&762)ǻ9-TETRAHYDROCANNABINOL 
ON PROGRESSIVE-RATIO SCHEDULE PERFORMANCE 
REINFORCED WITH SUCROSE OR CORN OIL UNDER FOOD 
DEPRIVATION AND FREE FEEDING CONDITIONS 
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7.1. Introduction 
 
The psychoactive properties of the Marihuana plant (Cannabis sativa) have been known 
for more than 4000 years (Tucci et al. 2006). This plant has been used for centuries to 
induce appetite and more recently it has been used medicinally to treat the weight loss 
and cachexia caused by diseases such as AIDS (Di Marzo and Matias 2005). However, 
the principal compound, THC, responsible for the central properties of the Marihuana 
plant, was not discovered XQWLOWKH¶V 
 
The discovery of THC led to increasing interest in the effects of the cannabinoids and 
their possible interaction with endogenous mechanisms of food intake regulation (Gaoni 
and Mechoulam 1964). These findings were followed by the discovery of the 
cannabinoid receptors (CB1 and CB2 receptors) and endogenous cannabinoids, including 
anandamide, 2-arachidonoylglycerol (2AG), noladin ether, N-arachidonoyl dopamine 
(NADA) and virodhamine, and the development of selective CB1 receptor antagonists, 
including rimonabant (SR-141716) and surinabant (SR-147778) (Fride 2002; 2004). 
 
A number of experiments have investigated the effect of THC on feeding behaviour in 
animals and humans. Williams et al. (1998) conducted an experiment where oral THC 
was administered to pre-fed rats. The results showed that the rats ate significantly more 
when THC was given than when the vehicle (saline solution) was administered. Similar 
results were found when the endogenous CB1 receptor agonist anandamide was 
administered subcutaneously to rats (Williams and Kirkham 1999). 
 
Several experiments have shown that THC preferentially increases the consumption of 
palatable food, especially the sweet variety (Foltin et al. 1988; Haney et al. 1999; 
Hollister 1971). For example, Foltin et al. (1988) reported that humans consumed more 
sweet items (candy bars) after the administration of THC. Similar results have been 
obtained with anandamide and 2AG, administered centrally and peripherally to rats (Hao 
et al. 2000; Jamshidi and Taylor 2001; Kirkham and Williams 2001; Williams and 
Kirkham 1999). For instance in a study using a 10% sucrose solution, total number of 
licks was augmented by THC and reduced by the CB1 receptor antagonist rimonabant 
(Higgs et al. 2003). Although ingestion of sweet foods has been found to be especially 
sensitive to CB1 receptor agonists, ingestion of other palatable foods is also affected. For 
 - 166 - 
example, administration of THC has been found to increase the consumption of a high fat 
diet (Verty et al. 2011; Verty et al. 2004).    
 
Higgs et al. (2005) examined the motivational properties of two CB1 receptor agonists, 
THC and 1,1-dimethylheptyl-11-hydroxy-tetrahydrocannabinol (HU-210) using a 
progressive-ratio schedule. They found that THC but not HU-210 increased the 
breakpoint in the progressive-ratio schedule, and enhanced food intake in a free-feeding 
test. Higgs et al. used food pellets as reinforcers and a mixture of standard chow and 
condensed milk in the feeding test. Solinas and Goldberg (2005) also examined the effect 
of THC on progressive-ratio schedule performance. THC increased the breakpoint, an 
effect that was also produced by an increase in the severity of food deprivation. Both the 
THC-induced and the deprivation-induced increase in the breakpoint were reversed by 
the CB1 receptor antagonist rimonabant (Solinas and Goldberg 2005). More recently, 
Maccioni et al. (2008) reported that the breakpoint was reduced by the CB1 receptor 
antagonist rimonabant in rats reinforced with a low-calorie chocolate beverage.  It has 
also been shown that response rates of rats UHVSRQGLQJ IRU µQRUPDO IRRG¶ (standard rat 
chow) on a fixed-ratio schedule are enhanced by a CB1 receptor agonist, and this effect 
can be blocked by rimonabant (Freedland et al. 2000). These authors concluded that the 
use of highly palatable nutrients is not a necessary condition for revealing the anoretic 
effect of CB1receptor antagonists. 
 
In the experiment described in Chapter 5, THC was administered to rats that were 
responding for standard food pellets on a progressive-ratio schedule. None of the doses 
of THC administered (0.3, 1, 3 mg kg-1) produced a change in the breakpoint. 
Progressive-ratio schedule performance was also examined using .LOOHHQ¶V035PRGHO
(Killeen 1994) to analyse overall response rates and Rickard et al¶Vequation to 
analyse running response rates. The results showed that none of the parameters that are 
purportedly related to the incentive value of food reinforcers was altered by THC. 
Various factors may have contributed to the lack of effect of THC in that experiment. It 
was noted that the food pellets used as the reinforcer in that experiment, although more 
palatable than normal rat chow, have no carbohydrate content. As reviewed above, many 
EXW QRW DOO SUHYLRXV VWXGLHV KDYH LQGLFDWHG WKDW 7+&¶V RUH[LJHQLF HIIHFW LV PRVW
pronounced in the case of sweet foodstuffs.  
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Another possible factor could be the food deprivation level. In the experiment described 
in Chapter 5, the rats were maintained at 80% of their free-feeding body weights, 
whereas the majority of previous demonstrations of orexigenic effects of THC have 
employed mild food deprivation or free-feeding conditions. It has been reported that food 
deprivation increases the level of endocannabinoids and other orexigenic compounds 
such as neuropeptide-Y (NPY), melanin, orexins and ghrelin (Hanus et al. 2003; Lopez et 
al. 2000; Meister 2000; Sakurai et al. 1998). This raises the possibility that mechanisms 
induced by food deprivation might have over-ridden and masked the effect of THC on 
the motivational indices derived from progressive-ratio schedule performance in the 
previous experiment.   
 
As discussed above, THC has been found to augment the intake of palatable food. 
However the term µpalatable¶ is ambiguous, and it is unclear whether the effect of THC 
on food intake is related to the fat, carbohydrate or other component of certain foodstuffs. 
In the experiments described in this chapter, 100% corn oil and 0.6 M sucrose solution 
(approx 20%) were used as reinforcers in a progressive-ratio schedule and the effect of 
THC on performance was HYDOXDWHGZLWK.LOOHHQ¶V MPR model. The effects of 
THC on performance on the progressive-ratio schedule was also examined under food-
deprivation and free-IHHGLQJFRQGLWLRQV)LQDOO\WKHHIIHFWRI7+&RQµIUHHFRQVXPSWLRQ¶




The experiment was carried out in accordance with UK Home Office regulations 




The animals from the previous experiment were used. Twelve rats underwent training 
under the progressive-ratio schedule using sucrose reinforcement (0.6 M  ȝO; the 
UHPDLQLQJWZHOYHZHUHWUDLQHGXVLQJSXUHFRUQRLOȝODV WKHUHLQIRUFHU (see section 
6.2.1). Under the food deprivation condition, the rats were maintained at 80% of their 
free-feeding body weights, as in previous experiments (see section 2.2.1); under the free-
feeding condition, they had free access to standard laboratory rat chow in their home 
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The same operant conditioning chambers, control apparatus and software were used as in 
Experiment 5 (see section 6.2.2). 
 
7.2.3.  Behavioural procedures 
  
As the rats had previously undergone extensive training under the progressive-ratio 
schedule, no pre-training was necessary. Daily training under the progressive-ratio 
schedule was continued without interruption until the end of the operant behaviour 
experiment (see section 2.2.4.1).  
 
Three experiments were carried out with each group:  
 
(i)  The effect of THC (0.3, 1 and 3 mg kg-1) on progressive-ratio schedule 
performance was examined under conditions of food deprivation (the rats were 
maintained at 80% of their free-feeding body weights); 
(ii) The effect of THC (1 mg kg-1) on progressive-ratio schedule performance was 
examined in the absence of food restriction (the rats were allowed free access to 
food in their home cages); 
(iii) The effect of THC (1 mg kg-1) on consumption of the reinforcing substance 
(sucrose solution or corn oil) was measured during a 60-min period during which 
the substance was freely available (see section 2.2.4.3 for details of the testing 
procedure). 
 
7.2.4. Drug treatment 
 
As the subjects had been used in the previous experiment with dopamine receptor 
antagonists (see Chapter 6), THC treatment started after a 10-day wash-out period. The 
drug injection protocol was the same as in previous experiment (see section 6.2.4). The 
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doses of THC and the drug preparation procedure were the same as in Experiment 4 (see 
section 5.2.4). 
 
7.2.5.       Data analysis 
 
The data from the two groups (sucrose reinforcer, oil reinforcer) were analysed 
separately, in the same way as in the previous experiment. The behavioural measures and 




7.3.1. Sucrose reinforcement 
 
7.3.1.1. Effect of THC on progressive-ratio schedule performance maintained under 
the food deprivation condition 
 
7.3.1.1.1. Peak response rate 
 
There was no significant effect of THC on peak response rate [F<1] (see Table 7.1). 
 
7.3.1.1.2. Highest completed ratio and breakpoint 
 
THC had no significant effect on the highest completed ratio [F<1] or breakpoint  
[F(3,33) = 1.1, NS] (see Table 7.1) 
 
Table 7.1. Progressive-ratio schedule performance: sucrose reinforcer, food deprivation 
condition. Effects of THC on the highest completed ratio, breakpoint and peak response 






0.3 mg kg-1 
THC 
1 mg kg-1 
THC 
3 mg kg-1 
Highest completed 
ratio 
170.8 ± 43.6 178.7 ± 44.0 176.3 ± 43.1 175.3 ± 43.2 
Breakpoint  160.3 ± 43.6 172.7 ± 44.8 166.0 ± 43.9 175.3 ± 43.9 
Peak response rate 144.8 ± 15.6 150.6 ± 21.6 160.9 ± 17.9 157.5 ± 19.6 
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7.3.1.1.3. Overall response rate 
 
THC produced no significant effect on the overall response rate (Fig 7.1 left hand panel). 
Analysis of variance revealed a significant main effect of ratio [F(14,154) = 25.8, 
p<0.001], but no significant main effect of  treatment [F(3,33) = 2.3, NS]  and no 
significant interaction [F<1].  Equation 1 accounted for over 90% of the variance of the 
group mean data (vehicle: r2 = 0.95; THC 0.3 mg kg-1: r2 = 0.95; THC 1 mg kg-1: r2 = 
0.93: THC 3 mg kg-1: r2 = 0.94). Table 7.2 shows the parameters of Equation 1; none of 
the parameters was significantly affected by any of the doses of THC [a: F<1; ȕ: F<1; į: 
F(3,33) = 1.1, NS]. 
 
20%SUCROSE REINFORCER (0.6 M, 50 Pl)




















OVERALL RESPONSE RATE RUNNING RESPONSE RATE















THC 3 mg 
 
Figure 7.1. Effects of ǻ9tetrahydrocannabinol (THC) on progressive-ratio schedule 
performance under the food deprivation condition. Left-hand graph: relation between 
overall response rate and the response/reinforcer ratio, N. Unfilled circles: vehicle-alone 
treatment; filled circles: THC 0.3 mg kg-1; upright filled triangles: THC 1mg kg-1; 
inverted filled triangles: THC  3mg kg-1  (see inset). Curves are fits of Equation 1 to the 
data. Right-hand graph: relation between running response rate and N. The curves are fits 
of Equation 2 to the data; other conventions are as in the left-hand graph. 
 
VEHICLE 
THC 0.3 mg kg-1 
THC 1 mg kg-1 
THC 3 mg kg-1 
VEHICLE 
THC 0.3 mg kg-1 
THC 1 mg kg-1 
THC 3 mg kg-1 
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Table 7.2 Progressive-ratio schedule performance: sucrose reinforcer, food deprivation 





7.3.1.1.4. Running response rate 
 
THC did not produce any significant effect on the running response rate (Fig 7.1 right 
hand panel). Analysis of the variance revealed a significant main effect of ratio 
[F(13,143) = 43.3, p<0.001],  but no significant main effect of treatment [F(3,33) = 1.1, 
NS] or interaction  [F<1]. Equation 2 counted over 95% of the variance of the group 
mean data (vehicle: r2 = 0.97; THC 0.3 mg kg-1: r2 = 0.98; THC 1 mg kg-1: r2 = 0.96: 
THC 3 mg kg-1: r2 = 0.96). As can be seen for Table 7.2,  none of the three parameters 









0.3 mg kg-1 
THC 
1 mg kg-1 
THC 
3 mg kg-1 
 
 
Equation 1 (overall response rate)         
a (s) 85.2 ± 87.9 87.9 ± 23.6 83.4 ± 22.0 78.5 ± 22.6 
įV 0.50 ± 0.05 0.51 ± 0.06 0.48 ± 0.05 0.49 ± 0.06 
ȕ 0.64 ± 0.08 0.59 ± 0.07 0.52 ± 0.08 0.60 ± 0.08 
r2 0.82 ± 0.05 0.91 ± 0.11 0.78 ± 0.05 0.80 ± 0.04 
 
Equation 2 (running response rate)         
Ri (resp. min-1) 238.3 ± 18.1 233.7 ± 20.5 245.0 ± 16.8 233.1 ± 27.8 
b 39.1 ± 6.3 40.7 ± 6.6 43.3 ± 8.6 45.9 ± 9.1 
c 1.6 ± 0.3 1.6 ± 0.2 1.6 ± 0.2 1.8 ± 0.3 
r2 0.92 ± 0.01 0.90 ± 0.01 0.90 ± 0.1 0.91 ± 0.02 
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7.3.1.2. Effect of THC on progressive-ratio schedule performance maintained under 
the free feeding condition 
 
7.3.1.2.1. Peak response rate 
 
THC had no effect in this measure [F(1,11) = 1.9, NS] (see Table 7.3). 
 
7.3.1.2.2. Highest completed ratio and breakpoint 
 
Neither of these two measures was significantly affected by THC [highest completed 
ratio: F(1,11) = 2.3, NS; breakpoint: F<1] (see Table 7.3). 
 
Table 7.3. Progressive-ratio schedule performance: sucrose reinforcer, free feeding 
condition. Effects of THC on the highest completed ratio, breakpoint and peak response 










7.3.1.2.3. Overall response rate 
 
Overall response rate was substantially lower under the free feeding condition than under 
the food deprivation condition (see section 7.3.1.3). Group mean overall response rates 
under the vehicle and THC 1 mg kg-1 treatment conditions are shown in Fig. 7.2 (left 
hand panel). Analysis of variance showed a significant effect of ratio [F(7,77) = 43.1,  
P<0.001]; the main effect of treatment was of borderline significance [F(1,11) = 4.6, p = 
0.55], but the interaction was not significant [F(7,77) = 1.4, NS]. Equation 1 accounted 
for over 90% of the total variance of the group mean data (vehicle: r2 = 0.95; THC 1 mg 






1 mg kg-1 
Highest completed 
ratio 
35.2 ± 4.5 32.9 ± 5.3 
Breakpoint  32.2 ± 4.7 39.1 ± 5.6 
Peak response rate 132.2 ± 11.1 140.5 ± 12.8 
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in Table 7.3; analysis of variance showed that none of the parameters was significantly 




Figure 7.2. Effects of ǻ9-tetrahydrocannabinol (THC) on progressive-ratio schedule 
performance under the free-feeding condition. Unfilled circles: vehicle-alone treatment; 
upright filled triangles: THC 1 mg kg-1 (see inset). Other conventions are as in Fig.7.1  
 
 
7.3.1.2.4. Running response rate 
 
Fig 7.2 (right hand panel) shows the group mean data for the vehicle and THC 1 mg kg-1 
treatment conditions. THC had no effect on the running response rate. Analysis of 
variance indicated that the main effect of ratio was significant [F(7,77) = 34.5,  p<0.001], 
however the main effect of treatment and the interaction were not significant [both 
Fs<1].  Equation 1 accounted for 99% of the variance of the group mean data (vehicle: r2 
> 0.99; THC 1 mg kg-1: r2 > 0.99). Table 7.4 shows the parameters of Equation 2; none 
of the parameters was significantly affected by  THC [Ri: F<1; b: F<1; c: F(3,33) = 1.1, 
NS].  
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Table 7.4. Progressive-ratio schedule performance: sucrose reinforcer, free feeding 




















7.3.1.3. Comparison of progressive-ratio schedule performance maintained under the 
food deprivation and free feeding conditions 
 
As described above, each rat experienced training under the progressive-ratio schedule 
under both the the food deprivation and free feeding conditions, and the 1 mg kg-1 dose 
of THC was tested under both conditions. The effects of food deprivation and THC 1 mg 
kg-1 on each performance measure were analysed by analysis of variance (condition 
[food deprived, free feeding] × treatment [vehicle, THC 1 mg kg-1]). For ease of 
comparison, the relevant data, extracted from  Tables 7.1, 7.2, 7.3, and 7.4, are displayed 
in Table 7.5. Analysis of variance showed that, compared to the free-feeding condition, 
food deprivation produced an increase in the highest completed ratio [F(1,11) = 9.9, 
p<0.01], the breakpoint [F(1,11) = 10.6, p<0.01] and the peak response rate [F(1,11) = 





 THC  
1 mg kg-1 
 
Equation 1 (overall response rate)   
a (s) 12.1 ± 3.0 10.3 ± 1.5 
į (s) 0.47 ± 0.07 0.43 ± 0.04 
ȕ 0.49 ± 0.06 0.49 ± 0.06 
r
2 0.86 ± 0.03 0.84 ± 0.04 
 
Equation 2 (running response rate)   
Ri (resp. min-1) 243.5 ± 19.1 242.1 ± 13.2 
b 10.9 ± 1.6 10.1 ± 1.1 
c 2.7 ± 0.4 2.8 ± 0.5 
r2 0.95 ± 0.01 0.93 ± 0.02 
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µDFWLYDWLRQ¶SDUDPHWHUa) of Equation 1 [F(1,11) 10.1, p<0.01] and the decay parameter 
(b) of Equation 2 [F(1,11) = 19.2, p<0.001]. None of the other parameters were 
significantly affected [deprivation condition, all Fs(1,11) < 1.7, NS], and in no case was 
there a significant effect of THC [drug treatment factor: all Fs(1,11) < 2.3, NS; 
deprivation × drug treatment interaction: all Fs(1,11) < 1.6, NS]. 
 
Table 7.5. Effect of food deprivation condition and THC 1 mg kg-1 on indices of 
performance on the progressive-ratio schedule  
* Significant effect of the food deprivation condition (p < 0.05); no significant effect of 
the treatment condition and no significant interaction.  
 food deprivation   free feeding 
 
 
vehicle THC  1 mg kg-1 vehicle 
THC 





170.8 ± 43.6 166.0 ± 43.9 35.2 ± 4.7* 39.1 ± 5.6* 




171.7 ± 18.3 179.4 ± 21.0 132.1 ± 11.2* 140.5 ± 12.8* 
 
Equation 1 (overall response rate)         
a (s) 85.2 ± 87.9 83.4 ± 22.0 12.1 ± 3.0* 10.3 ± 1.5* 
į (s) 0.50 ± 0.05 0.48 ± 0.05 0.47 ± 0.07 0.43 ± 0.04 
ȕ 0.64 ± 0.08 0.52 ± 0.08 0.49 ± 0.06 0.49 ± 0.06 
r
2 0.82 ± 0.05 0.78 ± 0.05 0.86 ± 0.03 0.84 ± 0.04 
Equation 2 (running response rate)         
Ri (resp. min-1) 283.3 ± 18.1 245.0 ± 16.8 243.5 ± 19.1 242.1 ± 13.2 
b 39.1 ± 6.3 43.3 ± 8.6 10.9 ± 1.6* 10.1 ± 1.1* 
c 1.6 ± 0.3 1.6 ± 0.2 2.7 ± 0.4 2.8 ± 0.5 
r
2 0.92 ± 0.01 0.90 ± 0.1 0.95 ± 0.01 0.93 ± 0.02 
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7.3.2. Corn oil reinforcement 
 
7.3.2.1. Effect of THC on progressive-ratio schedule performance maintained under 
the food deprivation condition 
 
7.3.2.1.1. Peak response rate 
 
The peak response was somewhat higher under the THC 1 mg kg-1 treatment condition 
that under the other treatment conditions (see Table 7.6). However this increment did not 
reach statistical significance [F(2,30) = 2.3, p = 0.09] .  
 
7.3.2.1.2. Highest completed ratio and breakpoint 
 
THC had no significant effect on the highest completed ratio [F(3,30) = 1.8, NS] or the 
breakpoint [F(3,30) = 2.1, NS] (see Table 7.6).  
 
Table 7.6. Progressive-ratio schedule performance: corn oil reinforcer, food deprivation 
condition. Effects of THC on the highest completed ratio, breakpoint and peak response 
rate (responses min-1) (group mean values ± SEM) 
 
 
7.3.2.1.3. Overall response rate 
 
The group mean data are shown in Figure 7.3 (left hand panel). THC 1mg kg-1 tended to 
produce an increase of the response rate. Analysis of variance yielded a significant effect 
of treatment [F(3,33) = 4.3, p<0.05] and ratio [F(14,154) = 5.8, p<0.001]. However, the 






0.3 mg kg-1 
THC 
1 mg kg-1 
THC 
3 mg kg-1 
Highest completed 
ratio 
170.0 ± 49.8 154.9 ± 42.3 173.3 ± 52.4 169.6 ± 51.0 
Breakpoint  172.5 ± 50.9 146.5 ± 38.4 172.9 ± 52.5 168.7 ± 51.2 
Peak response rate 115.6 ± 13.4 116.1 ± 13.3 129.0 ± 15.8 116.2 ± 11.4 
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80% of the variance of the group mean data (vehicle: r2 = 0.92; THC 0.3 mg kg-1: r2 = 
0.84; THC 1 mg kg-1: r2 = 0.87: THC 3 mg kg-1: r2 = 0.81). Analysis of variance revealed 
that none of the parameters of Equation 1 was significantly affected by THC [a: F(3,30) 
= 2.1, NS;  ȕ: F<1;  į: F<1] (see Table 7.7). 
 
   100% CORN OIL REINFORCER (FOOD DEPRIVED)
RATIO, N





















THC 0.3 mg kg-1 
THC 1mg kg-1 
THC 3 mg kg-1 
RATIO, N









THC 0.3 mg kg-1 
THC 1mg  kg-1 
THC 3 mg kg-1 
 
Figure 7.3 Effects of ǻ9-tetrahydrocannabinol (THC) on progressive-ratio schedule 
performance under food deprivation conditions. Unfilled circles: vehicle-alone treatment; 
filled circles: THC 0.3 mg kg-1; upright filled triangles: THC 1mg kg-1; inverted filled 
triangles: THC  3mg kg-1  (see inset). Other conventions are as in Fig.7.1.  
 
 
7.3.2.1.4. Running response rate 
 
The group mean data are shown in Figure 7.3 (right-hand panel). THC did not have a 
significant effect on the running response rate. Analysis of variance showed a significant 
main effect of ratio [F(13,130) = 27.9, p<0.001] but the main effect of treatment [F(3,30) 
= 1.3, NS] and the interaction [F<1] were not significant. Equation 2 accounted for over 
95% of the variance of the group mean data (vehicle: r2 = 0.97; THC 0.3 mg kg-1: r2 = 
0.98; THC 1 mg kg-1: r2 = 0.95: THC 3 mg kg-1: r2 = 0.96). Analysis of variance revealed 
that none of the parameters of Equation 2 was significantly affected by THC [Ri: F(3,30) 
= 2.1, NS;  b: F<1; c: F<1] (see Table 7,7). 
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Table 7.7. Progressive-ratio schedule performance: corn oil reinforcer, food deprivation 






7.3.2.2. Effect of THC on progressive-ratio schedule performance maintained under 
the free feeding condition 
 
7.3.2.2.1. Peak response rate 
  
As can be seen from Table 7.8, the peak response tended to increase under the THC 1 mg 









0.3 mg kg-1 
THC 
1 mg kg-1 
THC 
3 mg kg-1 
 
 
Equation 1 (overall response rate)         
a (s) 328.3 ± 129.9 375.9 ± 158.3 405.1 ± 164.4 302.4 ± 133.8 
į (s) 0.98 ± 0.15 0.86 ± 0.15 0.97 ± 0.29 0.88 ± 0.12 
ȕ 0.39 ± 0.11 0.30 ± 0.03 0.46 ± 0.13 0.40 ± 0.12 
r2 0.71 ± 0.04 0.60 ± 0.07 0.63 ± 0.06 0.73 ± 0.03 
 
Equation 2 (running response rate)         
Ri (resp. min-1) 226.1 ± 22.9 237.9 ± 19.5 219.6 ± 24.6 257.3 ± 19.4 
b 48.7 ± 24.6 24.6 ± 6.4 49.6 ± 16.6 20.3 ± 5.6 
c 2.5 ± 0.8 1.3 ± 0.3 1.4 ± 0.2 2.1 ± 0.8 
r2 0.84 ± 0.06 0.84 ± 0.05 0.77 ± 0.04 0.83 ± 0.03 
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7.3.2.2.2. Highest completed ratio and breakpoint 
 
Neither of the two variables was significantly affected by THC [highest completed ratio: 
F(1,10) = 1.4, NS; breakpoint: F(1,10) = 1.3, NS] (see Table 7.8.). 
 
 
Table 7.8. Progressive-ratio schedule performance: corn oil reinforcer, free feeding 
condition. Effects of THC on the highest completed ratio, breakpoint and peak response 











7.3.2.2.3. Overall response rate 
 
The group mean data are shown in Figure 7.4. THC tended to increase the response rate 
in the lower ratios in comparison with the vehicle condition. Analysis of variance yielded 
a borderline significant main effect of treatment [F(1,11) = 5.6, p=0.04] and a significant 
effect of ratio [F(7,77) = 6.3, p<0.001]. However, the treatment × ratio interaction was 
not significant [F<1]. Equation 1 accounted for over 80% of the variance of the group 
mean data (vehicle: r2 = 0.91; THC 1 mg kg-1: r2 = 0.80). The values of the parameters of 
Equation 1 are shown in Table 7.9. Analysis of the variance showed a non-significant 
trend for a to be reduced by THC mg kg-1 [F(1,10) = 3.4, p=0.07]. ȕ was significantly 
reduced by THC [F(1,10) = 5.0, P<0.05]. The response time parameter į was not 










1 mg kg-1 
Highest completed 
ratio 
40.1 ± 9.8 33.1 ± 4.6 
Breakpoint  37.9 ± 9.1 31.3 ± 4.6 
Peak response rate 71.5 ± 7.0 79.7 ± 8.6 
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7.3.2.2.4. Running response rate 
 
The group mean data are shown in Figure 7.4 (right hand panel). Analysis of variance 
revealed that THC had no effect on the running response rate. There was a significant 
main effect of ratio [F(7,70) = 27.9, p<0.001]. However, the main effect of treatment 
[F<1] and the treatment × ratio interaction [F<1] were not statistically significant. 
Equation 2 accounted for over 99% of the variance of the group mean data (vehicle: r2 = 
0.99; THC 1 mg kg-1: r2 = 0.99). The parameters of Equation 2 are shown in table 7.9. 
None of the parameters was significantly affected by THC [Ri: F<1; b: [F(1,10) = 1.5, 





Figure 7.4 Effects of THC on progressive-ratio schedule performance. Unfilled circles: 
vehicle-alone treatment; filled triangles: THC 1 mg kg-1 (see inset). Other conventions 
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Table 7.9. Progressive-ratio schedule performance: corn oil reinforcer, free feeding 





















7.3.2.3. Comparison of progressive-ratio schedule performance maintained under the 
food deprivation and free feeding conditions 
 
As described above, each rat experienced training under both the food deprivation and 
free feeding conditions, and the 1 mg kg-1 dose of THC was tested under both conditions. 
The effects of food deprivation and THC 1 mg kg-1 on each performance measure were 
analysed by analysis of variance (condition [food deprived, free feeding] × treatment 
[vehicle, THC 1 mg kg-1]). For ease of comparison, the relevant data, extracted from 
Tables 7.6, 7.7, 7.8, and 7.9, are displayed in Table 7.10. Analysis of variance showed 
that, compared to the free-feeding condition, food deprivation produced an increase in 
the highest completed ratio [F(1,11) = 11.3, p<0.01], the breakpoint [F(1,11) = 11.7, 
p<0.01] and the peak response rate [F(1,11) = 12.0, p<0.01]. The deprivation condition 





 THC  
1 mg kg-1 
 
Equation 1 (overall response rate)   
a (s) 69.1 ± 26.6 34.4 ± 10.7 
į (s) 1.83 ± 0.63 1.17 ± 0.20 
ȕ 0.64 ± 0.11 0.49 ± 0.11* 
r2 0.70 ± 0.05 0.65 ± 0.06 
 
Equation 2 (running response rate)   
Ri (resp. min-1) 220.0 ± 24.2 206.6 ± 29.8 
b 4.7 ± 1.3 5.9 ± 1.8 
c 5.5 ± 3.5 2.2 ± 0.4 
r2 0.87 ± 0.07 0.85 ± 0.08 
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p@DQGWKHµFXUUHQF\¶SDUDPHWHU (ȕ) [F(1,11) = 10.0, p<0.01] of Equation 1 and the 
decay parameter (b) of Equation 2 [F(1,11) = 11.2, p<0.01]. None of the other parameters 
was significantly affected [deprivation condition: all Fs(1,11) < 1.7, NS], and in no case 
was there a significant effect of THC [drug treatment factor: all Fs(1,11) < 4.8, NS; 
deprivation × drug treatment interaction: all Fs(1,11) < 3.1, NS]. 
 
 
Table 7.10. Effect of food deprivation condition and THC 1 mg kg-1 on indices of 
performance on the progressive-ratio schedule 
 
 
* Significant effect of the food restriction condition (p < 0.05); no significant effect of 
the treatment condition and no significant interaction 
 food deprivation   free feeding 
 
 
vehicle THC  1 mg kg-1 vehicle 
THC 





170.0 ± 49.8 173.3 ± 52.4 40.1 ± 9.8* 33.1 ± 4.6* 




115.6 ± 13.4 129.0 ± 15.8 71.5 ± 7.0* 79.7 ± 8.6* 
 
Equation 1 (overall response rate) 
     
   
a (s) 328.3 ± 129.9 405.1 ± 164.4 69.1 ± 26.6* 34.4 ± 10.7* 
į (s) 0.98 ± 0.15 0.97 ± 0.29 1.83 ± 0.63 1.17 ± 0.20 
ȕ 0.39 ± 0.11 0.46 ± 0.13 0.64 ± 0.11* 0.49 ± 0.11* 
r2 0.71 ± 0.04 0.63 ± 0.06 0.70 ± 0.05 0.65 ± 0.06 
Equation 2 (running response rate)         
Ri (resp. min-1) 226.1 ± 22.9 219.6 ± 24.6 220.0 ± 24.2 206.6 ± 29.8 
b 48.7 ± 24.6 49.6 ± 16.6 4.7 ± 1.3* 5.9 ± 1.8* 
c 2.5 ± 0.8 1.4 ± 0.2 5.5 ± 3.5 2.2 ± 0.4 
r2 0.84 ± 0.06 0.77 ± 0.04 0.87 ± 0.07 0.85 ± 0.08 
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7.3.3. Effect of THC on consumption of the sucrose solution and corn oil  
 
THC 1 mg kg-1 produced a borderline increase in intake of the sucrose solution [t(11) = 

















Fig 7.5. Left hand graph, effect of THC 1 mg kg-1 on on intake (g) of the sucrose solution 
(0.6 M, 50 µl) and corn oil (100%) during 60-min test sessions. Unfilled bars: vehicle-
alone treatment; filled bars: THC 1 mg kg-1 (see inset). The right hand graph shows the 
same data, but the quantity of food is expressed as its calorific content rather than weight; 
other conventions are as in the left hand graph. Difference from the vehicle treatment: * 





The performance of the rats in this experiment was similar to that seen in previous 
studies (Bezzina et al. 2008b; Bezzina et al. 2008c; Bizo and Killeen 1997; den Boon et 
al. 2011; Ho et al. 2003; Kheramin et al. 2005; Mobini et al. 2000; Rickard et al. 2009; 
Zhang et al. 2005a; Zhang et al. 2005b) and in Experiments 1-5 of this thesis. As in 
Experiment 5, described in the previous chapter, corn oil proved to be an effective 
reinforcer in the progressive-ratio schedule. 
 
Unexpectedly, none of the doses of THC had any significant effect on the parameters of 
Equations 1 and 2 (a and b, respectively) that are purported to measure the incentive 
value of reinforcers (Killeen 1994; Rickard et al. 2009), nor did they affect the traditional 
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measure derived from progressive-ratio schedule performance, the breakpoint.  This lack 
of effect, which was apparent with both reinforcers, corn oil and sucrose, is consistent 
with the results obtained in Experiment 4 (see Chapter 5) obtained using food-pellet 
reinforcers. These results are in apparent disagreement with previous experiments in 
which THC has been found to increase the breakpoint in progressive-ratio schedules 
(Higgs et al. 2005; Solinas and Goldberg 2005). There are a number of methodological 
differences between the present experiment and the two previous studies that reported 
significant effects of THC on the breakpoint. In the present experiment the food 
restriction condition was more stringent (the rats were maintained at 80% of their free 
feeding body weights) than in those two experiments. Furthermore, the session duration 
in the present experiment was somewhat shorter (40 minutes), than in the previous 
experiments (approx 60 minutes) (see section 6.4 for discussion of this matter). Finally, 
the reinforcers used in the present experiment were different (0.6 M sucrose solution and 
100% corn oil in the present experiment in comparison with pellets containing a mixture 
of nutrients in the previous studies by Higgs et al. (2005) and Solinas and Goldberg 
(2005). There is evidence that THC has a stronger effect on the rewarding value of 
palatable foods such as sweet (Foltin et al. 1988; Haney et al. 1999; Hollister 1971) or 
fatty foodstuffs (Verty et al. 2011; Verty et al. 2004). However as mentioned above 
(section 7.1) it is difficult to attribute the effect of THC (or other drugs) to a selective 
effect on sweet food when the reinforcers used contain a mixture of nutrients.  
 
There were grounds for suspecting that the deprivation condition used in this experiment 
and in Experiment 4 might have masked the effect of THC on the indices of incentive 
value. For example, Williams et al. (1998) argued that the failure of some previous 
experiments to demonstrate a hyperphagic effect of THC was due to inappropriate test 
conditions. According to these authors, the optimal conditions to test the effect of THC 
on food intake include the use of non-food-deprived animals. Therefore, in the present 
experiment, the effect of THC 1 mg kg-1 (the dose that has been used in most previous 
studies that have found an orexigenic effect of THC; e.g. Williams et al. 1998) was also 
tested under free-feeding conditions. As expected, response rates under the progressive 
ratio schedule decreased when the animals were transferred from the food deprivation 
condition to ad libitum feeding (see below). Unexpectedly, however, there was no effect 
of THC on the parameters a and b or on the breakpoint in the case of either reinforcer.  
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According to a recent report, THC exerted different locomotor effects depending on the 
diet to which the animals were exposed. Specifically, THC was found to induce 
hypomotility and cataplexy-like behaviour in rats maintained on a diet enriched with fat 
(Wiley et al. 2011). Informal observations of the rats did not indicate that THC had any 
such effect in the rats in the present experiment that received corn oil reinforcement, and 
there was no effect of THC on the motor indices of operant performance, į and Ri. The 
corn oil intake that resulted from reinforcement under the progressive-ratio schedule in 
the present experiment (approximately 0.3-0.5 g per day) may have been insufficient to 
induce the effect noted by Wiley et al. (2011). However, it may be worth noting that the 
corn oil-reinforced group required a noticeably smaller daily food ration to maintain their 
body weights at the 80% target level than was the case with the sucrose-reinforced group, 
suggesting that the amount of corn oil earned in the daily experimental sessions made a 
substantial contribution to the total calorie intake of this group.  
 
In another experiment using progressive-ratio schedules (Maccioni et al. 2008), rats 
maintained under ad libitum feeding were reinforced with a chocolate beverage. After 
they were trained, these rats underwent treatment with the CB1 receptor antagonist, 
rimonabant. Rimonabant produced a significant reduction of the breakpoint. The authors 
concluded that CB1 receptors were a crucial component of the system that regulates the 
rewarding and motivating properties of palatable food (Maccioni et al. 2008). The 
present experiment did not support this hypothesis. One possible argument could be that 
corn oil or sucrose on their own are not sufficiently palatable to generate an effect on 
reinforced operant behaviour when the cannabinoid system is manipulated, in contrast to 
chocolate, which contains a mixture of sucrose and fat. Further research is needed using 
reinforcers whose composition is fully known in order to further understand the effect of 
THC on the rewarding value of µSDODWDEOHIRRG¶ 
  
Another aim of this experiment was to test whether the rats would respond on the 
progressive-ratio schedule even under free-feeding conditions.  Interestingly, the rats not 
only responded on the schedule, but also the data derived from this condition could be 
used for fitting Killeen¶Vequation in a similar way to experiments that employed 
conventional food deprivation conditions (Bezzina et al. 2008b; Bezzina et al. 2008c; 
Bizo and Killeen 1997; den Boon et al. 2011; Ho et al. 2003; Kheramin et al. 2005; 
Mobini et al. 2000; Rickard et al. 2009; Zhang et al. 2005a; Zhang et al. 2005b; also 
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Experiments 1,2,3,4 and 5 in this thesis).  As expected, when the animals were 
transferred from the food deprived condition to the free-feeding condition, all the 
measures related to the incentive value of food reinforcers (a [Equation 1], b [Equation 
2], and the breakpoint) were reduced (see Table 7.10). Furthermore, in agreement with 
Killeen¶V 035 , the response-time parameter į (which is supposed to be 
independent from a) was not altered. These findings are also supported by a decrement in 
the decay parameter b without any change in the maximum running response rate 
parameter Ri, derived from Equation 2 (Rickard et al. 2009). This last observation 
indicates that b and Ri behave as indepent parameters. In this context it may be of interest 
to note that another quantitatiYH PRGHO RI RSHUDQW SHUIRUPDQFH +HUUQVWHLQ¶V 
K\SHUEROLF µUHVSRQVH VWUHQJWK¶ HTXDWLRQ DOVR UHYHDOV D VHOHFWLYH HIIHFW RI GHSULYDWLRQ
level on an index of reinforcer value, with no effect on an index of motor capacity 
(Bradshaw et al. 1983).  
 
The free feeding condition was associated with somewhat higher values of the currency 
parameter, ȕ, compared to the food deprivation condition. The reason for this effect, 
which was only apparent in the case of the corn oil reinforcer, is unclear. In MPR, this 
parameter expresses the weight given to the most recent response in the reinforcement 
process (Killeen 1994). It is possible that the corn oil reinforcer was less effective in 
controlling longer trains of responses under free feeding condition than under food 
deprivation conditions. However, this interpretation remains speculative, pending a more 
V\VWHPDWLF H[DPLQDWLRQ RI WKH VHQVLWLYLW\ RI ȕ WR PDQLSXODWLRQ RI variables such as 
deprivation level, reinforcer size and reinforcer quality (for further discussion, see 
Bezzina et al. 2008a; Rickard et al. 2009). 
 
As discussed in session 6.4 the parameters derived from behaviour maintained by the two 
reinforcers could not be compared quantitatively, as the two reinforcers were not 
matched in terms of any relevant variables, such as their calorific content, volume, etc. 
However, it may be of interest to cRPSDUHWKHµLQFHQWLYHYDOXH¶SDUDPHWHUa, obtained in 
this experiment with values of the parameter obtained by Rickard et al. (2009) for a range 
of volumes of a 0.6 M sucrose solution. In Figure 7.6, the value of a (s) is plotted against 
the calorific values of the reinforcers (kcal). It is apparent that the value of a derived 
from the sucrose-reinforcement group in the present experiment is similar to the value 
obtained by Rickard et al. (2009) using the same reinforcer (50µl of a 0.6 M sucrose 
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solution). The calorific of the corn oil reinforcer used in this experiment is similar to the 
calorific content of 250 µl of a 0.6 M sucrose solution. Comparison of the values of a for 
these two reinforcers suggests that the value obtained for corn oil (data from the present 
experiment) was somewhat higher than that obtained for 300 µl of the sucrose reinforcer 
(data from Rickard et al. 2009). It may also be noted that the between-rat variability in 
the parameter values was considerably higher in the case of the corn oil reinforcer. The 
apparently greater incentive value of the corn oil reinforcer than a calorifically equivalent 
VXFURVH UHLQIRUFHU DSSHDUV WR EH LQFRQVLVWHQW ZLWK WKH FODLP WKDW µFDORULH-for-FDORULH¶
sucrose makes a greater contribution to the overall value of a food reinforcer than corn 
oil in progressive-ratio schedule-controlled operant behaviour (Naleid et al. 2008). It 
VKRXOG QRWHG KRZHYHU WKDW 1DOHLG HW DO¶V FODLP LV EDVHG RQ experiments in which 





parameter, a (Equation 1). Ordinate: value of a (s); abscissa: calorific content (kcal). 
Filled symbols: 0.6 M sucrose solution; open symbols: 100% corn oil. Connected filled 
triangles: data from Rickard et al. (2009) for a range of volumes of the sucrose solution; 
filled circle: data from present experiment using 50 µl of the sucrose solution. Unfilled 
circle: data from the present experiment using the corn oil reinforcer. Filled and unfilled 
lozenges: data from the free-feeding condition of the present experiment (filled lozenge: 
sucrose solution; unfilled lozenge: corn oil); all other points indicate data obtained under 
the food deprivation condition (rats maintained at 80% of free-feeding body weight). See 
text for further explanation. 
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both components were considerably lower than the concentrations of the pure substances 
used in the present experiment. Once again, it would seem that more research is needed 
before any definite conclusion can be reached about the relative efficacies of sucrose and 
corn oil as reinforcers. It should also be emphasized that calorific content is only one 
aspect of food reinforcement; sensory quality is likely to exert at least as great an 
influence on incentive value as energy content. In this context, it is of interest that 
Covarrubias and Aparicio (2008) have shown that saccharin pellets, with calorific value 
close to zero, generated a higher value of  a and higher breakpoints than standard food 
pellets (Covarrubias and Aparicio 2008). This fascinating line of investigation needs to 
be further investigated in other to determine the way in which calories, nutritional 
content and  flavours can affect the parameters of Equations 1 and 2 (Killeen 1994; 
Rickard et al. 2009).  
 
The feeding experiment showed that there was a trend (not significant) for THC to 
increase the intake of the sucrose solution (Figure 7.5). These results are qualitatively in 
agreement with previous research (Williams et al. 1998). The fact that a single dose was 
used leaves open the possibility that a higher dose might have produced a significant 
increment of food intake, although it may be noted that the dose used in this experiment 
(1 mg kg-1) has been reported to increase food intake in previous studies (e.g. Williams et 
al. 2008). Another potentially relevant factor is the time of the day when the rats were 
tested. In the present experiment, testing took place during the light phase of the daily 
cycle; however, Williams et al. (1998) noted that the effect of THC on food intake was 
more pronounced in the dark phase than the light phase. Perhaps the most surprising 
finding was the fact that THC significantly reduced the amount of corn oil intake. It can 
be seen from Figure 7.5 that under the vehicle treatment condition the rats consumed a 
much smaller quantity of corn oil than of the sucrose solution. However in terms of the 
calorific content, the rats that received corn oil consumed considerably more calories 
than the rats that received the sucrose solution. 
 
In summary, the present results indicate than under food restriction conditions THC (0.3-
3 mg kg-1) had no significant effect on progressive-ratio schedule performance, with the 
concentrations of sucrose and corn oil used in this experiment. Moreover, removal of the 
food-restriction condition failed to unmask any significant effect of THC (1 mg kg-1) on 
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performance. The results obtained from the feeding experiment indicate that THC may 
enhance sucrose intake when there is no operant response requirement; in contrast, corn 
oil intake was substantially reduced by THC. Furthermore, this experiment showed that 
the incentive value parameters a and b, but not to the motor parameters į and Ri, are 
sensitive to the food restriction condition. This adds more evidence for the utility of MPR 
(Equation 1) and Equation 2 as a basis for measuring the incentive value of food 
reinforcers. However the disparity between the effects of THC on progressive-ratio 
schedule performance and on unrestricted food intake indicates that caution is needed in 
the use of data from feeding tests to draw conclusions about the reinforcing value of 
IRRGVWXIIV ,W VHHPV WKDW µSDODWDELOLW\¶ DQG µUHZDUGLQJ YDOXH¶ VKRXOG QRW EH XVHG DV
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8.1 Summary of results 
 
The aim of the work described in this thesis was to answer some questions related to the 
neurobiological basis of the control of operant behaviour by food reinforcement. The 
main behavioural technique used in the research was the progressive-ratio schedule. The 
behavioural data generated by this schedule were analysed using a quantitative approach 
EDVHGRQ.LOOHHQ¶V0DWKHPDWLFDO3ULQFLSOHVof Reinforcement model (MPR). The 
ratio-schedule equation derived from MPR (Equation 1) was used to analyse the overall 
response rates in successive ratios of the schedule, and in addition, Rickard et al¶V (2009) 
logistic equation was used to analyse the running response rate data. The rationale for 
adopting this approach was that MPR provides a theoretical basis for discriminating 
between the effects of interventions on incentive and motor-related processes, which are 
represented by separate parameters in Equation 1 (a DQGįUHVSHFWLYHO\,QWKLVUHVSHFW
analysis of performance based on MPR was deemed to be more informative than the 
traditional measure of performance on the progressive-ratio schedule, the breakpoint 
(Hodos 1961), which, according to MPR, confounds the influences of incentive and 
motor processes (Killeen et al. 2009; Rickard et al. 2009). 
 
The first three experiments of this the project (Chapters 2-4) examined the effects of 
manipulating orexinergic function to assess the putative role of the orexinergic pathways 
in reward processes. $FFRUGLQJ WR WKH µGLFKRWRP\ RI RUH[LQHUJLF IXQFWLRQ¶ K\SRWKHVLV
(Harris and Aston-Jones 2006), orexinergic neurones in the LHA are purported to play an 
important role in reward processes, whereas orexinergic neurones in the adjacent PFA are 
purported to control arousal and wakefulness. OxSap, a neurotoxin that (in small doses) 
selectively targets those neurones that bear OX2 receptors, was used to destroy 
orexinergic neurones of the LHA  In Experiment 1, bilateral lesions were inflicted in the 
LHA. Neither a nor ȕ was significantly altered by the lesion. However, the response time 
parameter į was significantly increased, which indicated that motor and not motivational 
processes were impaired by the lesion. Application of the logistic equation (Rickard et al 
2009) to the running response rate data also indicated a motor deterioration, as shown by 
a reduction of the parameter Ri. The decay parameter b and the exponent c were not 
affected. Furthermore, feeding and locomotor activity experiment failed to show any 
differences between the sham-lesioned and OxSap-lesioned groups. The 
immunohistochemistry data showed selective depletion of orexin-containing neurones 
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from the LHA, consistent with the dose dependent selectivity of OxSap as a neurotoxin 
affecting OX2 receptor-bearing neurones. These data support the hypothesis that OX2 
receptor-bearing neurones of the LHA are involved in the control of motor processes. 
 
In Experiment 2, OxSap-induced lesions were used to sever the connections between the 
LHA and the VTA, one of the main projection areas of the orexinergic pathways. The 
results ZHUH VLPLODU WR WKRVH RI ([SHULPHQW  LQ WKDW WKH µmotor parameter¶ į was 
increased in the disconnection-lesioned group, compared to the control group, whereas 
the other parameters were not significantly affected. Also in agreement with the previous 
experiment, Ri was reduced in the disconnection group. Overall, the results suggest that  
orexinergic neurotransmission in the VTA mediated by OX2 receptors are involved in 
motor and arousal processes, but no evidence was obtained for a significant role of OX2 
receptors in motivation-related processes.  
 
In Experiment 3, the LHA was unilaterally lesioned with OxSap, following which the  
animals were implanted with guide cannulae targeting the AcbS. Then the rats received 
acute intra-AcbS injections of the OX1 receptor antagonist SB-334867-A ipsilaterally 
(unilateral group) or contralaterally (disconnection group). It was found that thH µDFXWH
GLVFRQQHFWLRQ¶SURFHGXUHreduced the incentive value of food reinforcer as indicated by a 
significant decrease in the parameter a. Treatment with SB-334867-A did not affect the 
motor parameter į or the currency parameter ȕ. The analysis derived from the running 
rate (Equation 2) revealed a trend for the decay parameter b to be increased whereas Ri 
and c were not affected. The results from this experiment are consistent with the 
hypothesis of differential functions of the two orexin receptors, since blockade of OX1 
receptor-mediated transmission in the AcbS reduced reinforcer value as defined by MPR.   
  
Experiment 4 examined the effect of cyproheptadine on progressive-ratio schedule 
performance. Cyproheptadine is a non-specific 5-HT and histamine receptor antagonist 
that has been proposed as a potential adjunct to conventional antipsychotic treatment 
which might confer beneficial effects in the management of negative symptoms of 
schizophrenia (Goudie et al. 2007). The effect of cyproheptadine was compared with 
those of the conventional antipsychotic (D2-like rdopamine receptor antagonist) 
haloperidol, the atypical antipsychotic clozapine, and two drugs with known 
orexinegenic effects, chlordiazepoxide and THC. The effects of haloperidol and 
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clozapine were similar to previous reports using MPR (e.g. Zhang et al. 2005a; den Boon 
et al. 2011). In addition clozapine and cyproheptadine showed similar patterns of effect 
on the parameters of the equations; that is, both drugs increased a and į  (Equation 1) and 
reduced Ri (Equation 2). The fact that the breakpoint was not significantly increased by 
clozapine showed once more the utility of quantitative analysis of progressive-ratio 
schedule performance based on MPR (1994). Unexpectedly, THC had no effect on the 
parameters of MPR. 
 
Experiment 5 examined the effects of blocking the D1-like (SKF-83566) and D2-like 
(haloperidol) dopamine receptors on progressive-ratio performance maintained by two 
different reinforcers, sucrose and corn oil. MPR revealed that the two antagonists had 
different effects on behaviour maintained by the two reinforcers. Haloperidol was able to 
reduce the µincentive value¶ of both corn oil and sucrose, as indicated by a decrease of a. 
However the D1-like receptor antagonist SKF-83566 reduced both a and į in the case of 
sucrose but had no effect on the values of the parameters in the case of corn oil.  These 
results are consistent with the notion that D1-like and D2-like dopamine receptors may be 
differentially involved in the regulation of the incentive value of different foods (Yoneda 
et al. 2007b).  
 
The last experiment (Experiment 6, Chapter 7) examined the effect of THC on 
progressive-ratio schedule performance maintained by sucrose and corn oil under food-
deprived and free-feeding conditions. No significant effects of THC on the parameters of 
the two equations were seen when THC was administered under either condition. 
HoweverFRQVLVWHQWZLWKWKHWHQHWVRI035WKHµDFWLYDWLRQ¶SDUDPeter was sensitive to 
food deprivation, higher values of a being seen when the rats were maintained under the 
food deprived condition than when they were given free access to food. Interestingly, in 
feeding tests, THC produced a (borderline significant) increase in sucrose consumption, 
and a substantial reduction of oil consumption. 
 
8.2 Implications for the neurobiological substrate of reinforcement 
 
8.2.1. Orexinergic mechanisms 
 
According to the µdichotomy¶ theory of the orexinergic function, the orexinergic 
 - 194 - 
neurones of the LHA are assumed to control the LQFHQWLYHRU µrewardLQJ¶ properties of 
reinforcers, and those of the PFA are assumed to control motor and/or arousal functions 
(Harris and Aston-Jones 2006). The results from Experiments 1-3 did not provide 
unequivocal support for this hypothesis. In Experiment 1, bilateral destruction of 
orexinergic neurones in the LHA induced by the selective neurotoxin OxSap did not 
produce a decrement of any of the motivational indices (a, b or breakpoint), nor did it 
affect food intake. To some degree, the discrepancy between these findings and 
previously reported results may be ascribed to the use of different paradigms, different 
food restriction conditions and different reinforcers (see section 2.4). However, the fact 
that a µmotor performance¶ deficit was found in this experiment (an increment of į, and a 
decrement of Ri and the peak response rate), strongly suggests that the LHA orexinergic 
neurones may make a more important contribution to the motor aspects of operant 
behaviour than has previously been recognised (see also Berridge et al. 2010; Siegel 
2004; Siegel 2005b). In the following experiment, disconnection of the VTA from the 
orexinergic output of the LHA using OxSap had a very similar effect on performance to 
that seen in Experiment 1: the lesion produced an increase of į and a reduction of Ri and 
the peak response rate. This constitutes further evidence in favour of the notion that the 
LHA orexinergic projection contributes to the control of operant behaviour by regulating 
motor/arousal processes. 
 
Although the results of Experiments 1 and 2 appear to be incompatible with a 
straightforward link between the LHA orexinergic neurones and the regulation of 
LQFHQWLYH YDOXH DV SURSRVHG E\ WKH µGLFKRWRP\¶ WKHRU\ Experiment 3 provided 
preliminary evidence for a more circumscribed role of the LHA orexinergic projection in 
regulating incentive value. Since the neurotoxin used to lesion the orexinergic pathways 
shows some preference for neurones bearing the OX2 receptor rather than the OX1 
receptor, the possibility that OX1 receptors in the target region may be mainly 
responsible for the proposed role of orexinergic mechanisms in incentive processes. The 
results of Experiment 3 indicated that unilateral OxSap lesions in the LHA coupled with 
blockade of OX1 receptors in the contralateral AcbS using the OX1 receptor antagonist 
SB-334867-A produced a selective reduction of the activation parameter, a,  
Interpretation of this finding is complicated by the fact that the LHA lesion was induced 
by OxSap, which selectively targets neurones that express OX2 receptors. At the present 
time it is not known whether there are separate sub-populations of orexinergic neurones 
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in the LHA that exclusively express either OX1 or OX2 receptors, although the existence 
of exclusively OX1 receptor-expressing orexinergic neurones might help to explain the 
findings that a low dose of OxSap only succeeded in destroying about 50% of orexin-
containing neurones in the LHA (Experiment 1), and that this proportion was not 
increased when the dose of OxSap was doubled (Experiment 2).  
 
In summary, the results of Experiments 1-3 lead to the idea that the putative 
µGLFKRWRQP\¶of the behavioural role of orexinergic function may be more related to the 
receptors involved than with the particular sub-region of the hypothalamus from which 
the orexinergic fibres arise. However this hypothesis needs further investigation before 
any definitive conclusion can be made.   
 
8.2.2. Antipsychotics and dopaminergic mechanisms 
 
It is generally accepted that the principal pharmacological DFWLRQ RI µFRQYHQWLRQDO¶
antipsychotics is antagonism of D2-like dopamine receptors (D2, D3 and D4 receptors). 
This action has been held responsible for both their therapeutic effects and their major 
side effects; blockade of D2-like receptors in the limbic cortex and subcortical limbic 
structures may underlie their antipsychotic action, whereas antagonism of D2-like 
receptors in the dorsal striatum is the basis of their extrapyramidal side-effects (see 
Cunningham-Owens 1999; King and Waddington 2004). Conventional antipsychotics are 
QRWRULRXVO\ XQVXFFHVVIXO LQ DOOHYLDWLQJ WKH µQHJDWLYH¶ V\PSWRPV RI VFKL]RSKUHQLD HJ
anhedonia); indeed in some cases they may exacerbate them (see King and Waddington 
2004). An antihedonic effect of D2-like receptor antagonists is widely believed to 
underlie the suppressant effect of these drugs on operant behaviour maintained by food 
and drug reinforcement (Wise 1982). In contrast, atypical antipsychotics such as 
clozapine do not aggravate negative symptoms, and some authors claim that these 
symptoms may respond favourably to these drugs (Corrigan et al. 2003; Müller-Spahn 
2002).  
 
The mode of action of atypical antipsychotics remains in dispute, although several 
theories have been proposed (see section 1.3.4.6). The possibility that simultaneous 
blockade of D2-like and 5-HT2A UHFHSWRUVPD\XQGHUOLHFOR]DSLQH¶VVXSHULRUWKHUDSHXWLF
profile (Meltzer 1995) led to the suggestion that the combination of a D2-like receptor 
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antagonist (e.g. haloperidol) and a 5-HT2A receptor antagonist (e.g. cyproheptadine) 
might provide a satisfactory treatment regimen in schizophrenia (Goudie et al. 2007). 
 
In Experiment 4, the effect of cyproheptadine on progressive-ratio schedule performance 
was compared with those RI FOR]DSLQH DQG KDORSHULGRO &\SURKHSWDGLQH¶V SURILOH RI
effect on the parameters of MPR closely resembled that of clozapine: Both drugs 
increased a and į, suggesting a dual effect of enhancing incentive value and impairing 
motor capacity. Since both drugs have quite complex pharmacologies, it is difficult to 
ascribe these effects to particular actions at the receptor level. However, as discussed in 
Chapter 5, histamine H1 receptor antagonism may account for the motor debilitating 
(possibly sedative) effects of both drugs. The mechanism responsible for the apparent 
increase of incentive value by clozapine and cyproheptadine needs to be further 
investigated; one possibility is that it may be related to the appetite enhancing effects 
which have been attributed to the combined blockade of 5HT2A, H1 and M1 receptors 
(Goudie et al. 2007).  
 
+DORSHULGRO¶VHIIHFWRQSHUIRUPDQFHFRPSULVHGDUHGXFWLRQRIa and an increase of į. As 
discussed above, both effects may be related to D2-like receptor antagonism, Blockade of 
these receptors in the dorsal striatum may underlie the motor debilitating effect (increase 
in į, reduction of Ri), whereas the reduction of a may reflect blockade of D2-like 
receptors in limbic structures. The reduction of a is, of course, consistent with the basic 
WHQHW RI WKH µDQKHGRQLD¶K\SRWKHVLV :LVH WKDW FRQYHQWLRQDO DQWLSV\FKRWLF
drugs reduce the rewarding effect of positive reinforcers. However it should be noted that 
although this experiment is not alone in finding that haloperidol reduced the value of a 
(den Boon et al. 2011), some other studies based on MPR did not observe this effect 
(Mobini et al. 2000; Zhang et al. 2005a). 
 
In Experiment 6, haloperidol and a D1-like receptor antagonist SKF-83566 were used to 
test the hypothesis WKDW WKH WZR µVXEIDPLOLHV¶ RI dopamine receptor exert different 
regulatory effects on the reinforcing property of sucrose and corn oil (Weatherford et al. 
1990; Yoneda et al. 2007a). The results showed that haloperidol was able to reduce both 
a and b in both in the corn oil and sucrose reinforced group. However SKF-83566 
reduced a in the sucrose-reinforced group, having no effect at all in the corn oil-
reinforced group. This suggests that the incentive properties of different reinforcers could 
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be mediated by different receptors (see section 7.4 for discussion). 
 
8.2.3. Cannabinoid receptors 
 
THC is a CB1 receptor agonist with is claimed to have powerful effects on food intake 
and  food motivation. In Experiment 4, THC failed to produce an effect RQWKHµLQFHQWLYH
YDOXH¶SDUDPHWHUVRI(TXDWLRQVDQGDFURVV a wide range of doses (see Chapter 5). A 
possible explanation that was considered for this unexpected finding was the lack of 
carbohydrate content of the pellet reinforcers, since most previous studies that had 
demonstrated an orexigenic effect of THC used sweet foodstuffs (see Chapters 5 and 7). 
Therefore, in Experiment 6, the effect THC on progressive-ratio schedule performance 
was investigated again with two different reinforcers ± sucrose and corn oil. When the 
rats were maintained under conventional food-restriction conditions (they were 
maintained at 80% of their free-feeding body weights), THC had no effect on any of the 
parameters of the two equations. Then the animals were tested again under free feeding 
conditions. The data from this condition conformed adequately to the two equations, with 
reduced values of a (Equation 1) and b (Equation 2), indicating a reduction of the 
incentive value of both reinforcers. Again, THC did not affect the parameters of the 
equations. Finally, a feeding test was carried out, in which THC was found to induce a 
(borderline significant) increase in the amount of sucrose solution consumed, and a 
significant reduction of corn oil intake. Therefore the results from this experiment 
provided no support the involvement of CB1 receptors in regulating the incentive value 
of sucrose or corn oil. The results also suggest that caution is needed in drawing 
FRQFOXVLRQV DERXW WKH HIIHFWV RI GUXJV RQ WKH µLQFHQWLYH YDOXH¶ RI IRRGV LQ RSHUDQW
behaviour paradigms on the basis of their effects on food intake.  
 
8.3 Implications for the Mathematical Principles of Reinforcement model 
 
The progressive-ratio schedule has been a very popular tool in studying the effects of 
centrally acting drugs, neurobiological interventions and brain self-stimulation on 
µmotivational processes¶VHH3LQ-Teng et al. 1996). The attraction of this tool no doubt 
GHULYHVIURP+RGRV¶RULJLQDOFODLPWKDWWKHEUHDNSRLQWSURYLGHVDYDOid index of 
WKH µHIILFDF\¶RI WKH UHLQIRUFHUNevertheless, as discussed earlier in this thesis (section 
1.4.1), a number of authors have raised doubts about the reliability of the breakpoint as a 
 - 198 - 
behavioural measure, and its validity as a measure of reinforcer efficacy or incentive 
value. Perhaps the greatest problem with the breakpoint is the discovery that it is 
sensitive to a number of variables that are believed to affect motor, rather than 
motivational, processes (see Arnold and Roberts 1997). MPR offers a means of 
overcoming many of the technical and theoretical problems that have been identified 
with the breakpoint. At a technical level, the use of the reponse rate function (response 
rate plotted against the response/reinforcer ratio) overcomes the weakness of reliance on 
a single data point to define the breakpoint. At a theoretical level, MPR provides an index 
of incentive value (the activation parameter, a) that is founded on a comprensive model 
of schedule-controlled operant behaviour, and, most importantly, this index is theoretical 
and empirically distinguishable from DQ LQGH[ RI µPRWRU FDSDFLW\¶ WKH UHVSRQVH-time 
parameter, į) (Killeen 1994).  
 
The equation used to describe progressive-ratio schedule performance (Equation 1) was 
originally developed for fixed-ratio schedules (Killeen 1994). It has been successfully 
used in progressive-ratio schedules, including a number of studies of the behavioural 
effects of drugs (see section 1.4.4). The results described in this thesis confirm the 
findings of previous experiments that changes in the breakpoint may be associated with a 
change in either a or į (or both), in keeping with the 035¶V LQWHUSUHWDWLRQ RI WKH
breakpoint as ratio of these two parameters (a/į) (Killeen 1994).  
 
The work described in this thesis extends the application of MPR to a number of new 
situations. Equation 1 was found to provide a good description of progressive-ratio 
schedule performance maintained with a novel reinforcer, corn oil, as well as confirming 
previous work with other reinforcers (sucrose solutions and food pellets: e.g. den Boon et 
al. 2011; Rickard et al. 2009). In Experiment 6 rats were tested under food deprivation 
and free feeding conditions. The rats continued to respond on the progressive-ratio 
schedule under the free-feeding condition, and their response rates could be 
accommodated by Equation 1. When the rats were transferred to the free-feeding 
condition, the activation parameter a decreased (as expected), whereas the response-time 
parameter į was not affected. Therefore these results provide further support for the 
independence of the two parameters.  
 
Despite its evident advantages over the breakpoint, the application of Equation 1 to 
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progressive-ratio schedule performance is not without problems.  One difficulty is  the 
systematic departure from linearity of the descending limb of the response rate function. 
This was first noted by Mobini et al. (2000), who recommended an operational criterion 
for removal of data points corresponding to very low response rates maintained by the 
highest ratios. Killeen et al. (2009) noted that the curvature of the descending limb is less 
marked in arithmetic progressive-ratio sequences than in exponential sequences, and 
suggested that arithmetic sequences might be preferable in order to avoid this deviation 
from the form defined by Equation 1, although they acknowledged that psychophysical 
considerations favour the use of exponential rather than arithmetic progressions (for 
discussion, see Rickard et al. 2009).  
 
Killeen et al. (2009) described a modification of Equation 1 which takes into account the 
K\SRWKHWLFDO HIIHFW RI WKH µUHLQIRUFLQJ FRQWH[W¶ RQ SURJUHVsive-ratio schedule 
performance 7KHVH DXWKRUV SURSRVHG WKDW µFRQWH[WXDO¶ HIIHFWV PD\ DULVH EHFDXVH WKH
previous and upcoming ratios may distort the relationship between response rate and 
response/reinforce ratio (Baron and Derenne 2000) .LOOHHQ HW DO¶V PRGLILHG HTXDWLRQ
incorporates a fourth parameter, cZKLFKUHSUHVHQWVWKHµFRQWH[W¶:KLOHWKHDGGLWLRQRI
this parameter enables better fits to empirical data to be achieved, work in this laboratory 
has found that a and c often interact in such a way that the two parameters respond 
inconsistently to interventions.  
 
Another difficulty with the application of MPR to progressive-ratio schedule 
performance is the failure of Equation 1 to accommodate the data derived from the 
running response rates, although, according to Killeen (1994), the same equation should 
be applicable to both overall and running response rates. Rickard et al. (2009) found that 
running rates could be described by a logistic decay function (Equation 2), and also 
found a strong relationship between the activation parameter a (Equation 1) and  the 
decay parameter b (Equation 2). One practical advantage of the use of running rates is 
that since running rates do not incorporate the post-reinforcement pause, any effect of an 
intervention on the post-reinforcement pause cannot be reflected in the recovered values 
of the parameters. This can be seen in the results of Experiment 4, where cyproheptadine, 
clozapine and haloperidol all increased the response-time parameter į (Equation 1), but 
did not affect the maximum response rate parameter Ri (Equation 2). This may suggest 
that the effect of the treatments on į mainly reflects an increase in post-reinforcement 
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pausing, and that none of the treatments interfered with the rapid emission of trains of 
responses after the post-reinforcement pause.  However, it is important to emphasise, as 
Rickard et al (2009) pointed out, that Equation 2 is entirely based on empirical 
description of the data and has no theoretical basis in MPR.   
 
The lack of a unified model of progressive-ratio schedule performance that satisfactorily 
accounts for both overall and running response rates is a significant weakness of MPR in 
its present form. Ongoing theoretical work is attempting to rectify this shortcoming 
(Killeen 2011, personal communication). 
 
8.4 Future directions 
 
Although this project has provided some preliminary evidence about the different roles of 
the two subtypes of orexin receptor, OX1 and OX2 receptors, the former mediating 
motivational functions and the latter mediating arousal/motoric functions, this evidence is 
by no means conclusive. Therefore more experiments are needed. A significant problem 
that besets research in this area is the shortage of selective pharmacological tools. For 
example, the only available neurotoxin that shows any selectivity for the orexinergic 
system is OxSap, which preferentiually targets neurones that express OX2 receptors; 
there is no available toxin that shows preference for OX1 receptor-bearing neurones. As 
an alternative to OxSap, excitotoxins may be used to lesion the point of origin of the 
orexinergic pathways (e.g. Harris et al. 2007). While this approach is likely to be 
successful in destroying OX1 receptor-bearing neurones of the LHA, it would inevitably 
destroy other neuronal populations within the LHA.  
 
Further studies are needed to answer some questions raised by Experiments 2 and 3. A 
disconnection study between the LHA and AcbS, but targeting OX2 rather than OX1 
receptors in the AcbS, as in Experiment 3, could help to resolve the issue of whether 
OX2 receptor-mediated transmission is mainly responsible for the motor debilitating 
effects of destruction of the orexinergic projection. If such a disconnection lesion results 
in an increase of į and a reduction of Ri, this would add further support to the hypotheses 
that  the two populations of orexin receptors are differentially involved in motor and 
incentive processes. Another relevant experiment would be to disconnect LHA and VTA, 
targeting the OX1 receptor population in the VTA (for example using SB-334867-A), 
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rather than the OX2 receptor population as in Experiment 2.  
 
The possibility that D1-like and D2-like receptors may make different contributions to 
regulating the reinforcing values of qualitatively different reinforcers  (e.g. sucrose vs. 
corn oil) requires further investigation. The present preliminary observations with 
selective antagonists could be extended to include selective agonists of the two receptors 
followed by studies of agonist/antagonist interaction. The feasibility of such studies using 
MPR has been demonstrated previously (Ho et al. 2003).  
 
The data shown in Fig 7.6 suggest that, calorie for calorie, corn oil may be more 
reinforcing than sucrose. This is another area that merits further investigation. Ho et al. 
(1999) proposed that the incentive value of a reinforcer is related to its magnitude 
according to a hyperbolic function, and Rickard et al. (2009) provided some evidence 
that the relationship between a and reinfocrcer size could be used to characterize this 
relationship. This approach could be used to compare the efficacies of these two 
reinforcers.  
 
The need for further development of MPR has been discussed above. One aspect of the 
model that has received very little attention is the coupling parameter ȕ (Killeen 1994). 
There have been no previous investigations specifically aimed at manipulating this 
parameter. This parameter is assumed to reflect, in part, the contingencies specified by 
WKHVFKHGXOHRI UHLQIRUFHPHQWZKLFKHQDEOH WKH LQGH[ UHVSRQVH WREHFRPHµFRXSOHG¶ WR
reinforcer delivery. Coupling is also assumed to be affected by the retention of traces of 
recently emitted responses in a short-term memory buffer (Bizo and Killeen 1997; Bizo 
et al. 2001; Killeen 1994; Killeen et al. 2009). It would be of interest to examine the 
effects of interventions that are known to affect working memory on this parameter.   
 
In conclusion, the results obtained in this project offer encouragement for the application 
of quantitative models of operant behaviour to behavioural neuroscience. More 
specifically, they indicate that models such as MPR have the potential to differentiate  
between the effects of neurobiological interventions on different behavioural processes 
that may be difficult to disentangle using qualitative behavioural tests. Some possible 
directions for future research with MPR have been suggested, and the need for further 
development of MPR itself has been discussed.   
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